

# Improved Survival of Patients With Human Papillomavirus-Associated Squamous Cell Carcinoma in a Prospective Clinical Trial

Journal of the National Cancer Institute

100, 261-269

DOI: [10.1093/jnci/djn011](https://doi.org/10.1093/jnci/djn011)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2012, 6, 282.	0.6	6
4	Papillomavirus humains (HPV) et cancers associ�s : aspects �pid�miologiques. Revue Francophone Des Laboratoires, 2008, 2008, 27-34.	0.0	5
5	Chemotherapy in the treatment of locally advanced head and neck cancer. Journal of Surgical Oncology, 2008, 97, 701-707.	0.8	67
6	HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer, 2008, 113, 3036-3046.	2.0	438
7	Does Pharma Fund the Pipers? �� Scottish Intercollegiate Guidelines Network (SIGN) Guidelines 90 �� Diagnosis and Management of Head and Neck Cancer, October 2006. Clinical Oncology, 2008, 20, 661-663.	0.6	3
8	Human Papillomavirus-Related Diseases: Oropharynx Cancers and Potential Implications for Adolescent HPV Vaccination. Journal of Adolescent Health, 2008, 43, S52-S60.	1.2	122
9	The changing face of head and neck cancer. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2008, 106, 315-316.	1.6	1
10	Human Papillomavirus in HNSCC: Recognition of a Distinct Disease Type. Hematology/Oncology Clinics of North America, 2008, 22, 1125-1142.	0.9	143
11	Viruses in head and neck cancers: prevention and therapy. Expert Review of Anticancer Therapy, 2008, 8, 1365-1371.	1.1	1
12	Distinct Risk Factor Profiles for Human Papillomavirus Type 16��Positive and Human Papillomavirus Type 16��Negative Head and Neck Cancers. Journal of the National Cancer Institute, 2008, 100, 407-420.	3.0	1,339
13	Prognostic Significance of Head-and-Neck Cancer Biomarkers Previously Discovered and Identified Using iTRAQ-Labeling and Multidimensional Liquid Chromatography��Tandem Mass Spectrometry. Journal of Proteome Research, 2008, 7, 2078-2087.	1.8	82
14	HPV-Positive Head and Neck Cancer Patients Fare Better than HPV-Negative Patients. Journal of the National Cancer Institute, 2008, 100, 227-227.	3.0	1
15	Controversies in the Management of Oropharynx Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 707-714.	2.3	16
16	Chemotherapy for Laryngeal Cancer - An Apoptotic Approach. Current Drug Targets, 2008, 9, 878-886.	1.0	11
18	Pharmacotherapy of head and neck squamous cell carcinoma. Expert Opinion on Pharmacotherapy, 2009, 10, 2291-2302.	0.9	19
19	Validation of Lysyl Oxidase As a Prognostic Marker for Metastasis and Survival in Head and Neck Squamous Cell Carcinoma: Radiation Therapy Oncology Group Trial 90-03. Journal of Clinical Oncology, 2009, 27, 4281-4286.	0.8	72
20	Oropharyngeal Cancer, Race, and the Human Papillomavirus. Cancer Prevention Research, 2009, 2, 769-772.	0.7	28
21	Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications. Clinical Cancer Research, 2009, 15, 6758-6762.	3.2	357

#	ARTICLE	IF	CITATIONS
22	Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinomas: Primary Tumor Burden and Survival in Surgical Patients. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2009, 118, 368-373.	0.6	27
23	Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 225-230.	0.6	9
25	Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus-Related Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2009, 135, 1137.	1.5	220
26	The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. <i>Annals of Oncology</i> , 2009, 20, 1094-1099.	0.6	39
27	Genetic Signatures of HPV-related and Unrelated Oropharyngeal Carcinoma and Their Prognostic Implications. <i>Clinical Cancer Research</i> , 2009, 15, 1779-1786.	3.2	186
28	Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 6213-6221.	0.8	289
30	Determinants of outcome following surgery for oral squamous cell carcinoma. <i>Future Oncology</i> , 2009, 5, 51-61.	1.1	21
31	Cross-Talk between Estrogen Receptor and Epidermal Growth Factor Receptor in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 6529-6540.	3.2	71
32	Prognostic factors in oropharyngeal cancer - analysis of 627 cases receiving definitive radiotherapy. <i>Acta Oncologica</i> , 2009, 48, 1026-1033.	0.8	28
33	Does Detection of Merkel Cell Polyomavirus in Merkel Cell Carcinoma Provide Prognostic Information?. <i>Journal of the National Cancer Institute</i> , 2009, 101, 905-907.	3.0	14
34	Pretreatment Health Behaviors Predict Survival Among Patients With Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1969-1975.	0.8	133
35	Tradition, Teamwork, and Tailored Treatment< subtitle>Surgical Oncology in the Genomic Era</ subtitle>. <i>JAMA Otolaryngology</i> , 2009, 135, 337.	1.5	4
36	Human Papillomavirus and Head and Neck Squamous Cell Carcinoma: Recent Evidence and Clinical Implications. <i>Journal of Dental Research</i> , 2009, 88, 300-306.	2.5	138
37	Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 1645-1654.	3.2	110
38	Elevated Levels of Urinary Prostaglandin E Metabolite Indicate a Poor Prognosis in Ever Smoker Head and Neck Squamous Cell Carcinoma Patients. <i>Cancer Prevention Research</i> , 2009, 2, 957-965.	0.7	23
39	Matched-Pair Analysis of Race or Ethnicity in Outcomes of Head and Neck Cancer Patients Receiving Similar Multidisciplinary Care. <i>Cancer Prevention Research</i> , 2009, 2, 782-791.	0.7	51
40	A Genetic Expression Profile Associated with Oral Cancer Identifies a Group of Patients at High Risk of Poor Survival. <i>Clinical Cancer Research</i> , 2009, 15, 1353-1361.	3.2	57
41	Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas. <i>Seminars in Radiation Oncology</i> , 2009, 19, 53-62.	1.0	16

#	ARTICLE	IF	CITATIONS
42	Contemporary Management of Oropharyngeal Cancer. <i>Current Problems in Surgery</i> , 2009, 46, 119-184.	0.6	16
43	Cancer of the Oral Cavity and Pharynx in Young Females: Increasing Incidence, Role of Human Papilloma Virus, and Lack of Survival Improvement. <i>Seminars in Oncology</i> , 2009, 36, 451-459.	0.8	41
44	Use of combined molecular biomarkers for prediction of clinical outcomes in locally advanced tonsillar cancers treated with chemoradiotherapy alone. <i>Head and Neck</i> , 2009, 31, 9-20.	0.9	29
45	Preclinical models of HPV+ and HPV+/- HNSCC in mice: An immune clearance of HPV+ HNSCC. <i>Head and Neck</i> , 2009, 31, 911-918.	0.9	93
46	Three synchronous HPV-associated squamous cell carcinomas of Waldeyer's ring: Case report and comparison with Slaughter's model of field cancerization. <i>Head and Neck</i> , 2010, 32, 1118-1124.	0.9	46
47	Never-smokers, never-drinkers: Unique clinical subgroup of young patients with head and neck squamous cell cancers. <i>Head and Neck</i> , 2010, 32, 499-503.	0.9	108
49	Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. <i>International Journal of Cancer</i> , 2009, 125, 2159-2165.	2.3	138
50	Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality?. <i>International Journal of Cancer</i> , 2010, 126, 1256-1262.	2.3	156
51	Nuclear receptors in head and neck cancer: current knowledge and perspectives. <i>International Journal of Cancer</i> , 2010, 126, 801-809.	2.3	21
52	Targeted therapies in squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2009, 115, 922-935.	2.0	122
53	Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. <i>Cancer</i> , 2009, 115, 2701-2709.	2.0	150
54	Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. <i>Laryngoscope</i> , 2009, 119, 1542-1549.	1.1	129
55	Transoral laser microsurgery (TLM) ± adjuvant therapy for advanced stage oropharyngeal cancer. <i>Laryngoscope</i> , 2009, 119, 1709-1719.	1.1	177
56	Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. <i>Laryngoscope</i> , 2009, 119, 1951-1957.	1.1	91
57	A contemporary review of indications for primary surgical care of patients with squamous cell carcinoma of the head and neck. <i>Laryngoscope</i> , 2009, 119, 2124-2134.	1.1	49
58	HPV-16 E6 L83V variant in squamous cell carcinomas of the upper aerodigestive tract. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 559-566.	1.2	34
59	Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. <i>European Archives of Oto-Rhino-Laryngology</i> , 2009, 266, 1845-1855.	0.8	69
60	Radiation Response in Two HPV-Infected Head-and-Neck Cancer Cell Lines in Comparison to a Non-HPV-Infected Cell Line and Relationship to Signaling Through AKT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 928-933.	0.4	93

#	ARTICLE	IF	CITATIONS
61	Laryngeal Squamous Cell Carcinoma in a 13-Year-Old Child Associated with Human Papillomaviruses 16 and 18: A Case Report and Review of the Literature. <i>Head and Neck Pathology</i> , 2009, 3, 37-41.	1.3	13
62	The Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer. <i>Head and Neck Pathology</i> , 2009, 3, 78-81.	1.3	218
63	Human Papillomavirus and Oropharyngeal Cancer: What You Need to Know in 2009. <i>Current Treatment Options in Oncology</i> , 2009, 10, 296-307.	1.3	48
65	HPV & head and neck cancer: a descriptive update. <i>Head &amp; Neck Oncology</i> , 2009, 1, 36.	2.3	162
66	Defining the Risk of Involvement for Each Neck Nodal Level in Patients With Early T-Stage Node-Positive Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1356-1364.	0.4	61
67	Prospective Trial Incorporating Pre-/Mid-Treatment [18F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 101-108.	0.4	126
68	Oropharyngeal Squamous Cell Carcinoma Treated With Radiotherapy or Radiochemotherapy: Prognostic Role of TP53 and HPV Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1053-1059.	0.4	39
69	The Relationship Between Human Papillomavirus Status and Other Molecular Prognostic Markers in Head and Neck Squamous Cell Carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 553-561.	0.4	195
70	Prognostic Significance of Vascular Endothelial Growth Factor in Squamous Cell Carcinomas of the Tonsil in Relation to Human Papillomavirus Status and Epidermal Growth Factor Receptor. <i>Annals of Surgical Oncology</i> , 2009, 16, 2908-2917.	0.7	38
71	Î²-Tubulin-II Expression Strongly Predicts Outcome in Patients Receiving Induction Chemotherapy for Locally Advanced Squamous Carcinoma of the Head and Neck: A Companion Analysis of the TAX 324 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 6222-6228.	0.8	55
72	Replication and Assembly of Human Papillomaviruses. <i>Journal of Dental Research</i> , 2009, 88, 307-317.	2.5	116
73	Human papilloma virus in head and neck cancer: The need for a standardised assay to assess the full clinical importance. <i>European Journal of Cancer</i> , 2009, 45, 2935-2939.	1.3	77
74	HPVâ€16â€infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2009, 140, 228-234.	1.1	104
75	Selective Versus Comprehensive Neck Dissection after Chemoradiation for Advanced Oropharyngeal Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2009, 141, 737-742.	1.1	26
76	Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and Treatment. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2009, 4, 49-70.	9.6	380
77	p16 as a diagnostic marker of cervical neoplasia: a tissue microarray study of 796 archival specimens. <i>Diagnostic Pathology</i> , 2009, 4, 22.	0.9	57
79	Therapeutic Human Papillomavirus Vaccination. <i>Public Health Genomics</i> , 2009, 12, 331-342.	0.6	20
80	Management of Head and Neck Cancer in Elderly Patients. <i>Drugs and Aging</i> , 2009, 26, 571-583.	1.3	22

#	ARTICLE	IF	CITATIONS
81	Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients. <i>Cancer Prevention Research</i> , 2009, 2, 776-781.	0.7	260
82	Prospective Risk-Adjusted [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2509-2515.	0.8	156
83	Class III $\beta$ -tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2009, 20, 1414-1419.	0.6	52
84	Effect of HPV-Associated p16 <sup>INK4A</sup> Expression on Response to Radiotherapy and Survival in Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2009, 27, 1992-1998.	0.8	548
85	Individualizing therapy for oropharyngeal cancer patients. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1181-1184.	1.1	0
86	HPV and prognosis for patients with oropharynx cancer. <i>European Journal of Cancer</i> , 2009, 45, 383-385.	1.3	49
87	Multimodal Treatment for Head and Neck Cancer. <i>Surgical Clinics of North America</i> , 2009, 89, 43-52.	0.5	26
88	Human papillomavirus-related head and neck tumors: clinical and research implication. <i>Current Opinion in Oncology</i> , 2009, 21, 201-205.	1.1	64
89	Human Papillomavirus and Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 535-539.	0.6	52
90	Basaloid Squamous Cell Carcinoma of the Esophagus: Assessment for High-risk Human Papillomavirus and Related Molecular Markers. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1608-1614.	2.1	45
91	Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents. <i>Current Opinion in Oncology</i> , 2009, 21, 232-237.	1.1	11
92	Head and neck cancer emerging strategies: advances and new challenges. <i>Current Opinion in Oncology</i> , 2009, 21, 191-193.	1.1	8
93	A 25-Year Analysis of Veterans Treated for Tonsillar Squamous Cell Carcinoma. <i>JAMA Otolaryngology</i> , 2009, 135, 1147.	1.5	12
94	Understanding the link between HPV and oropharyngeal cancers. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2009, 22, 42-46.	0.1	3
95	Oropharyngeal carcinoma: a sexually transmitted disease. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2010, 52, 576-578.	0.2	0
96	Clinical Nodal Staging of T1-2 Tonsillar Squamous Cell Carcinoma Stratified by p16 Status and Implications for Ipsilateral Neck Irradiation. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 284-287.	1.0	16
97	The Role of Chronic Periodontitis in Prevention and Treatment of Head and Neck Cancers. <i>Current Cancer Therapy Reviews</i> , 2010, 6, 323-333.	0.2	1
98	Human Papillomaviruses Are Identified in a Subgroup of Sinonasal Squamous Cell Carcinomas With Favorable Outcome. <i>Yearbook of Pathology and Laboratory Medicine</i> , 2010, 2010, 164-165.	0.0	0

#	ARTICLE	IF	CITATIONS
99	Searching for metachronous tumours in patients with head and neck cancer: the ideal protocol!. Current Opinion in Otolaryngology and Head and Neck Surgery, 2010, 18, 124-133.	0.8	20
100	Design and performance of clinical trials in head and neck cancer. Current Opinion in Oncology, 2010, 22, 184-185.	1.1	0
101	Lymphoepithelial-like Carcinoma of the Oropharynx. American Journal of Surgical Pathology, 2010, 34, 800-805.	2.1	115
102	Human Papillomavirus-associated Squamous Cell Carcinoma of the Upper Aerodigestive Tract. American Journal of Surgical Pathology, 2010, 34, e15-e24.	2.1	40
103	Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. , 2010, , CD006386.		34
104	p16 Positive Oropharyngeal Squamous Cell Carcinoma:An Entity With a Favorable Prognosis Regardless of Tumor HPV Status. American Journal of Surgical Pathology, 2010, 34, 1088-1096.	2.1	369
105	A Phase I/II Study of Altered Fractionated IMRT Alone for Intermediate T-Stage Oropharyngeal Carcinoma. Strahlentherapie Und Onkologie, 2010, 186, 489-495.	1.0	12
108	Which is the single most important factor in deciding the management and determining the prognosis of head and neck cancer?. European Archives of Oto-Rhino-Laryngology, 2010, 267, 325-326.	0.8	4
109	Oral tongue squamous cell carcinoma: recurrent disease is associated with histopathologic risk score and young age. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1039-1048.	1.2	56
110	Human papillomavirus in head and neck tumors: epidemiological, molecular and clinical aspects. Wiener Medizinische Wochenschrift, 2010, 160, 305-309.	0.5	13
111	Update on role of chemotherapy in head and neck squamous cell cancer. Indian Journal of Surgical Oncology, 2010, 1, 85-95.	0.3	8
112	Human Papillomavirus: Changing Paradigms in Oropharyngeal Cancer. Current Oncology Reports, 2010, 12, 115-120.	1.8	27
113	Transoral robotic surgery and a paradigm shift in the management of oropharyngeal squamous cell carcinoma. Journal of Robotic Surgery, 2010, 4, 79-86.	1.0	9
114	Time trends in pharyngeal cancer incidence in Norway 1981â€“2005: a subsite analysis based on a reabstraction and recoding of registered cases. Cancer Causes and Control, 2010, 21, 1397-1405.	0.8	49
115	Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. Oral Oncology, 2010, 46, 100-104.	0.8	99
116	Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncology, 2010, 46, 492-496.	0.8	104
117	Human papilloma virus in locally advanced stage III/IV squamous cell cancer of the oropharynx and impact on choice of therapy. Oral Oncology, 2010, 46, 705-711.	0.8	21
118	Oropharyngeal squamous cell carcinoma: A unique disease on the rise?. Oral Oncology, 2010, 46, 780-785.	0.8	69



#	ARTICLE	IF	CITATIONS
119	Primary surgery for oropharyngeal cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2010, 143, 644-649.	1.1	10
120	Survey on human papillomavirus/p16 screening use in oropharyngeal carcinoma patients in the United States. <i>Cancer</i> , 2010, 116, 514-519.	2.0	17
121	Radiotherapy for patients with the human immunodeficiency virus: Are special precautions necessary?. <i>Cancer</i> , 2010, 116, 273-283.	2.0	50
122	Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. <i>Cancer</i> , 2010, 116, 2166-2173.	2.0	371
123	Human papillomavirus status in head and neck cancer. <i>Cancer</i> , 2010, 116, 4221-4226.	2.0	19
124	Future of the TNM classification and staging system in head and neck cancer. <i>Head and Neck</i> , 2010, 32, 1693-1711.	0.9	90
125	Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. <i>International Journal of Cancer</i> , 2010, 126, 1882-1894.	2.3	194
126	Induction chemotherapy in the management of head and neck cancer. <i>Journal of Surgical Oncology</i> , 2010, 101, 292-298.	0.8	11
127	Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis. <i>Laryngoscope</i> , 2010, 120, 261-266.	1.1	35
128	Human papillomavirus and oropharynx cancer: Biology, detection and clinical implications. <i>Laryngoscope</i> , 2010, 120, 1756-1772.	1.1	154
129	Human papillomavirus-active head and neck cancer and ethnic health disparities. <i>Laryngoscope</i> , 2010, 120, 1531-1537.	1.1	50
130	Population-based analysis of oral and oropharyngeal carcinoma: Changing trends of histopathologic differentiation, survival and patient demographics. <i>Laryngoscope</i> , 2010, 120, 2203-2212.	1.1	72
131	HPV status in head and neck tumors. <i>Pathology Research and Practice</i> , 2010, 206, 229-234.	1.0	23
132	The Changing Aetiology of Head and Neck Cancer: the Role of Human Papillomavirus. <i>Clinical Oncology</i> , 2010, 22, 538-546.	0.6	34
133	ACR Appropriateness Criteria®: Local/Regional Therapy for Resectable Oropharyngeal Squamous Cell Carcinomas. <i>Current Problems in Cancer</i> , 2010, 34, 175-192.	1.0	5
134	Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 667-674.	0.4	21
135	Candidate Dosimetric Predictors of Long-Term Swallowing Dysfunction After Oropharyngeal Intensity-Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1356-1365.	0.4	156
136	Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). <i>Head &amp; Neck Oncology</i> , 2010, 2, 15.	2.3	423



#	ARTICLE	IF	CITATIONS
137	EDITORIAL: Evidence-based management of oropharyngeal cancer. <i>Clinical Otolaryngology</i> , 2010, 35, 273-276.	0.6	3
138	Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. <i>British Journal of Cancer</i> , 2010, 103, 1510-1517.	2.9	125
139	Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. <i>British Journal of Cancer</i> , 2010, 103, 1858-1869.	2.9	52
140	The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. <i>Biologics: Targets and Therapy</i> , 2010, 4, 173.	3.0	39
141	Prevalence of high-risk human papillomavirus types (HPV-16, HPV-18) and their physical status in primary laryngeal squamous cell carcinoma. <i>Neoplasia</i> , 2010, 57, 594-600.	0.7	16
142	Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. <i>International Journal of Epidemiology</i> , 2010, 39, 166-181.	0.9	322
143	Functional p53 Status As a Biomarker for Chemotherapy Response in Oral-Cavity Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 715-717.	0.8	9
144	Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 8-14.	0.8	234
145	Screening for Oral Premalignancy and Cancer: What Platform and Which Biomarkers?. <i>Cancer Prevention Research</i> , 2010, 3, 1056-1059.	0.7	28
146	Epidemiology, Pathogenesis, and Prevention of Head and Neck Cancer. , 2010, , .		8
147	Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2010, 21, 864-870.	0.6	51
148	The role of human papillomavirus infection in head and neck cancers. <i>Annals of Oncology</i> , 2010, 21, vii243-vii245.	0.6	146
149	Lessons from Australia: Human Papillomavirus Is Not a Major Risk Factor for Esophageal Squamous Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1889-1892.	1.1	16
150	Spectral Clustering of Microarray Data Elucidates the Roles of Microenvironment Remodeling and Immune Responses in Survival of Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2881-2888.	0.8	72
151	Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. <i>Annals of Oncology</i> , 2010, 21, 342-347.	0.6	52
152	Bcl2 and Human Papilloma Virus 16 as Predictors of Outcome following Concurrent Chemoradiation for Advanced Oropharyngeal Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2138-2146.	3.2	62
153	Comparison of Molecular Methods for Detection of HPV in Oral and Oropharyngeal Squamous Cell Carcinoma. <i>Diagnostic Molecular Pathology</i> , 2010, 19, 218-223.	2.1	9
154	Human Papillomavirus Detection in Head and Neck Squamous Cell Carcinomas. <i>Advances in Anatomic Pathology</i> , 2010, 17, 394-403.	2.4	70

#	ARTICLE	IF	CITATIONS
155	A Systematic Review of p53 as a Prognostic Factor of Survival in Squamous Cell Carcinoma of the Four Main Anatomical Subsites of the Head and Neck. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 574-587.	1.1	77
156	Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROC 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 2989-2995.	0.8	339
157	p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. <i>Annals of Oncology</i> , 2010, 21, 1961-1966.	0.6	110
158	Basaloid squamous cell carcinoma of the head and neck: role of HPV and implication in treatment and prognosis. <i>Journal of Clinical Pathology</i> , 2010, 63, 857-866.	1.0	65
159	Oncogenic impact of human papilloma virus in head and neck cancer. <i>Journal of Laryngology and Otology</i> , 2010, 124, 941-944.	0.4	11
160	p16 Expression As a Predictive Biomarker of Hypoxic Cell-Sensitizing Agents in Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4103-4104.	0.8	6
161	Survival Trends in Head and Neck Cancer: Opportunities for Improving Outcomes. <i>Oncologist</i> , 2010, 15, 921-923.	1.9	17
162	Transoral Robotic Surgery for Advanced Oropharyngeal Carcinoma. <i>JAMA Otolaryngology</i> , 2010, 136, 1079.	1.5	296
163	Emerging drugs to treat squamous cell carcinomas of the head and neck. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 355-373.	1.0	96
164	Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 339-344.	1.1	26
165	Evidence-Based Clinical Recommendations Regarding Screening for Oral Squamous Cell Carcinomas. <i>Journal of the American Dental Association</i> , 2010, 141, 509-520.	0.7	281
166	Targeting the RB-pathway in Cancer Therapy. <i>Clinical Cancer Research</i> , 2010, 16, 1094-1099.	3.2	177
167	Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee. <i>Annals of Oncology</i> , 2010, 21, 1952-1960.	0.6	22
168	Prognostic Significance of p16 <sup>INK4A</sup> and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROC 02.02 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4142-4148.	0.8	679
169	Oropharyngeal Cancer, Human Papilloma Virus, and Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1-3.	0.8	78
170	Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer. <i>Annals of Oncology</i> , 2010, 21, vii246-vii251.	0.6	14
171	Immune Suppression in Head and Neck Cancers: A Review. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-15.	3.3	141
172	Human papillomavirus-associated oropharyngeal cancer: a new clinical entity. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010, 103, 229-236.	0.2	39

#	ARTICLE	IF	CITATIONS
173	Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 206-211.	1.1	22
174	More Lessons Learned From the Suffocation of Hypoxia. <i>Journal of Clinical Oncology</i> , 2010, 28, 2941-2943.	0.8	24
175	Head and neck cancer--Part 2: Treatment and prognostic factors. <i>BMJ: British Medical Journal</i> , 2010, 341, c4690-c4690.	2.4	72
176	Head and Neck Cancer. <i>Medical Clinics of North America</i> , 2010, 94, 1031-1046.	1.1	33
177	Cancer Epigenome. <i>Advances in Genetics</i> , 2010, 70, 247-276.	0.8	37
178	Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1471-1484.	1.1	29
179	Tobacco Use in Human Papillomavirus-Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence. <i>Clinical Cancer Research</i> , 2010, 16, 1226-1235.	3.2	271
180	The prognostic significance of p16 overexpression in oropharyngeal squamous cell carcinoma: implications for treatment strategies and future clinical studies. <i>Annals of Oncology</i> , 2010, 21, 1931-1934.	0.6	49
181	Expression of p16 in benign and malignant cystic squamous lesions of the neck. <i>Human Pathology</i> , 2010, 41, 535-539.	1.1	74
182	Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and Women. <i>Journal of Adolescent Health</i> , 2010, 46, S20-S26.	1.2	295
183	HPV-induced oropharyngeal cancer, immune response and response to therapy. <i>Cancer Letters</i> , 2010, 288, 149-155.	3.2	66
184	Unravelling the biology of human papillomavirus (HPV) related tumours to enhance their radiosensitivity. <i>Cancer Treatment Reviews</i> , 2010, 36, 629-636.	3.4	21
185	Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. <i>European Journal of Cancer</i> , 2010, 46, 2088-2096.	1.3	79
186	Cetuximab in the management of locoregionally advanced head and neck cancer: Expanding the treatment options?. <i>European Journal of Cancer</i> , 2010, 46, 1979-1989.	1.3	29
187	Can saliva-based HPV tests establish cancer risk and guide patient management?. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2010, 110, 273-274.	1.6	7
188	Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. <i>Vaccine</i> , 2010, 28, 3269-3272.	1.7	120
189	Detection of novel Human papilloma virus type 82 in laryngeal cancer: case report. <i>Auris Nasus Larynx</i> , 2010, 37, 648-650.	0.5	4
190	HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2010, 94, 30-35.	0.3	177

#	ARTICLE	IF	CITATIONS
191	HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors. <i>Radiotherapy and Oncology</i> , 2010, 95, 365-370.	0.3	36
192	The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. <i>Radiotherapy and Oncology</i> , 2010, 95, 371-380.	0.3	144
193	Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. <i>Lancet Oncology</i> , The, 2010, 11, 66-74.	5.1	92
194	Optimising the therapeutic ratio in head and neck cancer. <i>Lancet Oncology</i> , The, 2010, 11, 287-291.	5.1	59
195	HPV-associated head and neck cancer: a virus-related cancer epidemic. <i>Lancet Oncology</i> , The, 2010, 11, 781-789.	5.1	1,533
196	Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 24-35.	13.9	5,481
197	Genomic Evaluation of Head and Neck Cancer. , 2010, , 511-521.		1
198	Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. <i>The Cochrane Library</i> , 2010, 2010, CD006387.	1.5	40
199	Trends in the survival of patients diagnosed with cancers of the lip, oral cavity, and pharynx in the Nordic countries 1964â€“2003 followed up to the end of 2006. <i>Acta OncolÃ³gica</i> , 2010, 49, 561-577.	0.8	32
200	Estrogen and Cytochrome P450 1B1 Contribute to Both Early- and Late-Stage Head and Neck Carcinogenesis. <i>Cancer Prevention Research</i> , 2011, 4, 107-115.	0.7	44
201	Identifying the risk factors for late-stage head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1321-1325.	1.1	37
202	Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. <i>Journal of Clinical Oncology</i> , 2011, 29, 4294-4301.	0.8	3,060
203	Human Papillomavirus Infection and Its Association with HIV. <i>Advances in Dental Research</i> , 2011, 23, 84-89.	3.6	35
204	Postoperative Therapy in Head and Neck Cancer: State of the Art, Risk Subset, Prognosis and Unsolved Questions. <i>Oncology</i> , 2011, 81, 21-29.	0.9	23
205	Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. <i>Journal of Clinical Pathology</i> , 2011, 64, 308-312.	1.0	129
206	Oral cancer aetiopathogenesis; past, present and future aspects. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2011, 16, e306-e311.	0.7	71
207	Squamous Cell Carcinoma of the Oral Cavity and Oropharynx. <i>Surgical Pathology Clinics</i> , 2011, 4, 1127-1151.	0.7	10
208	Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. <i>The Cochrane Library</i> , 2011, , CD006205.	1.5	49

#	ARTICLE	IF	CITATIONS
209	Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. The Cochrane Library, 2011, , CD006386.	1.5	86
210	Papillary squamous cell carcinoma of the head and neck: a clinicopathologic series. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2011, 32, 557-563.	0.6	34
211	Comparison of 2 line blot assays for defining HPV genotypes in oral and oropharyngeal squamous cell carcinomas. Diagnostic Microbiology and Infectious Disease, 2011, 70, 240-245.	0.8	3
212	The increasing clinical relevance of human papillomavirus type 16 (HPV-16) infection in oropharyngeal cancer. British Journal of Oral and Maxillofacial Surgery, 2011, 49, 423-429.	0.4	42
213	Impact of HPV status on treatment of squamous cell cancer of the oropharynx: What we know and what we need to know. Cancer Letters, 2011, 304, 71-79.	3.2	36
214	EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas. European Journal of Cancer, 2011, 47, 2364-2372.	1.3	29
215	Is Human Papillomavirus a Causative Factor of Glottic Cancer?. Journal of Voice, 2011, 25, 770-774.	0.6	14
216	The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine, 2011, 29, 9112-9122.	1.7	58
217	Infections À papillomavirus humains (HPV) des voies aéro-digestives supérieures (VADS). Revue Francophone Des Laboratoires, 2011, 2011, 65-75.	0.0	3
218	The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial. Radiotherapy and Oncology, 2011, 100, 49-55.	0.3	176
219	Phase III Study of Radiation Therapy With or Without Cis-Platinum in Patients With Unresectable Squamous or Undifferentiated Carcinoma of the Head and Neck: An Intergroup Trial of the Eastern Cooperative Oncology Group (E2382). International Journal of Radiation Oncology Biology Physics, 2011, 81, 719-725.	0.4	48
220	Concurrent Cisplatin and Radiation Versus Cetuximab and Radiation for Locally Advanced Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 915-922.	0.4	137
221	Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates, 2011, 14, 260-279.	6.5	30
222	Infectious Aetiology of Cancer: Developing World Perspective. , 2011, , .		1
223	Viruses and Cancer. African Journal of Clinical and Experimental Microbiology, 2011, 13, .	0.1	0
224	Human Papillomavirus-Related Squamous Cell Carcinoma of the Oropharynx. JAMA Otolaryngology, 2011, 137, 163.	1.5	58
225	Impact of HPV in Oropharyngeal Cancer. Journal of Oncology, 2011, 2011, 1-6.	0.6	60
226	Prediction of Local Failures with a Combination of Pretreatment Tumor Volume and Apparent Diffusion Coefficient in Patients Treated with Definitive Radiotherapy for Hypopharyngeal or Oropharyngeal Squamous Cell Carcinoma. Journal of Radiation Research, 2011, 52, 522-530.	0.8	33

#	ARTICLE	IF	CITATIONS
227	À propos de la 53e r�union de l'American Society for Therapeutic Radiology and Oncology (Astro) Miami (�tats-Unis), 2-6 octobre 2011. Bulletin Du Cancer, 2011, 98, 1524-1528.	0.6	0
228	Genomic Profiling of Advanced-Stage Oral Cancers Reveals Chromosome 11q Alterations as Markers of Poor Clinical Outcome. PLoS ONE, 2011, 6, e17250.	1.1	47
229	Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer. PLoS ONE, 2011, 6, e24148.	1.1	65
230	Diagnosis and treatment of oral medicine conditions. Dental Nursing, 2011, 7, 560-563.	0.0	0
231	Head and Neck Cancer Among Lifelong Never-Smokers and Ever-Smokers. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 270-275.	0.6	26
232	Value of p16INK4a in the Pathology of Invasive Penile Squamous Cell Carcinomas. American Journal of Surgical Pathology, 2011, 35, 253-261.	2.1	104
233	High-Risk Human Papillomavirus E6/E7 mRNA Detection by a Novel In Situ Hybridization Assay Strongly Correlates With p16 Expression and Patient Outcomes in Oropharyngeal Squamous Cell Carcinoma. American Journal of Surgical Pathology, 2011, 35, 1343-1350.	2.1	270
234	Role of molecular markers in the management of head and neck cancers. Current Opinion in Oncology, 2011, 23, 259-264.	1.1	26
235	Commentary. Cancer Journal (Sudbury, Mass ), 2011, 17, 273-275.	1.0	2
236	Detection of High-Risk HPV in Head and Neck Squamous Cell Carcinomas. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 574-578.	0.6	14
237	Human Papillomavirus-Related Small Cell Carcinoma of the Oropharynx. American Journal of Surgical Pathology, 2011, 35, 1679-1684.	2.1	123
238	Oropharyngeal Carcinoma. , 2011, 16, 173-175.		1
239	Human papillomavirus in head and neck cancers. Anti-Cancer Drugs, 2011, 22, 586-590.	0.7	30
240	Clinicopathological and prognostic implications of genetic alterations in oral cancers. Oncology Letters, 2011, 2, 445-451.	0.8	24
241	The Benefit of Early PET/CT Surveillance in HPV-Associated Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology, 2011, 137, 1106.	1.5	27
242	Head and Neck Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 596-650.	2.3	213
243	The Epidemic of HPV-Associated Oropharyngeal Cancer Is Here: Is It Time to Change Our Treatment Paradigms?. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 665-673.	2.3	178
244	Controversies in the Locoregional Management of Head and Neck Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 653-662.	2.3	12

#	ARTICLE	IF	CITATIONS
245	Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. <i>Oncology Reports</i> , 2011, 27, 467-74.	1.2	13
246	Self-reported competence of urethral catheterization in interns. <i>ANZ Journal of Surgery</i> , 2011, 81, 583-584.	0.3	0
247	Should the treatment paradigms for oral and oropharyngeal cancers be changed now: the role of human papilloma virus?. <i>ANZ Journal of Surgery</i> , 2011, 81, 581-583.	0.3	3
248	The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 236-251.	0.7	19
249	An overview of the molecular pathology of head and neck cancer, and its clinical implications. <i>Periodontology 2000</i> , 2011, 57, 132-149.	6.3	5
250	Genetics/epigenetics of oral premalignancy: current status and future research*. <i>Oral Diseases</i> , 2011, 17, 7-22.	1.5	106
251	The Promise of Dynamic Contrast-Enhanced Imaging in Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2011, 21, 147-156.	1.0	99
252	Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 2011, 47, 487-496.	0.8	73
253	Differential survival trends for patients with tonsillar, base of tongue and tongue cancer in Sweden. <i>Oral Oncology</i> , 2011, 47, 636-641.	0.8	19
254	Does human papillomavirus infection imply a different prognosis in vulvar squamous cell carcinoma?. <i>Gynecologic Oncology</i> , 2011, 122, 509-514.	0.6	82
255	Role and Impact of Human Papillomavirus in Cervical Metastasis From Unknown Primary. <i>Laryngoscope</i> , 2011, 121, S118-S118.	1.1	1
256	Oropharyngeal cancer incidence trends: diminishing racial disparities. <i>Cancer Causes and Control</i> , 2011, 22, 753-763.	0.8	79
257	Update of prognostic and predictive biomarkers in oropharyngeal squamous cell carcinoma: a review. <i>European Archives of Oto-Rhino-Laryngology</i> , 2011, 268, 5-16.	0.8	19
258	Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2011, 268, 165-179.	0.8	105
259	Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2011, 268, 721-726.	0.8	25
260	Evidence for a causal association for HPV in head and neck cancers. <i>European Archives of Oto-Rhino-Laryngology</i> , 2011, 268, 1541-1547.	0.8	51
261	Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 626-632.	1.0	36
264	Tobacco Smoking During Radiation Therapy for Head-and-Neck Cancer Is Associated With Unfavorable Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 414-419.	0.4	182



#	ARTICLE	IF	CITATIONS
265	Expression of p16 in Sinonasal Undifferentiated Carcinoma (SNUC) Without Associated Human Papillomavirus (HPV). <i>Head and Neck Pathology</i> , 2011, 5, 349-354.	1.3	62
266	High-risk human papillomavirus (HPV) screening and detection in healthy patient saliva samples: a pilot study. <i>BMC Oral Health</i> , 2011, 11, 28.	0.8	34
267	Long-term outcome and patterns of failure in patients with advanced head and neck cancer. <i>Radiation Oncology</i> , 2011, 6, 70.	1.2	48
268	Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein. <i>Infectious Agents and Cancer</i> , 2011, 6, 18.	1.2	23
269	The role of human papillomavirus in the pathogenesis of head & neck squamous cell carcinoma: an overview. <i>Infectious Agents and Cancer</i> , 2011, 6, 4.	1.2	90
270	The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head &amp; Neck Oncology</i> , 2011, 3, 11.	2.3	75
271	Swallowing function after transoral laser microsurgery (TLM) ± adjuvant therapy for advanced-stage oropharyngeal cancer. <i>Laryngoscope</i> , 2011, 121, 2381-2390.	1.1	61
272	Transoral robotic resection and reconstruction for head and neck cancer. <i>Laryngoscope</i> , 2011, 121, 1668-1674.	1.1	135
273	Outcomes of head and neck squamous cell carcinoma patients with N3 neck disease treated primarily with chemoradiation versus surgical resection. <i>Laryngoscope</i> , 2011, 121, 1881-1887.	1.1	14
274	Management of the "Violated Neck" in the era of chemoradiation. <i>Laryngoscope</i> , 2011, 121, 2349-2358.	1.1	8
275	Case-matching analysis of head and neck squamous cell carcinoma in racial and ethnic minorities in the United States—Possible role for human papillomavirus in survival disparities. <i>Head and Neck</i> , 2011, 33, 45-53.	0.9	61
276	Human papillomavirus infections in laryngeal cancer. <i>Head and Neck</i> , 2011, 33, 581-586.	0.9	131
277	Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy. <i>Head and Neck</i> , 2011, 33, 251-256.	0.9	35
278	Surgical salvage of the oropharynx after failure of organ-sparing therapy. <i>Head and Neck</i> , 2011, 33, 516-524.	0.9	55
279	Transoral robotic surgery and human papillomavirus status: Oncologic results. <i>Head and Neck</i> , 2011, 33, 573-580.	0.9	194
280	Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome. <i>Head and Neck</i> , 2011, 33, 1387-1393.	0.9	28
281	Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience. <i>Head and Neck</i> , 2011, 33, 1433-1440.	0.9	5
282	Association of p16 <sup>INK4a</sup> overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. <i>Head and Neck</i> , 2011, 33, 1622-1627.	0.9	109

#	ARTICLE	IF	CITATIONS
283	Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2011, 33, 1727-1734.	0.9	35
284	Clinical and pathological determinants in tonsillar cancer. <i>Head and Neck</i> , 2011, 33, 1703-1707.	0.9	5
285	Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: A united states multicenter study. <i>Head and Neck</i> , 2011, 33, 1683-1694.	0.9	323
286	Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. <i>Cancer</i> , 2011, 117, 318-326.	2.0	24
287	Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. <i>International Journal of Cancer</i> , 2011, 128, 1596-1605.	2.3	84
288	Use of cyclin D1 in conjunction with human papillomavirus status to predict outcome in oropharyngeal cancer. <i>International Journal of Cancer</i> , 2011, 128, 1532-1545.	2.3	32
289	Human papillomavirus and survival in patients with base of tongue cancer. <i>International Journal of Cancer</i> , 2011, 128, 2892-2897.	2.3	86
290	The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. <i>International Journal of Cancer</i> , 2011, 129, 1752-1760.	2.3	52
291	HPV involvement in tonsillar cancer: Prognostic significance and clinically relevant markers. <i>International Journal of Cancer</i> , 2011, 129, 101-110.	2.3	66
292	Matched Survival Analysis in Patients With Locoregionally Advanced Resectable Oropharyngeal Carcinoma: Platinum-Based Induction and Concurrent Chemoradiotherapy Versus Primary Surgical Resection. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 154-160.	0.4	21
293	Radiosensitization of Oropharyngeal Squamous Cell Carcinoma Cells by Human Papillomavirus 16 Oncoprotein E6. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 860-865.	0.4	51
294	High Stromal Carbonic Anhydrase IX Expression Is Associated With Decreased Survival in p16-Negative Head-and-Neck Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 249-257.	0.4	37
295	Correlation of Currently Used Radiobiological Parameters with Local Control and Acute and Late Mucosal Toxicity in Randomised Studies of Altered Fractionation for Locally Advanced Head and Neck Cancer. <i>Clinical Oncology</i> , 2011, 23, 29-33.	0.6	20
296	Extracapsular extension is a poor predictor of disease recurrence in surgically treated oropharyngeal squamous cell carcinoma. <i>Modern Pathology</i> , 2011, 24, 1413-1420.	2.9	160
298	Undifferentiated carcinoma of the oropharynx: a human papillomavirus-associated tumor with a favorable prognosis. <i>Modern Pathology</i> , 2011, 24, 1306-1312.	2.9	66
299	Rethinking the Head and Neck Cancer Population. <i>Clinical Journal of Oncology Nursing</i> , 2011, 15, 165-170.	0.3	8
300	A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. <i>Modern Pathology</i> , 2011, 24, 1295-1305.	2.9	178
301	Double Demonstration of Oncogenic High Risk Human Papilloma Virus DNA and HPV-E7 Protein in Oral Cancers. <i>International Journal of Immunopathology and Pharmacology</i> , 2011, 24, 95-101.	1.0	32

#	ARTICLE	IF	CITATIONS
302	The Role of the Adenosinergic Pathway in Immunosuppression Mediated by Human Regulatory T Cells (Treg). <i>Current Medicinal Chemistry</i> , 2011, 18, 5217-5223.	1.2	68
303	Pharmacotherapy for squamous-cell carcinoma of the head and neck. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 397-409.	0.9	13
304	Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. <i>Current Medical Research and Opinion</i> , 2011, 27, 2253-2259.	0.9	25
305	Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck. <i>Acta Oto-Laryngologica</i> , 2011, 131, 1333-1340.	0.3	7
306	Increasing Incidence of Oral Tongue Squamous Cell Carcinoma in Young White Women, Age 18 to 44 Years. <i>Journal of Clinical Oncology</i> , 2011, 29, 1488-1494.	0.8	319
307	Detection of Human Papillomavirus Using Hybrid Capture 2 in Oral Brushings From Patients With Oropharyngeal Squamous Cell Carcinoma: Table 1. <i>American Journal of Clinical Pathology</i> , 2011, 135, 766-769.	0.4	21
308	Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. <i>Annals of Oncology</i> , 2011, 22, 1071-1077.	0.6	413
309	Inhibition of p53 by Adenovirus Type 12 E1B-55K Deregulates Cell Cycle Control and Sensitizes Tumor Cells to Genotoxic Agents. <i>Journal of Virology</i> , 2011, 85, 7976-7988.	1.5	8
310	Race as a Social Construct in Head and Neck Cancer Outcomes. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 144, 381-389.	1.1	14
311	Screening for Human Papillomavirus in Basaloid Squamous Carcinoma: Utility of p16 <sup>INK4a</sup> , CISH, and PCR. <i>International Journal of Surgical Pathology</i> , 2011, 19, 309-314.	0.4	4
312	Second Primary Cancers After an Index Head and Neck Cancer: Subsite-Specific Trends in the Era of Human Papillomavirus-Associated Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 739-746.	0.8	295
313	Otolaryngology and the American Presidency: A Medical Legacy. <i>Orl</i> , 2011, 73, 105-109.	0.6	0
314	Human Papillomavirus in Metastatic Lymph Nodes from Unknown Primary Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 145, 51-57.	1.1	59
315	Increased p16 <sup>CDKN2A</sup> Protein Within Feline Cutaneous Viral Plaques, Bowenoid <i>In Situ</i> Carcinomas, and a Subset of Invasive Squamous Cell Carcinomas. <i>Veterinary Pathology</i> , 2011, 48, 460-465.	0.8	32
316	Gender and Ethnic Disparities in Incidence and Survival of Squamous Cell Carcinoma of the Oral Tongue, Base of Tongue, and Tonsils: A Surveillance, Epidemiology and End Results Program-Based Analysis. <i>Oncology</i> , 2011, 81, 12-20.	0.9	96
317	The meaning of p16 <sup>ink4a</sup> expression in tumors. <i>Cell Cycle</i> , 2011, 10, 2497-2503.	1.3	240
318	Associations between Oral HPV16 Infection and Cytopathology: Evaluation of an Oropharyngeal Pap-Test Equivalent in High-Risk Populations. <i>Cancer Prevention Research</i> , 2011, 4, 1378-1384.	0.7	139
319	Evaluation of Human Papilloma Virus Diagnostic Testing in Oropharyngeal Squamous Cell Carcinoma: Sensitivity, Specificity, and Prognostic Discrimination. <i>Clinical Cancer Research</i> , 2011, 17, 6262-6271.	3.2	304

#	ARTICLE	IF	CITATIONS
320	Human papilloma virus detection in neoplastic and non-neoplastic nasopharyngeal tissues in Taiwan. <i>Journal of Clinical Pathology</i> , 2011, 64, 571-577.	1.0	14
321	Implications of the Oropharyngeal Cancer Epidemic. <i>Journal of Clinical Oncology</i> , 2011, 29, 4222-4223.	0.8	22
322	Population-Based Study of Competing Mortality in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3503-3509.	0.8	172
323	Brush-based Cytology Screening in the Tonsils and Cervix: There Is a Difference!. <i>Cancer Prevention Research</i> , 2011, 4, 1350-1352.	0.7	28
324	The connection between human papillomavirus and oropharyngeal squamous cell carcinomas in the United States. <i>Journal of the American Dental Association</i> , 2011, 142, 915-924.	0.7	76
325	Oropharyngeal cancer: clinical implications of the HPV connection. <i>Annals of Oncology</i> , 2011, 22, 997-999.	0.6	14
326	Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 359-371.	1.1	7
327	Factors Associated With Mortality in 2-Year Survivors of Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2011, 137, 1100.	1.5	29
328	Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosineâ€“prostaglandin E2cooperation. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1203-1214.	1.4	24
329	Outcomes of Transoral Robotic Surgery. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 145, 248-253.	1.1	93
330	HPV-Associated Head and Neck Cancer: Molecular and Nano-Scale Markers for Prognosis and Therapeutic Stratification. <i>Sensors</i> , 2012, 12, 5159-5169.	2.1	13
331	Indications for Adjuvant Chemotherapy and Radiation Therapy. , 2012, , 445-449.		1
332	Immunological Treatment Options for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. <i>International Reviews of Immunology</i> , 2012, 31, 22-42.	1.5	10
333	A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2012, 18, 1735-1742.	3.2	16
334	Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1798-1807.	3.2	56
335	Oropharyngeal cancer â€“ is it time to change management according to human papilloma virus status?. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2012, 20, 120-124.	0.8	44
336	New promising molecular targets in head and neck squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2012, 24, 235-242.	1.1	31
337	Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1404-1414.	3.2	77

#	ARTICLE	IF	CITATIONS
338	Epigenetic Disregulation in Oral Cancer. <i>International Journal of Molecular Sciences</i> , 2012, 13, 2331-2353.	1.8	107
342	Squamous Cell Carcinomas of the Head and Neck in Fanconi Anemia: Risk, Prevention, Therapy, and the Need for Guidelines. <i>Klinische Padiatrie</i> , 2012, 224, 132-138.	0.2	35
343	Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy. <i>Current Molecular Medicine</i> , 2012, 12, 788-803.	0.6	5
344	An approach to identify, from DCE MRI, significant subvolumes of tumors related to outcomes in	1.6	59
345	Human Papillomavirus Outcomes in an Access-to-Care Laryngeal Cancer Cohort. <i>Otolaryngology - Head and Neck Surgery</i> , 2012, 146, 730-738.	1.1	49
346	Benefit of chemotherapy as part of treatment for HPV DNA-positive but p16-negative squamous cell carcinoma of the oropharynx. <i>British Journal of Cancer</i> , 2012, 106, 358-365.	2.9	30
347	Biomarkers of HPV in Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2012, 72, 5004-5013.	0.4	122
348	Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16-Positive and p16-Negative Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2102-2111.	0.8	447
349	Human papillomavirus infection and esophageal cancer: a case report. <i>Medwave</i> , 2012, 12, e5531-e5531.	0.2	0
350	Reply to P. Bossi et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 565-567.	0.8	3
351	Recent Advances in Biomarkers and Potential Targeted Therapies in Head and Neck Squamous Cell Carcinoma. <i>ISRN Surgery</i> , 2012, 2012, 1-7.	1.4	4
352	EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab. <i>Chemotherapy Research and Practice</i> , 2012, 2012, 1-10.	1.6	7
353	Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma. <i>Carcinogenesis</i> , 2012, 33, 1707-1716.	1.3	31
354	The Prevalence and Incidence of Oral Human Papillomavirus Infection Among Young Men and Women, Aged 18-30 Years. <i>Sexually Transmitted Diseases</i> , 2012, 39, 559-566.	0.8	143
355	The distribution of human papillomavirus in tissues from patients with head and neck squamous cell carcinoma. <i>Oncology Reports</i> , 2012, 28, 1750-1756.	1.2	26
356	Assessment of Fine Needle Aspiration Specimen Adequacy for High-Risk HPV Detection and Genotyping in Oropharyngeal Squamous Cell Carcinoma. <i>Acta Cytologica</i> , 2012, 56, 196-198.	0.7	37
357	Oral and dental management for head and neck cancer patients treated by chemotherapy and radiotherapy. <i>Dental Update</i> , 2012, 39, 135-140.	0.1	28
358	Detection of Transcriptionally Active High-risk HPV in Patients With Head and Neck Squamous Cell Carcinoma as Visualized by a Novel E6/E7 mRNA In Situ Hybridization Method. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1874-1882.	2.1	308

#	ARTICLE	IF	CITATIONS
359	Validation of LOH Profiles for Assessing Oral Cancer Risk. <i>Cancer Prevention Research</i> , 2012, 5, 1075-1077.	0.7	8
360	HPV Analysis in Distinguishing Second Primary Tumors From Lung Metastases in Patients With Head and Neck Squamous Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 142-148.	2.1	84
361	Malignant Transformation From Benign Papillomatosis of the External Auditory Canal. <i>Otology and Neurotology</i> , 2012, 33, 643-647.	0.7	17
362	Validation of Methods for Oropharyngeal Cancer HPV Status Determination in US Cooperative Group Trials. <i>American Journal of Surgical Pathology</i> , 2012, 36, 945-954.	2.1	333
363	Evaluation of ProExC as a Prognostic Marker in Oropharyngeal Squamous Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1158-1164.	2.1	11
364	HPV-associated Neuroendocrine Carcinoma of the Oropharynx. <i>American Journal of Surgical Pathology</i> , 2012, 36, 321-330.	2.1	102
366	Retrospective Review of Positron Emission Tomography With Contrast-Enhanced Computed Tomography in the Posttreatment Setting in Human Papillomavirus-Associated Oropharyngeal Carcinoma. <i>JAMA Otolaryngology</i> , 2012, 138, 1040.	1.5	38
368	Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy. <i>Oncology Reports</i> , 2012, 27, 1580-6.	1.2	7
369	Non-Cancer-Related Deaths From Suicide, Cardiovascular Disease, and Pneumonia in Patients With Oral Cavity and Oropharyngeal Squamous Carcinoma. <i>JAMA Otolaryngology</i> , 2012, 138, 25.	1.5	29
370	Epigenetic and genetic alterations-based molecular classification of head and neck cancer. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 279-290.	1.5	17
371	Easing acceleration of head and neck chemoradiotherapy. <i>Lancet Oncology</i> , The, 2012, 13, 113-115.	5.1	6
372	VEGF Trap for the treatment of malignant ascites. <i>Lancet Oncology</i> , The, 2012, 13, 115-116.	5.1	10
373	Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2012, 122, 2762-2768.	1.1	20
374	Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 291-298.	0.4	168
375	Primary Tumor Volume Is an Important Predictor of Clinical Outcomes Among Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck Treated With Definitive Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1823-1830.	0.4	103
376	Phase II Study Evaluating the Addition of Cetuximab to the Concurrent Delivery of Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy for Patients With Locally Advanced Squamous Cell Carcinomas of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1845-1850.	0.4	31
377	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Predictor of Outcome in Head-and-Neck Squamous Cell Carcinoma Patients With Nodal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1837-1844.	0.4	137
378	Prognostic Significance of p16 Expression in Advanced Cervical Cancer Treated With Definitive Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 153-157.	0.4	28



#	ARTICLE	IF	CITATIONS
379	Enteral Feeding Tubes in Patients Undergoing Definitive Chemoradiation Therapy for Head-and-Neck Cancer: A Critical Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 581-589.	0.4	77
380	HPV Genotypes Predict Survival Benefits From Concurrent Chemotherapy and Radiation Therapy in Advanced Squamous Cell Carcinoma of the Cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e499-e506.	0.4	24
381	p16 <sup>INK4a</sup> is a Marker of Good Prognosis for Primary Invasive Penile Squamous Cell Carcinoma: A Multi-Institutional Study. <i>Journal of Urology</i> , 2012, 187, 899-907.	0.2	68
382	De-intensification of treatment for human papilloma virus associated oropharyngeal squamous cell carcinoma: A discussion of current approaches. <i>Practical Radiation Oncology</i> , 2012, 2, 282-287.	1.1	8
384	Economic Impact of Human Papillomavirus-Associated Head and Neck Cancers in the United States. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, 899-917.	0.5	8
385	Transoral Endoscopic Surgery. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, 823-844.	0.5	37
386	Treatment Deintensification Strategies for HPV-Associated Head and Neck Carcinomas. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, 845-861.	0.5	44
387	Exfoliated cells of the oral mucosa for HPV typing by SPF10 in head and neck cancer. <i>Journal of Virological Methods</i> , 2012, 186, 99-103.	1.0	8
389	HPV et cancer ORL. <i>Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale</i> , 2012, 129, 32-38.	0.0	1
390	Impact of HPV-Related Head and Neck Cancer in Clinical Trials. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, 795-806.	0.5	16
391	Scoring and classification of oropharyngeal carcinoma based on HPV-related p16-expression. <i>Radiotherapy and Oncology</i> , 2012, 105, 269-270.	0.3	25
392	Detection of Human Papillomavirus in Clinical Samples. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, 765-777.	0.5	28
393	Next-Generation Sequencing for Simultaneous Determination of Human Papillomavirus Load, Subtype, and Associated Genomic Copy Number Changes in Tumors. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 104-111.	1.2	50
394	The Psychosocial Care Needs of Patients with HPV-Related Head and Neck Cancer. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, 879-897.	0.5	23
395	Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival. <i>Clinical Cancer Research</i> , 2012, 18, 1257-1267.	3.2	77
396	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. <i>Radiotherapy and Oncology</i> , 2012, 103, 49-56.	0.3	167
397	Morphology, DNA ploidy and HPV in lung cancer and head and neck cancer. <i>Pathology Research and Practice</i> , 2012, 208, 1-8.	1.0	8
398	mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas. <i>Clinical Cancer Research</i> , 2012, 18, 2558-2568.	3.2	159



#	ARTICLE	IF	CITATIONS
399	Biomarkers of HPV Infection in Oropharyngeal Carcinomas: Can We Find Simplicity in the Puzzle of Complexity?. <i>Cancer Research</i> , 2012, 72, 4896-4898.	0.4	4
400	Changing trends in human papillomavirus-associated head and neck squamous cell carcinoma. <i>Annals of Diagnostic Pathology</i> , 2012, 16, 7-12.	0.6	26
401	Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma?. <i>Annals of Diagnostic Pathology</i> , 2012, 16, 91-99.	0.6	77
402	Incidence of human papillomavirus in oropharyngeal squamous cell carcinomas: now and 50 years ago. <i>Human Pathology</i> , 2012, 43, 17-22.	1.1	36
403	HPV genotypes and their prognostic significance in head and neck squamous cell carcinomas. <i>Journal of Clinical Virology</i> , 2012, 53, 116-120.	1.6	47
404	An unusual human papillomavirus type 82 detection in laryngeal squamous cell carcinoma: Case report and review of literature. <i>Journal of Clinical Virology</i> , 2012, 54, 190-193.	1.6	12
405	HPV DNA, E6*I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer – How valid is p16INK4A as surrogate marker?. <i>Cancer Letters</i> , 2012, 323, 88-96.	3.2	79
407	Viral RNA Patterns and High Viral Load Reliably Define Oropharynx Carcinomas with Active HPV16 Involvement. <i>Cancer Research</i> , 2012, 72, 4993-5003.	0.4	152
408	Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. <i>Head and Neck</i> , 2012, 34, 1681-1703.	0.9	90
409	Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer. <i>Laryngoscope</i> , 2012, 122, S13-33.	1.1	133
410	Oral sex, cancer and death: sexually transmitted cancers. <i>Head &amp; Neck Oncology</i> , 2012, 4, 31.	2.3	10
411	Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma. <i>Cancer Science</i> , 2012, 103, 2127-2134.	1.7	44
412	Human Papillomavirus and Diseases of the Upper Airway: Head and Neck Cancer and Respiratory Papillomatosis. <i>Vaccine</i> , 2012, 30, F34-F54.	1.7	228
413	Epidemiology of Mucosotropic Papillomaviruses. <i>Monographs in Virology</i> , 2012, , 12-18.	0.6	0
414	Virology and molecular pathogenesis of HPV (human papillomavirus)associated oropharyngeal squamous cell carcinoma. <i>Biochemical Journal</i> , 2012, 443, 339-353.	1.7	60
415	Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1149-1159.	1.1	51
417	Squamous cell carcinoma of buccal mucosa: a 40-year review. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2012, 33, 673-677.	0.6	34
418	HPV and head and neck cancer. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2012, 129, 26-31.	0.4	29

#	ARTICLE	IF	CITATIONS
419	Pre-therapeutic histological and cytological assessment in head and neck squamous cell carcinomas. French Society of Otorhinolaryngology Guidelines 2012. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2012, 129, 319-326.	0.4	6
420	HPV infection in Brazilian patients with esophageal squamous cell carcinoma: Interpopulational differences, lack of correlation with surrogate markers and clinicopathological parameters. <i>Cancer Letters</i> , 2012, 326, 52-58.	3.2	29
421	Current issues in combined modality therapy in locally advanced head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 261-273.	2.0	20
422	Oropharynx Cancer. <i>Current Problems in Cancer</i> , 2012, 36, 334-415.	1.0	5
423	Frequency and genotype distribution of multiple human papillomavirus infections in cancer of the head and neck in a Mexican population. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012, 114, 350-357.	0.2	7
424	The value of tumor diameter in predicting prognosis of oropharynx cancer treated with chemoradiation. <i>Oral Oncology</i> , 2012, 48, 876-880.	0.8	2
425	Human papillomavirus and p16 detection in cervical lymph node metastases from an unknown primary tumor. <i>Oral Oncology</i> , 2012, 48, 1250-1256.	0.8	38
426	Human papillomavirus related head and neck cancer survival: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2012, 48, 1191-1201.	0.8	356
427	The future of induction chemotherapy for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2012, 48, 1065-1067.	0.8	18
428	Different cellular p16INK4a localisation may signal different survival outcomes in head and neck cancer. <i>British Journal of Cancer</i> , 2012, 107, 482-490.	2.9	39
430	HPV Positive Squamous Cell Carcinoma of the Oropharynx. Are we Observing an Unusual Pattern of Metastases?. <i>Head and Neck Pathology</i> , 2012, 6, 336-344.	1.3	64
431	Equivocal p16 Immunostaining in Squamous Cell Carcinoma of the Head and Neck: Staining Patterns are Suggestive of HPV Status. <i>Head and Neck Pathology</i> , 2012, 6, 422-429.	1.3	44
432	Long-term Functional and Oncologic Results of Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. <i>Mayo Clinic Proceedings</i> , 2012, 87, 219-225.	1.4	241
434	Prognostic value of pretreatment 18F-FDG PET/CT and human papillomavirus type 16 testing in locally advanced oropharyngeal squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1673-1684.	3.3	49
435	The relationship between <i>Helicobacter pylori</i> infection and the effects of chemotherapy in patients with advanced or metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 555-558.	1.1	24
436	3 Pathophysiology of Kallikrein-related Peptidases in Head and Neck Cancer. , 2012, , 45-60.		0
437	Epidemiology of Human Papillomavirus-Related Head and Neck Cancer. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, 739-764.	0.5	89
438	Partial p16 staining in oropharyngeal squamous cell carcinoma: extent and pattern correlate with human papillomavirus RNA status. <i>Modern Pathology</i> , 2012, 25, 1212-1220.	2.9	129

#	ARTICLE	IF	CITATIONS
439	Molecular Characterization of Head and Neck Cancer. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 209-222.	1.6	22
440	Tumor Infiltrating CD8+ and Foxp3+ Lymphocytes Correlate to Clinical Outcome and Human Papillomavirus (HPV) Status in Tonsillar Cancer. <i>PLoS ONE</i> , 2012, 7, e38711.	1.1	169
441	The Association between Genetic Polymorphism and the Processing Efficiency of miR-149 Affects the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2012, 7, e51606.	1.1	51
442	Complex Etiology Underlies Risk and Survival in Head and Neck Cancer Human Papillomavirus, Tobacco, and Alcohol: A Case for Multifactor Disease. <i>Journal of Oncology</i> , 2012, 2012, 1-9.	0.6	103
443	Oral Cavity and Pharynx Cancer Incidence Trends by Subsite in the United States: Changing Gender Patterns. <i>Journal of Oncology</i> , 2012, 2012, 1-10.	0.6	55
444	Significance of p16 in site-specific HPV positive and HPV negative HNSCC. <i>Cancer and Clinical Oncology</i> , 2012, 2, 51-61.	0.2	92
445	The molecular pathogenesis of head and neck squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2012, 122, 1951-1957.	3.9	298
446	New Concepts for Translational Head and Neck Oncology: Lessons from HPV-Related Oropharyngeal Squamous Cell Carcinomas. <i>Frontiers in Oncology</i> , 2012, 2, 36.	1.3	34
447	Tonsillar Cancer. <i>Monographs in Virology</i> , 2012, , 79-87.	0.6	0
448	Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab. <i>Clinical Medicine Insights Ear, Nose and Throat</i> , 2012, 5, CMENT.S5129.	1.5	17
450	Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go?. <i>Reviews in Medical Virology</i> , 2012, 22, 88-105.	3.9	31
451	TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome. <i>Laryngoscope</i> , 2012, 122, 1043-1050.	1.1	25
452	Polymorphisms in <i>GSTM1</i> and <i>XPD</i> genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy. <i>Molecular Carcinogenesis</i> , 2012, 51, E94-103.	1.3	25
453	The role of cytopathology in diagnosing HPV induced oropharyngeal lesions. <i>Diagnostic Cytopathology</i> , 2012, 40, 839-843.	0.5	12
454	Cytomorphologic diagnosis and HPV testing of metastatic and primary oropharyngeal squamous cell carcinomas: A review and summary of the literature. <i>Diagnostic Cytopathology</i> , 2012, 40, 491-497.	0.5	18
455	Tobacco carcinogen metabolites and DNA adducts as biomarkers in Head and Neck cancer: Potential screening tools and prognostic indicators. <i>Head and Neck</i> , 2012, 34, 441-447.	0.9	33
456	Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. <i>Head and Neck</i> , 2012, 34, 1147-1152.	0.9	54
457	Surgical management of T1 oropharyngeal carcinoma. <i>Head and Neck</i> , 2012, 34, 1277-1282.	0.9	19

#	ARTICLE	IF	CITATIONS
458	UMâ€SCCâ€104: A New human papillomavirusâ€16â€positive cancer stem cellâ€containing head and neck squamous cell carcinoma cell line. <i>Head and Neck</i> , 2012, 34, 1480-1491.	0.9	81
459	Volumetric change of human papillomavirusâ€related neck lymph nodes before, during, and shortly after intensityâ€modulated radiation therapy. <i>Head and Neck</i> , 2012, 34, 1640-1647.	0.9	17
460	Survival in patients with human papillomavirus positive tonsillar cancer in relation to treatment. <i>International Journal of Cancer</i> , 2012, 131, 1124-1130.	2.3	21
461	Characteristics and survival of head and neck cancer by HPV status: a cancer registryâ€based study. <i>International Journal of Cancer</i> , 2012, 131, 1179-1186.	2.3	98
462	Prevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer. <i>Cancer Medicine</i> , 2012, 1, 82-88.	1.3	73
463	Novel biomarker panel predicts prognosis in human papillomavirusâ€negative oropharyngeal cancer. <i>Cancer</i> , 2012, 118, 1811-1817.	2.0	28
464	Exploring biomarkers in head and neck cancer. <i>Cancer</i> , 2012, 118, 3882-3892.	2.0	56
465	A populationâ€based study of therapy and survival for patients with head and neck cancer treated in the community. <i>Cancer</i> , 2012, 118, 4452-4461.	2.0	44
467	Current Treatment Options for Metastatic Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 35-46.	1.3	197
468	Future Directions in Research, Treatment and Prevention of HPV-Related Squamous Cell Carcinoma of the Head and Neck. <i>Head and Neck Pathology</i> , 2012, 6, 121-128.	1.3	34
469	Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer. <i>Head and Neck Pathology</i> , 2012, 6, 91-97.	1.3	11
470	Biology of Human Papillomavirus Infections in Head and Neck Carcinogenesis. <i>Head and Neck Pathology</i> , 2012, 6, 3-15.	1.3	116
471	Human Papillomavirus in Non-Oropharyngeal Head and Neck Cancers: A Systematic Literature Review. <i>Head and Neck Pathology</i> , 2012, 6, 104-120.	1.3	204
472	The Morphologic Profile of HPV-Related Head and Neck Squamous Carcinoma: Implications for Diagnosis, Prognosis, and Clinical Management. <i>Head and Neck Pathology</i> , 2012, 6, 48-54.	1.3	140
473	Radiographic Imaging of Human Papillomavirus Related Carcinomas of the Oropharynx. <i>Head and Neck Pathology</i> , 2012, 6, 25-40.	1.3	43
474	Epidemiology and Clinical Aspects of HPV in Head and Neck Cancers. <i>Head and Neck Pathology</i> , 2012, 6, 16-24.	1.3	219
476	Recognition of nonkeratinizing morphology in oropharyngeal squamous cell carcinoma â€ a prospective cohort and interobserver variability study*. <i>Histopathology</i> , 2012, 60, 427-436.	1.6	64
477	Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2012, 41, 40-46.	1.4	69

#	ARTICLE	IF	CITATIONS
478	Neighborhood deprivation and clinical outcomes among head and neck cancer patients. <i>Health and Place</i> , 2012, 18, 861-868.	1.5	40
479	Clinically Significant Human Papilloma Virus in Squamous Cell Carcinoma of the Head and Neck in UK Practice. <i>Clinical Oncology</i> , 2012, 24, e18-e23.	0.6	40
480	Association of HPV infections with second primary tumors in early-stage oral cavity cancer. <i>Oral Diseases</i> , 2012, 18, 809-815.	1.5	25
481	Human Papillomavirus as a Marker of the Natural History and Response to Therapy of Head and Neck Squamous Cell Carcinoma. <i>Seminars in Radiation Oncology</i> , 2012, 22, 128-142.	1.0	225
482	Management of Human Papillomavirus-Positive and Human Papillomavirus-Negative Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2012, 22, 194-197.	1.0	31
484	High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma. <i>Oral Oncology</i> , 2012, 48, 615-622.	0.8	52
485	Human papillomavirus as a favorable prognostic biomarker in squamous cell carcinomas of the vagina. <i>Gynecologic Oncology</i> , 2012, 125, 194-199.	0.6	45
486	Prevalence of human papillomavirus in mobile tongue cancer with particular reference to young patients. <i>Cancer Science</i> , 2012, 103, 161-168.	1.7	38
487	Human papillomavirus and gene mutations in head and neck squamous carcinomas. <i>ANZ Journal of Surgery</i> , 2012, 82, 362-366.	0.3	11
488	Management of the Neck in the Setting of Definitive Chemoradiation: Is There a Consensus? A GETTEC Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 2311-2319.	0.7	17
489	Application of the Hybrid Capture 2 assay to squamous cell carcinomas of the head and neck. <i>Cancer Cytopathology</i> , 2012, 120, 18-25.	1.4	59
490	High-risk human papillomavirus in oral squamous cell carcinoma of young patients. <i>International Journal of Cancer</i> , 2012, 130, 1726-1732.	2.3	68
491	Relationship between p53 overexpression, human papillomavirus infection, and lifestyle in Indian patients with head and neck cancers. <i>Tumor Biology</i> , 2012, 33, 543-550.	0.8	14
492	Improved survival among patients with base of tongue and tonsil cancer in the United States. <i>Cancer Causes and Control</i> , 2012, 23, 153-164.	0.8	14
494	Contemporary management of lymph node metastases from an unknown primary to the neck: II. A review of therapeutic options. <i>Head and Neck</i> , 2013, 35, 286-293.	0.9	99
495	Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2013, 35, 443-453.	0.9	33
496	Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. <i>Head and Neck</i> , 2013, 35, 294-306.	0.9	32
497	Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns. <i>Head and Neck</i> , 2013, 35, 160-164.	0.9	10

#	ARTICLE	IF	CITATIONS
498	Patient preferences for oropharyngeal cancer treatment de-escalation. <i>Head and Neck</i> , 2013, 35, 151-159.	0.9	55
499	Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer. <i>Head and Neck</i> , 2013, 35, 381-387.	0.9	16
500	A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2013, 119, 72-80.	2.0	67
501	An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center. <i>Cancer</i> , 2013, 119, 81-89.	2.0	145
502	Re: National prevalence of oral HPV infection and related risk factors in the U.S. adult population. <i>Oral Diseases</i> , 2013, 19, 107-108.	1.5	2
503	Expression of insulin-like growth factor II mRNA-binding protein 3 in squamous cell carcinomas of the head and neck. <i>Journal of Oral Pathology and Medicine</i> , 2013, 42, 125-132.	1.4	31
504	The Role of Systemic Treatment Before, During, and After Definitive Treatment. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, 645-656.	0.5	2
505	Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: patterns of failure and toxicity outcomes. <i>Radiation Oncology</i> , 2013, 8, 174.	1.2	27
506	Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. <i>Radiation Oncology</i> , 2013, 8, 21.	1.2	89
507	Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. <i>Genome Medicine</i> , 2013, 5, 15.	3.6	118
508	Human Papilloma Virus in Head and Neck Cancers—Role and Relevance in Clinical Management. <i>Indian Journal of Surgical Oncology</i> , 2013, 4, 59-66.	0.3	16
509	Human papillomavirus is independent prognostic factor on outcome of oropharyngeal squamous cell carcinoma. <i>Tumor Biology</i> , 2013, 34, 3363-3369.	0.8	8
510	Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 213-224.	2.1	32
511	High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. <i>Cancer</i> , 2013, 119, 3034-3042.	2.0	180
512	Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer. <i>Journal of Neuro-Oncology</i> , 2013, 112, 449-454.	1.4	74
513	Patterns of Disease Recurrence Following Treatment of Oropharyngeal Cancer With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 941-947.	0.4	99
514	Pitfalls in the Staging of Cancer of the Oropharyngeal Squamous Cell Carcinoma. <i>Neuroimaging Clinics of North America</i> , 2013, 23, 47-66.	0.5	17
515	Human Papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population. <i>BMC Cancer</i> , 2013, 13, 220.	1.1	74

#	ARTICLE	IF	CITATIONS
516	Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. <i>BMC Cancer</i> , 2013, 13, 26.	1.1	28
517	Cyclin D1 overexpression is associated with poor prognosis in oropharyngeal cancer. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2013, 42, 23.	0.9	24
518	Does HPV type affect outcome in oropharyngeal cancer?. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2013, 42, 9.	0.9	52
519	Is open surgery for head and neck cancers truly declining?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 2793-2802.	0.8	24
520	Prognostic biological features in neck dissection specimens. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 1581-1592.	0.8	48
521	Evidence That Alpha-9 Human Papillomavirus Infections are a Major Etiologic Factor for Oropharyngeal Carcinoma in Black South Africans. <i>Head and Neck Pathology</i> , 2013, 7, 361-372.	1.3	12
522	Spindle Cell Carcinomas of the Head and Neck Rarely Harbor Transcriptionally-Active Human Papillomavirus. <i>Head and Neck Pathology</i> , 2013, 7, 250-257.	1.3	35
523	Detection of HPV infection in head and neck squamous cell carcinoma: a practical proposal. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 381-389.	1.4	37
524	Pretreatment weight status and weight loss among head and neck cancer patients receiving definitive concurrent chemoradiation therapy: implications for nutrition integrated treatment pathways. <i>Supportive Care in Cancer</i> , 2013, 21, 2825-2833.	1.0	30
525	Epidemiology of Oral-Cavity and Oropharyngeal Carcinomas. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, 507-520.	0.5	35
526	Detection of Human Papillomavirus in biopsies of patients with cervical cancer, and its association with prognosis. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 643-648.	0.8	23
527	Promising New Molecular Targeted Therapies in Head and Neck Cancer. <i>Drugs</i> , 2013, 73, 315-325.	4.9	81
528	Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review. <i>Journal of Medical Economics</i> , 2013, 16, 763-776.	1.0	17
529	Impact of the HPV-positivity definition on the prognostic value of HPV status in patients with locally advanced squamous cell carcinoma of the head and neck. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 856-860.	1.0	14
530	Oral HPV infection and persistence in patients with head and neck cancer. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013, 116, 474-484.	0.2	18
531	Current role of human papillomavirus in head and neck oncology. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 260-261.	2.2	2
532	Two-Year and Lifetime Cost-Effectiveness of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 683-689.	0.4	27
533	The Prognostic Significance of the Biomarker p16 in Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Oncology</i> , 2013, 25, 630-638.	0.6	53



#	ARTICLE	IF	CITATIONS
534	Special Groups. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, 1123-1136.	0.5	13
535	Impact of Human Papillomavirus on Oropharyngeal Cancer Biology and Response to Therapy. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, 521-543.	0.5	49
536	Evaluation and Staging of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, 599-613.	0.5	16
537	Survivorship—Competing Mortalities, Morbidities, and Second Malignancies. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, 681-710.	0.5	12
538	Highly aggressive human papillomavirus-related oropharyngeal cancer: clinical, radiologic, and pathologic characteristics. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013, 116, 327-335.	0.2	32
539	Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells. <i>Radiotherapy and Oncology</i> , 2013, 108, 500-505.	0.3	95
540	Accurate HPV testing: a requirement for precision medicine for head and neck cancer. <i>Annals of Oncology</i> , 2013, 24, 2711-2713.	0.6	24
541	Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. <i>Annals of Oncology</i> , 2013, 24, 2740-2745.	0.6	172
542	MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2013, 49, 211-215.	0.8	305
543	Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers. <i>Journal of Clinical Oncology</i> , 2013, 31, 4550-4559.	0.8	1,046
544	Current status and future directions in induction chemotherapy for head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 57-74.	2.0	10
545	Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients. <i>International Journal of Cancer</i> , 2013, 133, 1994-2003.	2.3	45
546	Head and Neck Cancer Stem Cells. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 149, 252-260.	1.1	50
548	Aurora kinases in head and neck cancer. <i>Lancet Oncology</i> , The, 2013, 14, e425-e435.	5.1	55
549	Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. <i>Genome Medicine</i> , 2013, 5, 49.	3.6	188
550	Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma. <i>Radiation Oncology</i> , 2013, 8, 173.	1.2	8
551	Prognostic utility of basaloid differentiation in oropharyngeal cancer. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2013, 42, 57.	0.9	20
552	Histological subtypes and characteristic structures of HPV-associated oropharyngeal carcinoma; study with Japanese cases. <i>Diagnostic Pathology</i> , 2013, 8, 211.	0.9	10

#	ARTICLE	IF	CITATIONS
553	Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. <i>Virology Journal</i> , 2013, 10, 334.	1.4	14
554	Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1821-1830.	2.0	18
555	HPV Status of Oropharyngeal Cancer by Combination HPV DNA/p16 Testing: Biological Relevance of Discordant Results. <i>Annals of Surgical Oncology</i> , 2013, 20, 450-458.	0.7	26
556	Extracapsular spread in head and neck carcinoma: Impact of site and human papillomavirus status. <i>Cancer</i> , 2013, 119, 3302-3308.	2.0	159
557	Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2013, 119, 3462-3471.	2.0	86
558	Prognostic value of p16 expression and alcohol consumption in Japanese patients with oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2013, 119, 2005-2011.	2.0	36
559	Transoral robotic surgery and adjuvant therapy for oropharyngeal carcinomas and the influence of p16 <sup>INK4a</sup> on treatment outcomes. <i>Laryngoscope</i> , 2013, 123, 635-640.	1.1	44
560	p16 Expression in cutaneous squamous carcinomas with neck metastases: A potential pitfall in identifying unknown primaries of the head and neck. <i>Head and Neck</i> , 2013, 35, 1527-1533.	0.9	50
561	Acquired disorders of the thyroid following treatment for head and neck cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 461-467.	1.2	0
562	p16 immunohistochemistry alone is a better prognosticator in tonsil cancer than human papillomavirus in situ hybridization with or without p16 immunohistochemistry. <i>Acta Oto-Laryngologica</i> , 2013, 133, 297-304.	0.3	20
563	A phase 2 trial of induction nab <sup>pa</sup> and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2013, 119, 766-773.	2.0	31
564	Cutaneous Squamous Cell Carcinoma and Human Papillomavirus: Is There an Association?. <i>Dermatologic Surgery</i> , 2013, 39, 1-23.	0.4	91
565	PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer. <i>Cancer Research</i> , 2013, 73, 128-138.	0.4	554
566	Human Papillomavirus-16 Associated Adenocarcinoma NOS of Base of Tongue. <i>Head and Neck Pathology</i> , 2013, 7, 268-273.	1.3	20
567	Is human papillomavirus involved in laryngeal neuroendocrine carcinoma?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 719-725.	0.8	23
568	Prognostic impact of human papilloma virus (HPV) genotyping and HPV-16 subtyping in vaginal carcinoma. <i>Gynecologic Oncology</i> , 2013, 129, 406-411.	0.6	38
569	A new paradigm for the diagnosis and management of unknown primary tumors of the head and neck: A role for transoral robotic surgery. <i>Laryngoscope</i> , 2013, 123, 146-151.	1.1	135
570	Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer. <i>Laryngoscope</i> , 2013, 123, 152-157.	1.1	44

#	ARTICLE	IF	CITATIONS
571	Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16 positivity. <i>Laryngoscope</i> , 2013, 123, 164-170.	1.1	57
573	Head and neck cancer in the south west of England, Hampshire, and the Isle of Wight: trends in survival 1996-2008. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2013, 51, 19-24.	0.4	17
574	CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. <i>European Journal of Cancer</i> , 2013, 49, 2522-2530.	1.3	171
575	Anaesthesia for DaVinci assisted intraoral and tongue base operations. <i>Trends in Anaesthesia and Critical Care</i> , 2013, 3, 342-345.	0.4	2
576	Discussing the diagnosis of HPV-OSCC: Common questions and answers. <i>Oral Oncology</i> , 2013, 49, 863-871.	0.8	71
577	Le papillomavirus n'attaque pas que les femmes. <i>Revue Francophone Des Laboratoires</i> , 2013, 2013, 50-53.	0.0	0
578	Head and Neck Cancer. <i>Seminars in Roentgenology</i> , 2013, 48, 75-86.	0.2	22
579	The role of human papillomavirus in nongenital cancers. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 57-81.	157.7	178
580	Validation of a novel diagnostic standard in HPV-positive oropharyngeal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 1332-1339.	2.9	146
581	Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. <i>Histopathology</i> , 2013, 62, 161-175.	1.6	206
582	Matched-Pair Analysis in Patients with Advanced Oropharyngeal Cancer: Surgery versus Concurrent Chemoradiotherapy. <i>Oncology</i> , 2013, 84, 290-298.	0.9	20
583	Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. <i>Cell Cycle</i> , 2013, 12, 923-934.	1.3	48
584	Assessing oral brushing technique as a source to collect DNA and its use in detecting human papillomavirus. <i>Pathology Research and Practice</i> , 2013, 209, 291-295.	1.0	11
585	Immunotherapy for head and neck cancer patients: shifting the balance. <i>Immunotherapy</i> , 2013, 5, 49-61.	1.0	20
586	Staging and Risk Stratification in Penile Cancer. , 2013, , 11-42.		0
587	Nongenital Human Papillomavirus Disease. <i>Obstetrics and Gynecology Clinics of North America</i> , 2013, 40, 317-337.	0.7	4
588	Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. <i>International Journal of Cancer</i> , 2013, 133, 1389-1399.	2.3	55
589	Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients. <i>Lung Cancer</i> , 2013, 79, 215-220.	0.9	30

#	ARTICLE	IF	CITATIONS
590	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 697-710.	5.1	402
591	Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: Correlation with pathologic subtypes, p16INK4a expression, and prognosis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 73-82.	0.6	91
592	Salvage surgery for recurrent oropharyngeal cancer after chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , 2013, 18, 817-823.	1.0	21
593	Improved survival of Japanese patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2013, 18, 824-828.	1.0	38
594	Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: Systematic review and meta-analysis. <i>Head and Neck</i> , 2013, 35, 1048-1055.	0.9	59
595	Lessons learned from next-generation sequencing in head and neck cancer. <i>Head and Neck</i> , 2013, 35, 454-463.	0.9	58
596	A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. <i>International Journal of Cancer</i> , 2013, 132, 882-890.	2.3	91
597	CD8 $\alpha$ T cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis. <i>International Journal of Cancer</i> , 2013, 132, E26-36.	2.3	82
599	Role of Cytology in the Diagnosis and Management of HPV-Associated Head and Neck Carcinoma. <i>Acta Cytologica</i> , 2013, 57, 117-126.	0.7	49
601	Clinical management of squamous cell carcinoma of the oropharynx: how does this differ for HPV-related tumors?. <i>Future Oncology</i> , 2013, 9, 1413-1416.	1.1	3
602	Extended survival after chemotherapy and conservative radiotherapy for HPV-16 positive stage IVB oropharyngeal carcinoma. <i>Acta Oncol<sup>3</sup>gica</i> , 2013, 52, 1236-1237.	0.8	3
603	Human papillomavirus infection a favorable prognostic factor in laryngeal squamous cell carcinoma is associated with the expression of proliferating cell nuclear antigen. <i>Pakistan Journal of Medical Sciences</i> , 2013, 29, 1173-7.	0.3	4
604	Epigenetic Modulation of Signal Transduction Pathways in HPV-Associated HNSCC. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 149, 409-416.	1.1	32
605	Integrated virus-host methylome analysis in head and neck squamous cell carcinoma. <i>Epigenetics</i> , 2013, 8, 953-961.	1.3	31
606	A 13-Gene Signature Prognostic of HPV-Negative OSCC: Discovery and External Validation. <i>Clinical Cancer Research</i> , 2013, 19, 1197-1203.	3.2	124
607	Oral human papillomavirus infection and head and neck cancers in HIV-infected individuals. <i>Current Opinion in Oncology</i> , 2013, 25, 503-510.	1.1	81
608	Controversies in Treatment Deintensification of Human Papillomavirus-Associated Oropharyngeal Carcinomas: Should We, How Should We, and for Whom?. <i>Journal of Clinical Oncology</i> , 2013, 31, 520-522.	0.8	45
609	Improved Survival with HPV among African Americans with Oropharyngeal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 2486-2492.	3.2	58

#	ARTICLE	IF	CITATIONS
610	Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study. <i>Clinical Cancer Research</i> , 2013, 19, 2528-2540.	3.2	27
611	High-Risk Human Papillomavirus Detection in Oropharyngeal, Nasopharyngeal, and Oral Cavity Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013, 139, 1320.	1.2	93
612	ERCC1 Protein Expression Is Associated with Differential Survival in Oropharyngeal Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 149, 587-595.	1.1	12
613	A Patient-Centered Approach to Counseling Patients With Head and Neck Cancer Undergoing Human Papillomavirus Testing: A Clinician's Guide. <i>Oncologist</i> , 2013, 18, 180-189.	1.9	43
614	HPV Prevalence and Prognostic Value in a Prospective Cohort of 255 Patients with Locally Advanced HNSCC: A Single-Centre Experience. <i>International Journal of Otolaryngology</i> , 2013, 2013, 1-9.	1.0	23
616	Comprehensive Analysis of DNA Methylation in Head and Neck Squamous Cell Carcinoma Indicates Differences by Survival and Clinicopathologic Characteristics. <i>PLoS ONE</i> , 2013, 8, e54742.	1.1	46
617	Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation. <i>Head and Neck</i> , 2013, 35, 1698-1706.	0.9	41
618	Definitive radiation therapy without chemotherapy for human papillomavirus-positive head and neck cancer. <i>Head and Neck</i> , 2013, 35, 1652-1656.	0.9	37
619	Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients. <i>Oral Diseases</i> , 2013, 19, 577-584.	1.5	32
620	Nodal status is not a prognostic factor in patients with HPV-positive oral/oropharyngeal tumors. <i>Journal of Surgical Oncology</i> , 2013, 107, 625-633.	0.8	54
621	Human papillomavirus, smoking status and outcomes in tonsillar squamous cell carcinoma. <i>International Journal of Cancer</i> , 2013, 132, 2748-2754.	2.3	71
622	Prediction of Posttreatment Significant Body Weight Loss and Its Correlation with Disease-Free Survival in Patients with Oral Squamous Cell Carcinomas. <i>Nutrition and Cancer</i> , 2013, 65, 417-423.	0.9	21
623	Phospho-Rb (Ser780) as a biomarker in patients with cervical lymph node metastases from an unknown primary tumour: a retrospective cohort study. <i>Clinical Otolaryngology</i> , 2013, 38, 313-321.	0.6	4
624	Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma. <i>Cancer Medicine</i> , 2013, 2, 933-941.	1.3	27
625	Transoral Robotic Surgery Experience in 44 Cases. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2013, 23, 900-907.	0.5	36
626	Textural Features of Pretreatment <sup>18</sup> F-FDG PET/CT Images: Prognostic Significance in Patients with Advanced T-Stage Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1703-1709.	2.8	136
627	P16 <sup>INK4A</sup> as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: Consideration of some aspects. <i>Cancer Science</i> , 2013, 104, 1553-1559.	1.7	44
628	The effect of young age on outcomes in head and neck cancer. <i>Laryngoscope</i> , 2013, 123, 1896-1902.	1.1	8

#	ARTICLE	IF	CITATIONS
629	The Effect of tumor subsite on short-term outcomes and costs of care after oral cancer surgery. <i>Laryngoscope</i> , 2013, 123, 1652-1659.	1.1	22
630	Distinct Epidemiologic Characteristics of Oral Tongue Cancer Patients. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 148, 792-796.	1.1	35
631	Enhanced Radiation Sensitivity in HPV-Positive Head and Neck Cancer. <i>Cancer Research</i> , 2013, 73, 4791-4800.	0.4	317
632	Molecular genetic characterization of p53 mutated oropharyngeal squamous cell carcinoma cells transformed with human papillomavirus E6 and E7 oncogenes. <i>International Journal of Oncology</i> , 2013, 43, 383-393.	1.4	18
633	Relevance of infection with human papillomavirus: The role of the p53 tumor suppressor protein and E6/E7 zinc finger proteins. <i>International Journal of Oncology</i> , 2013, 43, 1754-1762.	1.4	57
634	Human Papillomavirus-related Carcinomas of the Sinonasal Tract. <i>American Journal of Surgical Pathology</i> , 2013, 37, 185-192.	2.1	247
635	Intranodal Cystic Changes. <i>Journal of Computer Assisted Tomography</i> , 2013, 37, 343-345.	0.5	39
636	Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck. <i>Experimental and Therapeutic Medicine</i> , 2013, 5, 1247-1253.	0.8	24
638	Molecular epidemiology of DNA repair gene polymorphisms and head and neck cancer. <i>Journal of Biomedical Research</i> , 2013, 27, 179-92.	0.7	30
640	B. Aerodigestive Neoplasms of the Head and Neck: Oropharynx Cancer. , 2013, , .		0
641	Human Papilloma Virus Infection in Head and Neck Cancer. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2013, 110, 184-90, 190e1.	0.6	30
642	Pre-Treatment Levels of C-Reactive Protein and Squamous Cell Carcinoma Antigen for Predicting the Aggressiveness of Pharyngolaryngeal Carcinoma. <i>PLoS ONE</i> , 2013, 8, e55327.	1.1	19
643	Oral cancer, HPV infection and evidence of sexual transmission. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2013, 18, e439-e444.	0.7	49
644	The Correlation between Chronic Periodontitis and Oral Cancer. <i>Case Reports in Dentistry</i> , 2013, 2013, 1-8.	0.2	25
645	The Role of Human Papillomavirus in Pre-Cancerous Lesions and Oral Cancers. , 0, , .		1
647	Transoral Surgery Alone for Human-Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma. <i>Ear, Nose and Throat Journal</i> , 2013, 92, 76-83.	0.4	57
648	Basaloid squamous cell carcinoma of oral cavity with incongruent clinical course. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013200441-bcr2013200441.	0.2	11
649	HPV and methylation indicators in paired tumor and saliva in HNSCC. <i>Cancer and Clinical Oncology</i> , 2013, 2, .	0.2	4



#	ARTICLE	IF	CITATIONS
650	Surgery in the HPV Era: The Role of Robotics and Microsurgical Techniques. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 154-159.	1.8	11
651	Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib. OncoTargets and Therapy, 2014, 7, 245.	1.0	8
652	Histopathologic risk factors in oral and oropharyngeal squamous cell carcinoma variants: An update with special reference to HPV-related carcinomas. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2014, 19, e377-e385.	0.7	28
653	Expression Microarray Analysis Reveals Alternative Splicing of LAMA3 and DST Genes in Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e91263.	1.1	35
654	Prognostic Significance of Overexpressed p16INK4a in Patients with Cervical Cancer: A Meta-Analysis. PLoS ONE, 2014, 9, e106384.	1.1	46
655	The Prognostic Value of HPV Status and p16 Expression in Patients with Carcinoma of the Anal Canal. PLoS ONE, 2014, 9, e108790.	1.1	28
656	Establishment of a Tongue Squamous Cell Carcinoma Cell Line from Indian Gutka Chewer. Journal of Oral Oncology, 2014, 2014, 1-9.	0.0	6
657	HPV Infection in Esophageal Squamous Cell Carcinoma and Its Relationship to the Prognosis of Patients in Northern China. Scientific World Journal, The, 2014, 2014, 1-9.	0.8	39
658	Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review. World Journal of Clinical Cases, 2014, 2, 172.	0.3	45
659	An updated overview of HPV-associated head and neck carcinomas. Oncotarget, 2014, 5, 3956-3969.	0.8	107
660	Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States. Emerging Infectious Diseases, 2014, 20, 822-828.	2.0	88
661	Epithelial-mesenchymal transition in human papillomavirus-positive and -negative oropharyngeal squamous cell carcinoma. Oncology Reports, 2014, 32, 2673-2679.	1.2	15
662	Differences in Oral Sexual Behaviors by Gender, Age, and Race Explain Observed Differences in Prevalence of Oral Human Papillomavirus Infection. PLoS ONE, 2014, 9, e86023.	1.1	173
663	La infecci3n por virus del papiloma humano afecta el pron3stico del c4ncer orofar4ngeo escamocelular. Revisi3n de la literatura / Human Papillomavirus Infection Affects Squamous Oropharyngeal Cancer Prognosis. Literature Review. Universitas Odontologica: Revista Cientifica De La Facultad De Odontologica, 2014, 33, 67.	0.2	3
664	Transoral Robotic Surgery and Oropharyngeal Cancer: A Literature Review. Ear, Nose and Throat Journal, 2014, 93, E14-E21.	0.4	14
665	p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary. Head and Neck, 2014, 36, 1677-1684.	0.9	91
666	Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes. Radiation Oncology, 2014, 9, 255.	1.2	39
667	Prognostic value of human papillomavirus in anal squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 2014, 74, 1033-1038.	1.1	22



#	ARTICLE	IF	CITATIONS
668	Transcervical Ultrasound Identifies Primary Tumor Site of Unknown Primary Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 1090-1092.	1.1	17
669	Tumour-infiltrating lymphocytes in the risk stratification of squamous cell carcinoma of the head and neck. <i>British Journal of Cancer</i> , 2014, 110, 269-270.	2.9	13
670	Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. <i>British Journal of Cancer</i> , 2014, 110, 489-500.	2.9	326
671	The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2014, 25, 2101-2115.	0.6	70
672	p16INK4a Impairs Homologous Recombination-Mediated DNA Repair in Human Papillomavirus-Positive Head and Neck Tumors. <i>Cancer Research</i> , 2014, 74, 1739-1751.	0.4	99
673	Association between the standardized uptake value and high-risk HPV in hypopharyngeal squamous cell carcinoma. <i>Acta Oto-Laryngologica</i> , 2014, 134, 1062-1070.	0.3	9
674	Human Papillomavirus Genotype Prevalence in Invasive Penile Cancers from a Registry-Based United States Population. <i>Frontiers in Oncology</i> , 2014, 4, 9.	1.3	48
675	Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinoma. <i>Ecancermedalscience</i> , 2014, 8, 480.	0.6	11
676	Biological Basis for Increased Sensitivity to Radiation Therapy in HPV-Positive Head and Neck Cancers. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	33
677	Management of the neck in node-positive tonsillar cancer. <i>Acta Oto-Laryngologica</i> , 2014, 134, 1094-1100.	0.3	2
678	Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. <i>Radiology and Oncology</i> , 2014, 48, 1-10.	0.6	122
679	Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC). <i>Annals of Oncology</i> , 2014, 25, 689-694.	0.6	22
680	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma. <i>The Cochrane Library</i> , 2014, 2014, CD010271.	1.5	28
682	Predictive value of epigenetic alterations in head and neck squamous cell carcinoma. <i>Molecular and Cellular Oncology</i> , 2014, 1, e954827.	0.3	15
683	Management of Human Papillomavirus-Related Head and Neck Cancer. <i>Current Problems in Dermatology</i> , 2014, 45, 236-251.	0.8	4
684	The expanding role of cytopathology in the diagnosis of HPV-related squamous cell carcinoma of the head and neck. <i>Diagnostic Cytopathology</i> , 2014, 42, 85-93.	0.5	49
685	Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 181-186.	1.6	19
686	Upregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 25-37.	1.5	25

#	ARTICLE	IF	CITATIONS
687	Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 269-281.	0.7	31
688	Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. <i>Head and Neck</i> , 2014, 36, 511-516.	0.9	71
689	Temporal trends in oropharyngeal cancer treatment and survival: 1998-2009. <i>Laryngoscope</i> , 2014, 124, 131-138.	1.1	70
690	Chemoradiotherapy-Induced Upregulation of PD-1 Antagonizes Immunity to HPV-Related Oropharyngeal Cancer. <i>Cancer Research</i> , 2014, 74, 7205-7216.	0.4	87
691	Correlation of p16 status, hypoxic imaging using [ <sup>18</sup> F]misonidazole positron emission tomography and outcome in patients with locally advanced head and neck cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 89-97.	0.9	35
692	Human papillomavirus prevalence and prognostic implication in oropharyngeal squamous cell carcinomas. <i>Head and Neck</i> , 2014, 36, 257-265.	0.9	31
693	Predictive accuracy of first post-treatment PET/CT in HPV-related oropharyngeal squamous cell carcinoma. <i>Laryngoscope</i> , 2014, 124, 1843-1847.	1.1	44
694	Prognostic Value of FDG PET Metabolic Tumor Volume in Human Papillomavirus-Positive Stage III and IV Oropharyngeal Squamous Cell Carcinoma. <i>American Journal of Roentgenology</i> , 2014, 203, 897-903.	1.0	44
695	Swallowing outcomes in patients with oropharyngeal cancer undergoing organ-preservation treatment. <i>Head and Neck</i> , 2014, 36, 1392-1397.	0.9	35
696	Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer. <i>Head and Neck</i> , 2014, 36, 1113-1119.	0.9	7
697	Performance of the Roche cobas 4800 high-risk human papillomavirus test in cytologic preparations of squamous cell carcinoma of the head and neck. <i>Cancer Cytopathology</i> , 2014, 122, 167-174.	1.4	49
698	Human papillomavirus infections as a marker to predict overall survival in lung adenocarcinoma. <i>International Journal of Cancer</i> , 2014, 134, 65-71.	2.3	23
699	The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines. <i>Radiotherapy and Oncology</i> , 2014, 113, 345-351.	0.3	50
700	HPV-positive oropharyngeal squamous cell carcinoma is associated with <i>TIMP3</i> and <i>CADM1</i> promoter hypermethylation. <i>Cancer Medicine</i> , 2014, 3, 1185-1196.	1.3	48
701	Human papillomavirus (HPV) assays for testing fine-needle aspiration specimens in patients with head and neck squamous cell carcinoma. <i>Cancer Cytopathology</i> , 2014, 122, 92-95.	1.4	15
702	Proton Pump Inhibitors and Histamine 2 Blockers Are Associated with Improved Overall Survival in Patients with Head and Neck Squamous Carcinoma. <i>Cancer Prevention Research</i> , 2014, 7, 1258-1269.	0.7	63
703	Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma. <i>Epigenetics</i> , 2014, 9, 194-203.	1.3	80
704	Cytology and human papillomavirus testing on cytobrushing samples from patients with head and neck squamous cell carcinoma. <i>Cancer</i> , 2014, 120, 3477-3484.	2.0	18

#	ARTICLE	IF	CITATIONS
705	Saliva and Plasma Quantitative Polymerase Chain Reaction-Based Detection and Surveillance of Human Papillomavirus-Related Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 846.	1.2	181
706	Molecular Determinants of Head and Neck Cancer. , 2014, , .		2
708	Human papillomavirus-related oropharyngeal squamous cell carcinoma: a new context for dysphagia rehabilitation. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2014, 2, 231-240.	0.3	2
709	Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status. <i>BMC Cancer</i> , 2014, 14, 824.	1.1	13
710	Radiotherapy Alone or Combined With Chemotherapy for the Treatment of Squamous Cell Carcinoma of the Base of the Tongue. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 535-538.	0.6	4
711	Keratinizing-Type Squamous Cell Carcinoma of the Oropharynx. <i>American Journal of Surgical Pathology</i> , 2014, 38, 809-815.	2.1	56
712	Five-Year Outcomes of Squamous Cell Carcinoma of the Tonsil Treated With Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 57-62.	0.6	5
713	Oropharyngeal squamous cell carcinoma treatment. <i>Current Opinion in Oncology</i> , 2014, 26, 252-258.	1.1	17
714	FDG PET/CT Imaging of Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Nuclear Medicine</i> , 2014, 39, 225-231.	0.7	79
715	New Chapter in Our Understanding of Human Papillomavirus-Related Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3349-3352.	0.8	12
716	Prognostic Value of Metastatic Nodal Volume and Lymph Node Ratio in Patients with Cervical Lymph Node Metastases from an Unknown Primary Tumor. <i>Oncology</i> , 2014, 86, 170-176.	0.9	15
717	Poor Survival for American Indians with Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 265-271.	1.1	19
718	Recurrent Epistaxis and Nasal Congestion. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 73.	1.2	0
719	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2014, 113, 317-323.	0.3	141
720	Initial Symptoms in Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 441.	1.2	107
721	Transoral Robotic Surgery in the HPV Era. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0010.	0.4	16
722	Ties That Bind: p16 As a Prognostic Biomarker and the Need for High-Accuracy Human Papillomavirus Testing. <i>Journal of Clinical Oncology</i> , 2014, 32, 3914-3916.	0.8	33
723	Prognostic Impact of p16 and p53 Expression in Oropharyngeal Squamous Cell Carcinomas. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 232-240.	0.6	25

#	ARTICLE	IF	CITATIONS
724	Evidence of association of human papillomavirus with prognosis worsening in glioblastoma multiforme. <i>Neuro-Oncology</i> , 2014, 16, 298-302.	0.6	34
725	Dysphagia in head and neck cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2014, 22, 195-200.	0.8	39
727	Hybrid Capture 2 human papilloma virus testing for head and neck cytology specimens. <i>Journal of the American Society of Cytopathology</i> , 2014, 3, 173-182.	0.2	16
728	Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: A critical analysis of patterns and outcomes. <i>Oral Oncology</i> , 2014, 50, 45-51.	0.8	81
729	Prognostic factors in patients with head and neck squamous cell carcinoma with cN3 neck disease: a retrospective case-control study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 117, 178-185.	0.2	4
730	The prevalence of human papilloma virus (HPV) infections in oral squamous cell carcinomas: A retrospective analysis of 88 patients and literature overview. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2014, 42, 1506-1514.	0.7	54
731	The prognostic significance of age in oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2014, 50, 431-436.	0.8	15
732	The interplay between HPV and host immunity in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , 2014, 134, 2755-2763.	2.3	101
733	Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications. <i>European Archives of Oto-Rhino-Laryngology</i> , 2014, 271, 211-223.	0.8	25
734	Oropharyngeal cancer related to Human Papilloma Virus: incidence and prognosis in Madrid, Spain. <i>Clinical and Translational Oncology</i> , 2014, 16, 301-306.	1.2	10
735	Small Cell Neuroendocrine Carcinoma of the Oropharynx Harboring Oncogenic HPV-Infection. <i>Head and Neck Pathology</i> , 2014, 8, 127-131.	1.3	28
736	Is biomarker research advancing in the era of personalized medicine for head and neck cancer?. <i>International Journal of Clinical Oncology</i> , 2014, 19, 211-219.	1.0	21
738	The Sinonasal Tract: Another Potential "Hot Spot" for Carcinomas with Transcriptionally-Active Human Papillomavirus. <i>Head and Neck Pathology</i> , 2014, 8, 241-249.	1.3	68
739	Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer. <i>Clinical and Translational Oncology</i> , 2014, 16, 418-424.	1.2	7
741	Reduced impact of nodal metastases as a prognostic factor for tonsil cancer in the HPV era. <i>European Archives of Oto-Rhino-Laryngology</i> , 2014, 271, 2523-2529.	0.8	8
742	New treatment strategies for HPV-positive head and neck cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2014, 271, 1861-1867.	0.8	54
743	The Role of Human Papillomavirus in Oral Disease. <i>Dental Clinics of North America</i> , 2014, 58, 385-399.	0.8	38
744	What is the best treatment for patients with human papillomavirus"positive and "negative oropharyngeal cancer?. <i>Cancer</i> , 2014, 120, 1462-1470.	2.0	58

#	ARTICLE	IF	CITATIONS
745	Oral epithelial stem cellsâ€™ Implications in normal development and cancer metastasis. <i>Experimental Cell Research</i> , 2014, 325, 111-129.	1.2	41
746	HPV: A factor in organ preservation for locally advanced larynx and hypopharynx cancer?. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2014, 35, 19-24.	0.6	29
747	Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. <i>Annals of Oncology</i> , 2014, 25, 1410-1416.	0.6	89
748	Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 832-838.	1.0	13
749	Epidemiology and survival of HPVâ€™related tonsillar carcinoma. <i>Cancer Medicine</i> , 2014, 3, 652-659.	1.3	12
750	Should Patients with HPV-Positive or Negative Tumors be Treated Differently?. <i>Current Oncology Reports</i> , 2014, 16, 384.	1.8	4
751	Occult Primary Head and Neck Squamous Cell Carcinoma: Utility of Discovering Primary Lesions. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 272-278.	1.1	50
752	Demystifying the role of tumor HPV status in recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2014, 25, 760-762.	0.6	7
753	Human papilloma virus testing in oropharyngeal squamous cell carcinoma: What the clinician should know. <i>Oral Oncology</i> , 2014, 50, 1-9.	0.8	85
754	Interleukin-32 expression is associated with a poorer prognosis in head and neck squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2014, 53, 667-673.	1.3	15
755	Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. <i>British Journal of Cancer</i> , 2014, 110, 501-509.	2.9	249
756	Regulation of Interleukin-6 in Head and Neck Squamous Cell Carcinoma Is Related to Papillomavirus Infection. <i>Journal of Proteome Research</i> , 2014, 13, 1002-1011.	1.8	13
757	Comparison of carboplatinâ€™paclitaxel to docetaxelâ€™cisplatin-5â€™flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 52-58.	0.8	18
758	The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 2014, 50, 565-574.	0.8	207
759	Presence of human papillomaviruses and p16 expression in hypopharyngeal cancer. <i>Head and Neck</i> , 2014, 36, 107-112.	0.9	44
760	Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality. <i>Laryngoscope</i> , 2014, 124, 1592-1597.	1.1	49
761	Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3365-3373.	0.8	449
762	T-category Remains an Important Prognostic Factor for Oropharyngeal Carcinoma in the Era of Human Papillomavirus. <i>Clinical Oncology</i> , 2014, 26, 643-647.	0.6	4

#	ARTICLE	IF	CITATIONS
764	Fractional Change in Apparent Diffusion Coefficient as an Imaging Biomarker for Predicting Treatment Response in Head and Neck Cancer Treated with Chemoradiotherapy. American Journal of Neuroradiology, 2014, 35, 379-385.	1.2	61
765	Squamous Cell Carcinoma Variants of the Upper Aerodigestive Tract: A Comprehensive Review With a Focus on Genetic Alterations. Archives of Pathology and Laboratory Medicine, 2014, 138, 731-744.	1.2	19
766	Recommended Patient-Reported Core Set of Symptoms to Measure in Head and Neck Cancer Treatment Trials. Journal of the National Cancer Institute, 2014, 106, .	3.0	57
767	Other HPV-Associated Cancers (Oropharyngeal and Penile). , 2014, , 289-297.		0
768	Cancers in People with HIV and AIDS. , 2014, , .		2
769	North-American survey on HPV-DNA and p16 testing for head and neck squamous cell carcinoma. Oral Oncology, 2014, 50, 942-946.	0.8	21
770	Prevalence of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma in the United States Across Time. Chemical Research in Toxicology, 2014, 27, 462-469.	1.7	80
771	Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer. Oral Oncology, 2014, 50, 863-868.	0.8	20
772	Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer. Journal of Clinical Virology, 2014, 61, 94-100.	1.6	28
773	HPV-related oropharyngeal cancers: From pathogenesis to new therapeutic approaches. Cancer Letters, 2014, 351, 198-205.	3.2	37
774	Current treatment of head and neck squamous cell cancer. Journal of Surgical Oncology, 2014, 110, 551-574.	0.8	127
775	Stereotactic body radiotherapy for recurrent oropharyngeal cancer – Influence of HPV status and smoking history. Oral Oncology, 2014, 50, 1104-1108.	0.8	23
776	Public Health Implications of Human Papillomavirus Oral Infection: A Brief Overview. Current Oral Health Reports, 2014, 1, 143-147.	0.5	1
778	PET/CT Imaging and Human Papilloma Virus – Positive Oropharyngeal Squamous Cell Cancer: Evolving Clinical Imaging Paradigm. Journal of Nuclear Medicine, 2014, 55, 431-438.	2.8	35
779	Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 299-312.	1.4	74
780	Comparison of HPV prevalence in HNSCC patients with regard to regional and socioeconomic factors. European Archives of Oto-Rhino-Laryngology, 2014, 271, 1737-1745.	0.8	12
781	Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection. Cancer Causes and Control, 2014, 25, 461-471.	0.8	67
782	Racial disparities in Human Papillomavirus (HPV) associated head and neck cancer. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2014, 35, 147-153.	0.6	42



#	ARTICLE	IF	CITATIONS
783	Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy. <i>Oral Oncology</i> , 2014, 50, 869-876.	0.8	34
784	Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma Survival: A Comparison by Tumor Site and Initial Treatment. <i>Head and Neck Pathology</i> , 2014, 8, 77-87.	1.3	56
785	Trends in oral cavity, pharyngeal, oesophageal and gastric cancer mortality rates in Spain, 1952-2006: an age-period-cohort analysis. <i>BMC Cancer</i> , 2014, 14, 254.	1.1	17
786	Human Papillomavirus (HPV) - Structure, epidemiology and pathogenesis. <i>Otolaryngologia Polska</i> , 2014, 68, 213-219.	0.2	36
787	African Americans with oropharyngeal carcinoma have significantly poorer outcomes despite similar rates of human papillomavirus-mediated carcinogenesis. <i>Human Pathology</i> , 2014, 45, 310-319.	1.1	34
788	Human papillomavirus (HPV) status of non-tobacco related squamous cell carcinomas of the lateral tongue. <i>Oral Oncology</i> , 2014, 50, 306-310.	0.8	74
789	Cancer stem cell enrichment marker CD98: A prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. <i>European Journal of Cancer</i> , 2014, 50, 765-773.	1.3	79
790	Combined P16 and human papillomavirus testing predicts head and neck cancer survival. <i>International Journal of Cancer</i> , 2014, 135, 2404-2412.	2.3	82
791	Human papilloma virus positive oropharyngeal squamous cell carcinoma: A growing epidemic. <i>Cancer Treatment Reviews</i> , 2014, 40, 215-219.	3.4	74
792	HPV and head and neck cancers: State-of-the-science. <i>Oral Oncology</i> , 2014, 50, 353-355.	0.8	32
794	Clinicopathologic Features of Oral Squamous Cell Carcinoma: Do They Vary in Different Age Groups?. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014, 72, 1291-1300.	0.5	39
795	Clinical significance of head and neck squamous cell cancer biomarkers. <i>Oral Oncology</i> , 2014, 50, 168-177.	0.8	88
796	The use of ultrasound in the search for the primary site of unknown primary head and neck squamous cell cancers. <i>Oral Oncology</i> , 2014, 50, 640-645.	0.8	44
797	Review of the Clinical and Biologic Aspects of Human Papillomavirus-Positive Squamous Cell Carcinomas of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 761-770.	0.4	95
798	Radiotherapy response in head and neck cancer - evaluation of the primary tumour site. <i>Acta Oto-Laryngologica</i> , 2014, 134, 646-651.	0.3	11
799	The Role of Human Papilloma Virus (HPV) Infection in Non-Anogenital Cancer and the Promise of Immunotherapy: A Review. <i>International Reviews of Immunology</i> , 2014, 33, 383-401.	1.5	33
800	Is radiation dose reduction the right answer for HPV-positive head and neck cancer?. <i>Oral Oncology</i> , 2014, 50, 560-564.	0.8	37
801	Detection of human papillomavirus (HPV) in clinical samples: Evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas. <i>Oral Oncology</i> , 2014, 50, 771-779.	0.8	143



#	ARTICLE	IF	CITATIONS
802	Next-generation sequencing analysis for detecting human papillomavirus in oral verrucous carcinoma. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 118, 117-125.e1.	0.2	18
803	Incidence of human papillomavirus-related oropharyngeal cancer and outcomes after chemoradiation in a population of heavy smokers. <i>Head and Neck</i> , 2014, 36, 782-786.	0.9	22
804	Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity. <i>Head and Neck</i> , 2014, 36, 34-42.	0.9	25
805	Predictive value of human papillomavirus in oropharyngeal carcinoma treated with radiotherapy: An updated systematic review and meta-analysis of 30 trials. <i>Head and Neck</i> , 2014, 36, 750-759.	0.9	51
806	Clinical and scientific impact of human papillomavirus on head and neck cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 781.	0.9	44
807	Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Multicenter Study in Japan. <i>Oncology</i> , 2014, 87, 173-182.	0.9	73
808	A comprehensive evaluation of human papillomavirus positive status and p16INK4a overexpression as a prognostic biomarker in head and neck squamous cell carcinoma. <i>International Journal of Oncology</i> , 2014, 45, 67-76.	1.4	78
809	Avatars of personalized cancer therapy can lead to a reduction in head and neck cancer survival disparities. <i>Personalized Medicine</i> , 2014, 11, 243-246.	0.8	0
810	Influence of Smoking History on Imaging Characteristics Among Patients With Human Papillomavirus-Positive Oropharyngeal Cancer. <i>Journal of Computer Assisted Tomography</i> , 2014, 38, 667-673.	0.5	5
812	Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck. <i>Cancer Medicine</i> , 2015, 4, 481-489.	1.3	18
813	What is the role of human papillomavirus testing in head and neck cancer?. <i>Laryngoscope</i> , 2015, 125, 2633-2634.	1.1	1
814	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Oncologist</i> , 2015, 20, 1247-1252.	1.9	28
815	TMEM16A/ANO1 is differentially expressed in HPV-negative versus HPV-positive head and neck squamous cell carcinoma through promoter methylation. <i>Scientific Reports</i> , 2015, 5, 16657.	1.6	37
817	Geographical and anatomical influences on human papillomavirus prevalence diversity in head and neck squamous cell carcinoma in Germany. <i>International Journal of Oncology</i> , 2015, 46, 414-422.	1.4	39
818	Disease-free and overall survival of patients diagnosed with HPV-associated or HPV-negative cervical cancer. <i>AIP Conference Proceedings</i> , 2015, , .	0.3	0
819	Selective participation of c-Jun with Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis in tongue cancer. <i>Scientific Reports</i> , 2015, 5, 16811.	1.6	46
820	Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy. <i>Rare Cancers and Therapy</i> , 2015, 3, 89-117.	0.2	13
821	A different entity: a population based study of characteristics and recurrence patterns in oropharyngeal squamous cell carcinomas. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2015, 44, 30.	0.9	2

#	ARTICLE	IF	CITATIONS
822	MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. <i>BMC Cancer</i> , 2015, 15, 861.	1.1	34
823	Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. <i>The Cochrane Library</i> , 2015, 2015, CD010341.	1.5	32
824	Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review. <i>Journal of Laryngology and Otology</i> , 2015, 129, 1046-1052.	0.4	6
825	Detection of HPV in oral rinse samples from OPSCC and non-OPSCC patients. <i>BMC Oral Health</i> , 2015, 15, 126.	0.8	17
826	Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety. <i>SpringerPlus</i> , 2015, 4, 208.	1.2	12
827	Correlation of PET-CT nodal SUVmax with p16 positivity in oropharyngeal squamous cell carcinoma. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2015, 44, 37.	0.9	20
828	Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. <i>Cancer</i> , 2015, 121, 2594-2602.	2.0	53
829	Multicentric human papillomavirus-associated head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 202-208.	0.9	17
830	Potential advantages of volumetric arc therapy in head and neck cancer. <i>Head and Neck</i> , 2015, 37, 909-914.	0.9	18
831	Otolaryngology-head and neck surgery at Johns Hopkins: The first 100 years (1914-2014). <i>Laryngoscope</i> , 2015, 125, S1-35.	1.1	5
832	Squamous Cell Carcinoma of the Vulva. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1045-1053.	2.1	93
833	The impact of human papillomavirus infection on the survival and treatment response of patients with esophageal cancers. <i>Journal of Digestive Diseases</i> , 2015, 16, 256-263.	0.7	18
834	Accuracy of computed tomography to predict extracapsular spread in p16-positive squamous cell carcinoma. <i>Laryngoscope</i> , 2015, 125, 1613-1618.	1.1	48
835	Human papilloma virus-related oropharyngeal cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2015, 23, 185-190.	0.8	9
836	Algorithm to predict postoperative complications in oropharyngeal and oral cavity carcinoma. <i>Head and Neck</i> , 2015, 37, 548-556.	0.9	17
837	Prognostic value of pretreatment <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status. <i>Head and Neck</i> , 2015, 37, 1524-1531.	0.9	32
838	Good tolerance and long-term complete remission after definitive intensity-modulated radiotherapy for locally advanced head and neck cancer in a patient with human immunodeficiency virus infection: A case report and literature review. <i>Head and Neck</i> , 2015, 37, E186-90.	0.9	3
839	Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. <i>Cancer</i> , 2015, 121, 3455-3464.	2.0	97

#	ARTICLE	IF	CITATIONS
840	The impact of transoral robotic surgery on the overall treatment of oropharyngeal cancer patients. <i>Laryngoscope</i> , 2015, 125, S1-S15.	1.1	47
841	Ciliated HPV-related Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1591-1595.	2.1	44
842	Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer. <i>Viruses</i> , 2015, 7, 5040-5065.	1.5	36
843	Radiology of Oropharyngeal Cancer - Institutional Experience and Literature Review -. <i>Current Cancer Therapy Reviews</i> , 2015, 11, 7-14.	0.2	0
844	Promoter Hypermethylation Profiling Identifies Subtypes of Head and Neck Cancer with Distinct Viral, Environmental, Genetic and Survival Characteristics. <i>PLoS ONE</i> , 2015, 10, e0129808.	1.1	58
845	Human Papillomavirus Infection, Infertility, and Assisted Reproductive Outcomes. <i>Journal of Pathogens</i> , 2015, 2015, 1-8.	0.9	41
847	Rapidly Increasing Trends in Oropharyngeal Carcinoma Assessed by Worldwide Epidemiologic Analysis. <i>Current Cancer Therapy Reviews</i> , 2015, 11, 15-20.	0.2	1
848	DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck. <i>DNA Repair</i> , 2015, 31, 64-72.	1.3	28
849	Treatment De-intensification in HPV-Associated Oropharyngeal Cancer: Evidence, Controversies, and Strategies. <i>Current Otorhinolaryngology Reports</i> , 2015, 3, 47-55.	0.2	0
850	<i>TP53</i> ; <i>Y220C</i> Is a Hotspot Mutation in Oropharyngeal Squamous Cell Carcinoma. <i>Pathobiology</i> , 2015, 82, 21-27.	1.9	3
851	HPV Status Determines the Efficacy of Adjuvant Chemotherapy With S-1, an Oral Fluorouracil Prodrug, in Oropharyngeal Cancer. <i>Annals of Otology, Rhinology and Laryngology</i> , 2015, 124, 400-406.	0.6	3
852	The role of sexual behavior in head and neck cancer: implications for prevention and therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 35-49.	1.1	67
853	The Rise of HPV-Positive Oropharyngeal Cancers in the United States. <i>Cancer Prevention Research</i> , 2015, 8, 9-11.	0.7	21
854	<i>IGSF4</i> Methylation as an Independent Marker of Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 257.	1.2	15
855	Genomic Applications in Head and Neck Cancers. , 2015, , 341-358.		0
856	Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CT. <i>Journal of Radiation Research</i> , 2015, 56, 553-560.	0.8	10
857	Novel Targeted Agents in Head and Neck Squamous Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 993-1009.	0.9	2
858	Emergence of HPV16-Positive Oropharyngeal Cancer in Black Patients Over Time: University of Maryland 1992-2007. <i>Cancer Prevention Research</i> , 2015, 8, 12-19.	0.7	30

#	ARTICLE	IF	CITATIONS
859	Genomic Copy Number Variations Characterize the Prognosis of Both P16-Positive and P16-Negative Oropharyngeal Squamous Cell Carcinoma After Curative Resection. <i>Medicine (United States)</i> , 2015, 94, e2187.	0.4	14
860	Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 976-985.	0.4	163
861	HPV-Associated Head and Neck Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv344.	3.0	153
862	The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. <i>Cancer Prevention Research</i> , 2015, 8, 583-589.	0.7	38
863	Composition of inflammatory cells regulating the response to concurrent chemoradiation therapy for HPV (+) tonsil cancer. <i>Oral Oncology</i> , 2015, 51, 1113-1119.	0.8	17
864	Subpath analysis of each subtype of head and neck cancer based on the regulatory relationship between miRNAs and biological pathways. <i>Oncology Reports</i> , 2015, 34, 1745-1754.	1.2	9
865	A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. <i>Investigational New Drugs</i> , 2015, 33, 1248-1256.	1.2	32
866	Human papillomavirus genotype and oropharynx cancer survival in the United States of America. <i>European Journal of Cancer</i> , 2015, 51, 2759-2767.	1.3	80
867	The role of cytology in the era of HPV-related head and neck carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 250-257.	1.0	20
868	Prevalence of human papillomavirus in laryngeal and hypopharyngeal squamous cell carcinomas in northern Spain. <i>Cancer Epidemiology</i> , 2015, 39, 37-41.	0.8	44
869	Frequency and prognostic significance of p16INK4A protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2015, 112, 1098-1104.	2.9	87
870	Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 795-805.	1.5	82
872	Current trends in the etiology and diagnosis of HPV-related head and neck cancers. <i>Cancer Medicine</i> , 2015, 4, 596-607.	1.3	98
873	Current Status of Clinical Trials in Head and Neck Cancer 2014. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 152, 410-417.	1.1	8
874	Staging and treatment of oropharyngeal cancer in the human papillomavirus era. <i>Head and Neck</i> , 2015, 37, 1002-1013.	0.9	49
875	Combination of p16 <sup>INK4a</sup> /Ki67 immunocytology and hpv polymerase chain reaction for the noninvasive analysis of HPV involvement in head and neck cancer. <i>Cancer Cytopathology</i> , 2015, 123, 219-229.	1.4	25
876	HPV-related squamous cell carcinoma of the head and neck: An update on testing in routine pathology practice. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 344-351.	1.0	99
877	Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. <i>Annals of Oncology</i> , 2015, 26, 1216-1223.	0.6	163

#	ARTICLE	IF	CITATIONS
878	Human papillomavirus-related head and neck squamous cell carcinoma variants. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 23-31.	1.0	30
879	The pathology of HPV-related head and neck cancer: Implications for the diagnostic pathologist. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 42-53.	1.0	51
880	Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 419-428.	3.3	103
881	The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 2015, 51, 423-430.	0.8	39
882	Intra-tumor Genetic Heterogeneity and Mortality in Head and Neck Cancer: Analysis of Data from The Cancer Genome Atlas. <i>PLoS Medicine</i> , 2015, 12, e1001786.	3.9	244
883	Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. <i>Annals of Oncology</i> , 2015, 26, 198-205.	0.6	13
884	Oropharyngeal Cancer. , 2015, , 171-192.		0
885	The epidemiology of head and neck squamous cell carcinoma in The Netherlands during the era of HPV-related oropharyngeal squamous cell carcinoma. Is there really evidence for a change?. <i>Oral Oncology</i> , 2015, 51, 901-907.	0.8	19
886	Correlation of p16 expression and HPV type with survival in oropharyngeal squamous cell cancer. <i>Oral Oncology</i> , 2015, 51, 862-869.	0.8	45
887	Using Texture Analysis to Determine Human Papillomavirus Status of Oropharyngeal Squamous Cell Carcinomas on CT. <i>American Journal of Neuroradiology</i> , 2015, 36, 1343-1348.	1.2	122
888	p16INK4a Status and Response to Induction Low-Dose Fractionated Radiation in Advanced Head and Neck Cancer. <i>Annals of Otology, Rhinology and Laryngology</i> , 2015, 124, 714-720.	0.6	3
889	The Fidelity of p16 Staining as a Surrogate Marker of Human Papillomavirus Status in Fine-Needle Aspirates and Core Biopsies of Neck Node Metastases: Implications for HPV Testing Protocols. <i>Acta Cytologica</i> , 2015, 59, 97-103.	0.7	63
890	Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 116, 75-81.	0.3	32
892	The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis. <i>Carcinogenesis</i> , 2015, 36, S128-S159.	1.3	40
893	HPV positive oropharyngeal cancer and treatment deintensification: How pertinent is it?. <i>Journal of Cancer Research and Therapeutics</i> , 2015, 11, 6.	0.3	11
894	Integrating genomics in head and neck cancer treatment: Promises and pitfalls. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 397-406.	2.0	29
895	HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx. <i>Clinical Cancer Research</i> , 2015, 21, 2861-2869.	3.2	59
897	Quantitative Diffusion-Weighted MRI Parameters and Human Papillomavirus Status in Oropharyngeal Squamous Cell Carcinoma. <i>American Journal of Neuroradiology</i> , 2015, 36, 763-767.	1.2	18

#	ARTICLE	IF	CITATIONS
898	HPVâ€­Positive Oropharyngeal Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 153, 758-769.	1.1	120
899	Increase in head and neck cancer in younger patients due to human papillomavirus (HPV). <i>Oral Oncology</i> , 2015, 51, 727-730.	0.8	168
900	Prevalence and prognostic value of human papillomavirus genotypes in tonsillar squamous cell carcinoma: A <sc>K</sc>orean multicenter study. <i>Cancer</i> , 2015, 121, 535-544.	2.0	28
901	Surgical salvage improves overall survival for patients with HPVâ€­positive and HPVâ€­negative recurrent locoregional and distant metastatic oropharyngeal cancer. <i>Cancer</i> , 2015, 121, 1977-1984.	2.0	116
902	Human Papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature. <i>Oral Oncology</i> , 2015, 51, 848-856.	0.8	25
903	Exploring the implications of HPV infection for head and neck cancer. <i>Sexually Transmitted Infections</i> , 2015, 91, 229-230.	0.8	8
904	Assessment and measurement of head and neck lymphedema: State-of-the-science and future directions. <i>Oral Oncology</i> , 2015, 51, 431-437.	0.8	40
905	Epidemiology of Head and Neck Cancer. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 379-396.	0.6	362
906	Epidermal Growth Factor Receptor Expression in Spindle Cell Carcinomas of the Head and Neck. <i>Head and Neck Pathology</i> , 2015, 9, 360-368.	1.3	8
907	The relationship between patterns of failure and human papilloma virus (HPV) status for squamous cell carcinoma of the oropharynx after definitive chemoradiotherapy: what role does elective nodal irradiation play?. <i>Journal of Radiation Oncology</i> , 2015, 4, 47-53.	0.7	0
908	Emerging drugs for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 313-329.	1.0	39
909	The association between human papillomavirus 16 and esophageal cancer in Chinese population: a meta-analysis. <i>BMC Cancer</i> , 2015, 15, 1096.	1.1	43
910	Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2015, 44, 8.	0.9	13
911	Cancer of the Oropharynx. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 509-520.	0.6	13
912	Definitive radiotherapy for head and neck squamous cell carcinoma: update and perspectives on the basis of EBM. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 235-243.	0.6	8
913	Systemic Therapy for Squamous Cell Carcinoma of the Head and Neck. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 437-454.	0.6	11
915	Genomic Landscape of Human Papillomavirusâ€­Associated Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 2009-2019.	3.2	104
916	Identification of transcriptionally active HPV infection in formalin-fixed, paraffin-embedded biopsies of oropharyngeal carcinoma. <i>Human Pathology</i> , 2015, 46, 681-689.	1.1	18



#	ARTICLE	IF	CITATIONS
917	Intensity-Modulated Radiation Therapy. , 2015, , .		7
918	Different prognostic models for different patient populations: validation of a new prognostic model for patients with oropharyngeal cancer in Western Europe. <i>British Journal of Cancer</i> , 2015, 112, 1733-1736.	2.9	42
919	Molecular Biology and Immunology of Head and Neck Cancer. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 397-407.	0.6	32
920	AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2601-2612.	3.2	94
921	Effect of Human Papillomavirus on Patterns of Distant Metastatic Failure in Oropharyngeal Squamous Cell Carcinoma Treated With Chemoradiotherapy. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 457.	1.2	104
922	18F-FDG PET/CT as a semiquantitative imaging marker in HPV-p16-positive oropharyngeal squamous cell cancers. <i>Nuclear Medicine Communications</i> , 2015, 36, 16-20.	0.5	8
923	Detailed Analysis of Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic Factors Between Surgically Treated HPV-Positive and Negative Oropharyngeal Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 4411-4421.	0.7	80
924	Human papilloma virus in head and neck cancer. <i>InnovAiT</i> , 2015, 8, 106-111.	0.0	0
925	Diagnosis of HPV-driven head and neck cancer with a single test in routine clinical practice. <i>Modern Pathology</i> , 2015, 28, 1518-1527.	2.9	78
926	New Strategies in Human Papillomavirus-Related Oropharynx Cancer: Effecting Advances in Treatment for a Growing Epidemic. <i>Clinical Cancer Research</i> , 2015, 21, 3821-3828.	3.2	20
928	Refusal of postoperative radiotherapy and its association with survival in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 343-350.	0.3	16
929	Transoral Endoscopic Head and Neck Surgery. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1075-1092.	0.9	10
930	Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. <i>Cancer Treatment Reviews</i> , 2015, 41, 844-852.	3.4	110
931	Oropharyngeal cancer survivorship in Denmark, 1977-2012. <i>Oral Oncology</i> , 2015, 51, 982-984.	0.8	18
932	Anticipation of the Impact of Human Papillomavirus on Clinical Decision Making for the Head and Neck Cancer Patient. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1045-1060.	0.9	19
933	MicroRNA Profiles of HPV-Associated Oropharyngeal Squamous Cell Carcinoma (OPSCC). , 2015, , 133-152.		1
934	Effective Biomarkers and Radiation Treatment in Head and Neck Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1379-1388.	1.2	11
935	Characteristics of Human Papillomavirus-Associated Head and Neck Cancers in a Veteran Population. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 790.	1.2	15



#	ARTICLE	IF	CITATIONS
937	HPV and Radiation Sensitivity. , 2015, , 243-289.		0
938	Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 886-893.	2.9	136
939	Long-term Functional Outcomes of Total Glossectomy With or Without Total Laryngectomy. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 797.	1.2	39
940	Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. <i>JAMA Oncology</i> , 2015, 1, 907.	3.4	82
941	Human papillomavirus DNA in pharyngeal scrapes as a marker of HPV-related squamous cell cancer of the oropharynx. <i>Journal of Clinical Virology</i> , 2015, 71, 34-39.	1.6	5
942	Management of Squamous Cancer Metastatic to Cervical Nodes With an Unknown Primary Site. <i>Journal of Clinical Oncology</i> , 2015, 33, 3328-3337.	0.8	94
943	Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 3243-3250.	0.8	118
944	The Growing Epidemic of HPV-Positive Oropharyngeal Carcinoma: A Clinical Review for Primary Care Providers. <i>Journal of the American Board of Family Medicine</i> , 2015, 28, 498-503.	0.8	42
945	Contribution of Demographic and Behavioral Factors on the Changing Incidence Rates of Oropharyngeal and Oral Cavity Cancers in Northern California. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 978-984.	1.1	7
946	Dose De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer: First Tracks on Powder. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 986-988.	0.4	16
947	Visualization of the Oropharynx With Transcervical Ultrasound. <i>American Journal of Roentgenology</i> , 2015, 205, 1288-1294.	1.0	32
949	Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 209-216.	1.0	35
950	The role of surgery for HPV-associated head and neck cancer. <i>Oral Oncology</i> , 2015, 51, 305-313.	0.8	41
951	Do high-risk human papillomaviruses cause oral cavity squamous cell carcinoma?. <i>Oral Oncology</i> , 2015, 51, 229-236.	0.8	76
952	The protective effect of p16INK4a in oral cavity carcinomas: p16Ink4A dampens tumor invasion-integrated analysis of expression and kinomics pathways. <i>Modern Pathology</i> , 2015, 28, 631-653.	2.9	35
953	Epigenetics in Head and Neck Cancer. <i>Methods in Molecular Biology</i> , 2015, 1238, 751-769.	0.4	15
954	Squamous Cell Carcinoma of the Upper Aerodigestive Tract. <i>Radiologic Clinics of North America</i> , 2015, 53, 81-97.	0.9	27
955	Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle. <i>Head and Neck Pathology</i> , 2015, 9, 223-235.	1.3	19

#	ARTICLE	IF	CITATIONS
956	MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway. <i>Oncogene</i> , 2015, 34, 1698-1708.	2.6	28
957	Treatment de-escalation in HPV-positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives. <i>International Journal of Cancer</i> , 2015, 136, 1494-1503.	2.3	199
958	Effect of multimodality treatment on overall survival for patients with metastatic or recurrent HPV-positive head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 630-635.	0.9	21
959	Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer. <i>Head and Neck</i> , 2015, 37, 636-643.	0.9	15
960	Relationship between insulin-like growth factor-1 receptor and human papillomavirus in patients with oropharyngeal cancer. <i>Head and Neck</i> , 2015, 37, 977-981.	0.9	10
961	When is chemotherapy in head and neck squamous cell carcinoma not indicated?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 781-787.	0.8	6
962	When is surgical therapy for head and neck malignant epithelial tumors not indicated?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 513-516.	0.8	0
963	Human papillomavirus DNA load and p16 <sup>INK4a</sup> expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. <i>International Journal of Cancer</i> , 2015, 136, 278-288.	2.3	75
964	Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer. <i>Head and Neck</i> , 2015, 37, 655-661.	0.9	30
965	Emerging biomarkers in head and neck cancer in the era of genomics. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 11-26.	12.5	264
966	Induction of epithelial-mesenchymal transition and loss of podoplanin expression are associated with progression of lymph node metastases in human papillomavirus-related oropharyngeal carcinoma. <i>Histopathology</i> , 2015, 66, 771-780.	1.6	23
967	Identification of human papillomavirus status specific biomarker in head and neck cancer. <i>Head and Neck</i> , 2015, 37, 1310-1318.	0.9	4
968	Treatment outcomes and prognostic factors, including human papillomavirus, for sinonasal undifferentiated carcinoma: A retrospective review. <i>Head and Neck</i> , 2015, 37, 366-374.	0.9	64
969	Development and preliminary testing of head and neck cancer related external lymphedema and fibrosis assessment criteria. <i>European Journal of Oncology Nursing</i> , 2015, 19, 75-80.	0.9	29
970	Genomic Applications in Pathology. , 2015, , .		1
971	Interactions between clinical factors, p16, and cyclin-D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 1650-1659.	0.9	9
972	Human papilloma virus and survival of oropharyngeal cancer patients treated with surgery and adjuvant radiotherapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 1755-1762.	0.8	7
973	Human Papillomaviruses. , 2016, , 413-426.		0

#	ARTICLE	IF	CITATIONS
974	Efficacy of Traditional Chinese Medicine in Xerostomia and Quality of Life during Radiotherapy for Head and Neck Cancer: A Prospective Pilot Study. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-10.	0.5	17
975	The etiologic spectrum of head and neck squamous cell carcinoma in young patients. Oncotarget, 2016, 7, 66226-66238.	0.8	24
976	Human papillomavirus and gastrointestinal cancer: A review. World Journal of Gastroenterology, 2016, 22, 7415.	1.4	46
977	Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine. Genes and Cancer, 2016, 7, 182-200.	0.6	41
978	16 Transoral Laser Microsurgery of the Oropharynx. , 2016, , .		0
979	HPV Associated Head and Neck Cancer. Cancers, 2016, 8, 75.	1.7	96
980	Human papilloma virus in oral cancer. Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2016, 42, 327.	0.3	70
981	Molecular analyses of unselected head and neck cancer cases demonstrates that human papillomavirus transcriptional activity is positively associated with survival and prognosis. BMC Cancer, 2016, 16, 367.	1.1	3
982	The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer. BMC Cancer, 2016, 16, 465.	1.1	34
983	Increasing Incidence and Imaging in Pediatric Head and Neck Cancer and Role of the Human Papilloma Virus and Epstein-Barr Virus. Journal of Pediatric Neuroradiology, 2016, 05, 221-228.	0.1	7
984	Adjuvant Radiation Therapy Alone for HPV Related Oropharyngeal Cancers with High Risk Features. PLoS ONE, 2016, 11, e0168061.	1.1	17
985	HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. Cancers, 2016, 8, 41.	1.7	100
986	HPV Infection and Prevention of HPV Infection in Men Who Have Sex with Men (MSM). , 0, , .		1
987	Human Papillomavirus in Head and Neck Cancer. , 0, , .		0
988	Nomograms predicting long-term overall survival and cancer-specific survival in head and neck squamous cell carcinoma patients. Oncotarget, 2016, 7, 51059-51068.	0.8	30
989	Noncancer-Related Health Events and Mortality in Head and Neck Cancer Patients After Definitive Radiotherapy. Medicine (United States), 2016, 95, e3403.	0.4	16
990	Clear Cell Carcinoma of the Penis: An HPV-related Variant of Squamous Cell Carcinoma. American Journal of Surgical Pathology, 2016, 40, 917-922.	2.1	33
991	Immune Checkpoint Therapy in Head and Neck Cancers. Cancer Journal (Sudbury, Mass ), 2016, 22, 108-116.	1.0	12

#	ARTICLE	IF	CITATIONS
992	Biomarkers p16, Human Papillomavirus and p53 Predict Recurrence and Survival in Early Stage Squamous Cell Carcinoma of the Vulva. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 252-256.	0.9	51
993	Clinical features and treatment strategy for HPV-related oropharyngeal cancer. <i>International Journal of Clinical Oncology</i> , 2016, 21, 827-835.	1.0	38
994	Interaction of quantitative <sup>18</sup> F-FDG PET/CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 529-535.	0.9	23
995	Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. <i>International Journal of Cancer</i> , 2016, 139, 510-517.	2.3	19
996	Prevalence of human papillomavirus in oral squamous cell carcinomas in northern Spain. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 4549-4559.	0.8	4
997	Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2185-2196.	1.2	32
998	p16 expression independent of human papillomavirus is associated with lower stage and longer disease-free survival in oral cavity squamous cell carcinoma. <i>Pathology</i> , 2016, 48, 441-448.	0.3	25
999	Vulvar cancer: initial management and systematic review of literature on currently applied treatment approaches. <i>European Journal of Cancer Care</i> , 2016, 25, 638-646.	0.7	13
1000	Rising population of survivors of oral squamous cell cancer in the United States. <i>Cancer</i> , 2016, 122, 1380-1387.	2.0	45
1001	Disease-free survival after salvage therapy for recurrent oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1501-9.	0.9	37
1002	Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E1554-61.	0.9	11
1003	Pretreatment serum xanthophyll concentrations as predictors of head and neck cancer recurrence and survival. <i>Head and Neck</i> , 2016, 38, E1591-7.	0.9	7
1004	Transoral laser microsurgery for oropharyngeal squamous cell carcinoma: A paradigm shift in therapeutic approach. <i>Head and Neck</i> , 2016, 38, 1263-1270.	0.9	28
1005	CD56-positive lymphocyte infiltration in relation to human papillomavirus association and prognostic significance in oropharyngeal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2016, 138, 2263-2273.	2.3	71
1006	Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, 1530-1538.	0.9	9
1007	Imaging characteristics of metastatic nodes and outcomes by HPV status in head and neck cancers. <i>Laryngoscope</i> , 2016, 126, 392-398.	1.1	18
1008	The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. <i>Laryngoscope</i> , 2016, 126, 894-900.	1.1	111
1009	p16 overexpression in high-grade neuroendocrine carcinomas of the head and neck: potential diagnostic pitfall with HPV-related carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 277-284.	1.4	70

#	ARTICLE	IF	CITATIONS
1010	ACR Appropriateness Criteria <sup>®</sup> Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. <i>Head and Neck</i> , 2016, 38, 1299-1309.	0.9	17
1011	Large Cell Neuroendocrine Carcinoma of the Head and Neck. <i>American Journal of Surgical Pathology</i> , 2016, 40, 471-478.	2.1	81
1012	Pharmacological activation of wild-type p53 in the therapy of leukemia. <i>Experimental Hematology</i> , 2016, 44, 791-798.	0.2	41
1013	Patterns of care and perioperative outcomes in transoral endoscopic surgery for oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 402-409.	0.9	38
1014	Oncologic outcomes of surgically treated early-stage oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 1467-1471.	0.9	24
1015	Oropharyngeal cancer and human papilloma virus: evolving diagnostic and management paradigms. <i>ANZ Journal of Surgery</i> , 2016, 86, 442-447.	0.3	6
1016	Carcinogenic human papillomavirus infection. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16086.	18.1	615
1017	Early detection and personalized treatment in oral cancer: the impact of omics approaches. <i>Molecular Cytogenetics</i> , 2016, 9, 85.	0.4	33
1018	Current Role of Surgery in the Management of Oropharyngeal Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 1176-1183.	2.5	21
1019	Nasopharynx and Oropharynx. , 2016, , 295-331.		0
1020	Survival and quality of life in oropharyngeal cancer patients treated with primary chemoradiation after salivary gland transfer. <i>Journal of Laryngology and Otology</i> , 2016, 130, 755-762.	0.4	10
1021	Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. <i>The Cochrane Library</i> , 2016, 2016, CD010963.	1.5	37
1022	De-escalation of radiation dose for human papillomavirus-positive oropharyngeal head and neck squamous cell carcinoma: A case report and preclinical and clinical literature review. <i>Oncology Letters</i> , 2016, 11, 141-149.	0.8	6
1023	Effects of HPV-16 infection on hypopharyngeal squamous cell carcinoma and FaDu cells. <i>Oncology Reports</i> , 2016, 35, 99-106.	1.2	9
1024	The biological significance of methylome differences in human papilloma virus associated head and neck cancer. <i>Oncology Letters</i> , 2016, 12, 4949-4956.	0.8	8
1025	Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 575-585.	2.0	24
1026	Future treatment directions for HPV-associated head and neck cancer based on radiobiological rationale and current clinical evidence. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 103, 27-36.	2.0	18
1027	Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 362-371.	0.4	22

#	ARTICLE	IF	CITATIONS
1028	Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. <i>Journal of Laryngology and Otology</i> , 2016, 130, S90-S96.	0.4	96
1029	Survival Benefit of Chemotherapy in Oropharyngeal Cancer Patients Treated With Surgery and Postoperative Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 964-965.	0.4	0
1030	Biological Features of Human Papillomavirus-related Head and Neck Cancers Contributing to Improved Response. <i>Clinical Oncology</i> , 2016, 28, 467-474.	0.6	29
1032	Candidate Biomarkers for HPV-Negative Head and Neck Cancer Identified via Gene Expression Barcode Analysis. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 155, 416-422.	1.1	5
1033	Prognostic Importance of Comorbidity and the Association Between Comorbidity and p16 in Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 568.	1.2	30
1034	Outcome and fewer indications for adjuvant therapy for patients with oral squamous cell carcinomas under standardized tumor board conditions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 505-520.	1.2	3
1035	Potential applications of polyoxometalates for the discrimination of human papillomavirus in different subtypes. <i>Dalton Transactions</i> , 2016, 45, 15457-15463.	1.6	12
1036	Induction chemotherapy for squamous cell carcinomas of the oral cavity: A cumulative meta-analysis. <i>Oral Oncology</i> , 2016, 61, 104-114.	0.8	32
1037	Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial. <i>Advances in Radiation Oncology</i> , 2016, 1, 252-259.	0.6	6
1039	Does elimination of planned postoperative radiation to the primary bed in p16-positive, transorally-resected oropharyngeal carcinoma associate with poorer outcomes?. <i>Oral Oncology</i> , 2016, 61, 127-134.	0.8	20
1040	Prevalence of human papillomavirus infection in squamous cell carcinoma of the oral cavity, oropharynx and larynx. <i>Cirurgiã Y Cirujanos (English Edition)</i> , 2016, 84, 363-368.	0.0	4
1041	Salivary and serum IL-10, TNF- $\alpha$ , TGF- $\beta$ , VEGF levels in oropharyngeal squamous cell carcinoma and correlation with HPV and EBV infections. <i>Infectious Agents and Cancer</i> , 2016, 11, 45.	1.2	65
1042	Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx. <i>Journal of Clinical Oncology</i> , 2016, 34, 4132-4141.	0.8	105
1043	Aptima HR-HPV testing from Diff-Quick-stained fine-needle aspiration smears of oropharyngeal squamous cell carcinoma. <i>Journal of the American Society of Cytopathology</i> , 2016, 5, 221-226.	0.2	11
1044	miR-15a induces cell apoptosis by targeting BCL2L2 and BCL2 in HPV-positive hypopharyngeal squamous cell carcinoma. <i>Oncology Reports</i> , 2016, 36, 2169-2176.	1.2	21
1045	Adoption of transoral robotic surgery compared with other surgical modalities for treatment of oropharyngeal squamous cell carcinoma. <i>Journal of Surgical Oncology</i> , 2016, 114, 405-411.	0.8	49
1046	Human papillomavirus in oropharyngeal cancer: The changing face of a disease. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 141-150.	3.3	48
1047	Novel p53 therapies for head and neck cancer. <i>World Journal of Otorhinolaryngology - Head and Neck Surgery</i> , 2016, 2, 68-75.	0.7	22

#	ARTICLE	IF	CITATIONS
1048	Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. <i>Gynecologic Oncology</i> , 2016, 142, 293-298.	0.6	87
1049	Treatment of head and neck cancer in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1903-1921.	0.9	15
1050	Pretreatment depression as a prognostic indicator of survival and nutritional status in patients with head and neck cancer. <i>Cancer</i> , 2016, 122, 131-140.	2.0	53
1051	The Role of Transoral Robotic Surgery in the Management of HPV Negative Oropharyngeal Squamous Cell Carcinoma. <i>Current Oncology Reports</i> , 2016, 18, 53.	1.8	24
1052	Human papillomavirus-related oropharyngeal cancer in the HIV-infected population. <i>Oral Diseases</i> , 2016, 22, 98-106.	1.5	27
1053	The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. <i>Acta Oto-Laryngologica</i> , 2016, 136, 1291-1298.	0.3	1
1054	HPV-16 infection modifies overall survival of Puerto Rican HNSCC patients. <i>Infectious Agents and Cancer</i> , 2016, 11, 47.	1.2	6
1055	Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis. <i>BMC Cancer</i> , 2016, 16, 689.	1.1	34
1056	Diffuse optical measurements of head and neck tumor hemodynamics for early prediction of chemoradiation therapy outcomes. <i>Journal of Biomedical Optics</i> , 2016, 21, 085004.	1.4	16
1057	Vulvar Cancer, HPV Infection, and HIV Status. <i>Current Obstetrics and Gynecology Reports</i> , 2016, 5, 196-202.	0.3	2
1058	Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 60, 55-60.	0.8	21
1059	Outcomes after surgical salvage for recurrent oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 60, 118-124.	0.8	27
1060	Clinicopathologic characteristics and outcomes of recurrent oropharyngeal squamous cell carcinoma. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2016, 37, 513-516.	0.6	0
1061	Human Papilloma Virus in Oral Cavity Cancer and Relation to Change in Quality of Life Following Treatment—a Pilot Study from Northern India. <i>Indian Journal of Surgical Oncology</i> , 2016, 7, 386-391.	0.3	6
1062	Is overexpression of TWIST, a transcriptional factor, a prognostic biomarker of head and neck carcinoma? Evidence from fifteen studies. <i>Scientific Reports</i> , 2016, 5, 18073.	1.6	11
1063	The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 61, 27-30.	0.8	8
1064	Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States. <i>JAMA Oncology</i> , 2016, 2, 1617.	3.4	114
1065	Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. <i>Oral Oncology</i> , 2016, 60, 61-67.	0.8	75



#	ARTICLE	IF	CITATIONS
1066	Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 847-858.	1.1	8
1067	Risk factors and treatment for recurrent vulvar squamous cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 1-13.	2.0	67
1069	Initial evidence for Sec62 as a prognostic marker in advanced head and neck squamous cell carcinoma. <i>Oncology Letters</i> , 2016, 11, 1661-1670.	0.8	34
1070	Human papillomavirus detection in fine needle aspiration cytology of lymph node metastasis of head and neck squamous cell cancer. <i>Journal of Clinical Virology</i> , 2016, 85, 22-26.	1.6	16
1071	Considerations in surgical versus non-surgical management of HPV positive oropharyngeal cancer. <i>Cancers of the Head &amp; Neck</i> , 2016, 1, 6.	6.2	10
1072	Treatment de-intensification strategies for head and neck cancer. <i>European Journal of Cancer</i> , 2016, 68, 125-133.	1.3	101
1073	Socio-economic deprivation: a significant determinant affecting stage of oral cancer diagnosis and survival. <i>BMC Cancer</i> , 2016, 16, 569.	1.1	47
1074	Management of Oropharyngeal Cancer in the HPV Era. <i>Cancer Control</i> , 2016, 23, 197-207.	0.7	11
1075	Head-and-neck squamous cell carcinoma risk in smokers: no association detected between phenotype and AHR, CYP1A1, CYP1A2, or CYP1B1 genotype. <i>Human Genomics</i> , 2016, 10, 39.	1.4	6
1076	De-intensification of adjuvant therapy in human papillomavirus-associated oropharyngeal cancer. <i>Cancers of the Head &amp; Neck</i> , 2016, 1, 18.	6.2	11
1077	Oncological and survival outcomes following transoral robotic surgery versus transoral laser microsurgery for the treatment of oropharyngeal squamous cell carcinoma. <i>JBIM Database of Systematic Reviews and Implementation Reports</i> , 2016, 14, 90-102.	1.7	2
1078	Automated Extraction of Formalin-Fixed, Paraffin-Embedded Tissue for High-Risk Human Papillomavirus Testing of Head and Neck Squamous Cell Carcinomas Using the Roche Cobas 4800 System. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 844-848.	1.2	26
1079	Metastatic HPV-related head and neck squamous cell carcinoma to the lung and mediastinal lymph nodes in aspirated cytology material: A diagnostic pitfall. <i>Diagnostic Cytopathology</i> , 2016, 44, 206-214.	0.5	6
1080	Human papillomavirus integration pattern and demographic, clinical, and survival characteristics of patients with oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 1139-1144.	0.9	29
1081	Detection of human papillomavirus in laryngeal squamous cell carcinoma: Systematic review and meta-analysis. <i>Laryngoscope</i> , 2016, 126, 885-893.	1.1	65
1082	In reference to <i>Natural history and management of fanconi anemia patients with head and neck cancer: A 10-year follow-up</i> . <i>Laryngoscope</i> , 2016, 126, E229.	1.1	3
1083	Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. <i>Cancer</i> , 2016, 122, 1523-1532.	2.0	128
1084	Racial differences in head and neck squamous cell carcinomas among non-Hispanic black and white males identified through the National Cancer Database (1998-2012). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1715-1726.	1.2	25

#	ARTICLE	IF	CITATIONS
1085	The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2016, 21, 819-826.	1.0	60
1086	Human papilloma virus prevalence in HIV patients with head and neck squamous cell carcinoma. <i>Aids</i> , 2016, 30, 1257-1266.	1.0	26
1088	Tumors of the Pharynx. , 2016, , 215-224.		0
1089	Unclear role of human papillomavirus infection in response to adjuvant radiotherapy: conflicting results on the prognostic significance of irradiation in vulvar cancer patients with lymph node metastasis. <i>Current Medical Research and Opinion</i> , 2016, 32, 1387-1388.	0.9	0
1090	Threonine Aspartase1: An unexplored protease with relevance for oral oncology?. <i>Oral Oncology</i> , 2016, 54, e10-e12.	0.8	2
1092	Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 155, 106-112.	1.1	8
1093	The Impact of HPV as an Etiological Factor in Gynecological and Oropharyngeal Cancer. <i>American Journal of Lifestyle Medicine</i> , 2016, 10, 253-261.	0.8	2
1094	Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. <i>Cancer</i> , 2016, 122, 634-641.	2.0	24
1095	The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. <i>Cancer</i> , 2016, 122, 2313-2323.	2.0	72
1096	Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines. <i>Cancer</i> , 2016, 122, 2057-2066.	2.0	38
1097	Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. <i>Cancer</i> , 2016, 122, 2021-2030.	2.0	30
1098	Trends in human papillomavirus-related oropharyngeal cancer in Israel. <i>Head and Neck</i> , 2016, 38, E274-8.	0.9	9
1099	Role of primary surgery in the treatment of advanced oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E571-9.	0.9	29
1100	Salvage surgery for locally recurrent oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E658-64.	0.9	66
1101	Human papillomavirus infection on initiating synchronous esophageal neoplasia in patients with head and neck cancer. <i>Laryngoscope</i> , 2016, 126, 1097-1102.	1.1	10
1102	Low prevalence of transcriptionally active human papilloma virus in Indian patients with HNSCC and leukoplakia. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 122, 609-618.e7.	0.2	31
1103	Evaluation for High-risk HPV in Squamous Cell Carcinomas and Precursor Lesions Arising in the Conjunctiva and Lacrimal Sac. <i>American Journal of Surgical Pathology</i> , 2016, 40, 519-528.	2.1	57
1104	Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. <i>BJU International</i> , 2016, 117, 118-125.	1.3	57

#	ARTICLE	IF	CITATIONS
1105	Relative expression of vascular endothelial growth factor isoforms in squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2016, 38, 775-781.	0.9	4
1106	Prognostic factors and outcomes for salvage surgery in patients with recurrent squamous cell carcinoma of the tongue. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e141-8.	0.7	18
1107	Changes in Unknown Primary Squamous Cell Carcinoma of the Head and Neck at Initial Presentation in the Era of Human Papillomavirus. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 223.	1.2	97
1108	Differences in human papillomavirus-positive and -negative head and neck cancers in Belgium: an 8-year retrospective, comparative study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 121, 456-460.	0.2	16
1109	Application of Dynamic Contrast-Enhanced MRI Parameters for Differentiating Squamous Cell Carcinoma and Malignant Lymphoma of the Oropharynx. <i>American Journal of Roentgenology</i> , 2016, 206, 401-407.	1.0	34
1110	Human Papillomavirus and Epidermal Growth Factor Receptor in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma: Correlation With Dynamic Contrast-Enhanced MRI Parameters. <i>American Journal of Roentgenology</i> , 2016, 206, 408-413.	1.0	17
1111	Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. <i>Cancer Treatment Reviews</i> , 2016, 43, 113-123.	3.4	9
1112	Genomic characterisation of canine papillomavirus type 17, a possible rare cause of canine oral squamous cell carcinoma. <i>Veterinary Microbiology</i> , 2016, 182, 135-140.	0.8	34
1113	Taspase1: a 'misunderstood' protease with translational cancer relevance. <i>Oncogene</i> , 2016, 35, 3351-3364.	2.6	20
1114	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). <i>International Journal of Cancer</i> , 2016, 138, 171-181.	2.3	184
1115	Impact of race on oropharyngeal squamous cell carcinoma presentation and outcomes among veterans. <i>Head and Neck</i> , 2016, 38, 44-50.	0.9	28
1117	Sickness behavior induced by cisplatin chemotherapy and radiotherapy in a murine head and neck cancer model is associated with altered mitochondrial gene expression. <i>Behavioural Brain Research</i> , 2016, 297, 241-250.	1.2	22
1118	Clinical implications of human papilloma virus and other biologic markers in nasopharyngeal cancer. <i>Oral Oncology</i> , 2016, 55, e7-e10.	0.8	6
1119	Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories. <i>Journal of Clinical Oncology</i> , 2016, 34, 1848-1854.	0.8	64
1120	Loop mediated isothermal amplification (LAMP) for the detection and subtyping of human papillomaviruses (HPV) in oropharyngeal squamous cell carcinoma (OPSCC). <i>Journal of Clinical Virology</i> , 2016, 75, 37-41.	1.6	19
1122	HPV-related head and neck squamous cell carcinoma: An update and review. <i>Journal of the American Society of Cytopathology</i> , 2016, 5, 203-215.	0.2	16
1123	Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 330-334.	0.3	84
1124	Optimal radiotherapy dose schedules under parametric uncertainty. <i>Physics in Medicine and Biology</i> , 2016, 61, 338-364.	1.6	16

#	ARTICLE	IF	CITATIONS
1125	18F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1239-1247.	3.3	34
1126	Virus del papiloma humano y cncer de orofaringe. <i>EMC - Otorrinolaringologa</i> , 2016, 45, 1-13.	0.0	0
1127	Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review. <i>Oral Oncology</i> , 2016, 53, 36-41.	0.8	9
1128	Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. <i>Mayo Clinic Proceedings</i> , 2016, 91, 386-396.	1.4	832
1129	The Emerging Role of HPV in Head and Neck Cancer. , 2016, , 21-36.		0
1130	RNA in-situ hybridization is a practical and effective method for determining HPV status of oropharyngeal squamous cell carcinoma including discordant cases that are p16 positive by immunohistochemistry but HPV negative by DNA in-situ hybridization. <i>Oral Oncology</i> , 2016, 55, 11-16.	0.8	65
1131	p16(INK4A) expression in invasive laryngeal cancer. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 52-55.	4.5	26
1132	Morbidity, mortality and cost from HPV-related oropharyngeal cancer: Impact of 2-, 4- and 9-valent vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1343-1347.	1.4	11
1133	A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 53, 54-59.	0.8	10
1134	Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. <i>Cancer Prevention Research</i> , 2016, 9, 135-141.	0.7	40
1135	Cost-Effectiveness Analysis of Chemoradiation Therapy Versus Transoral Robotic Surgery for Human Papillomavirus-Associated, Clinical N2 Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 512-522.	0.4	35
1136	E6 viral protein ratio correlates with outcomes in human papillomavirus related oropharyngeal cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 181-187.	1.5	5
1137	Predictors of quality of life in head and neck cancer survivors up to 5years after end of treatment: a cross-sectional survey. <i>Supportive Care in Cancer</i> , 2016, 24, 2463-2472.	1.0	46
1138	Comparative evaluation of the GP5+/6+, MY09/11 and PGMY09/11 primer sets for HPV detection by PCR in oral squamous cell carcinomas. <i>Experimental and Molecular Pathology</i> , 2016, 100, 13-16.	0.9	17
1139	Oropharyngeal Cancer. , 2016, , 597-628.e6.		1
1140	Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 52, 97-103.	0.8	33
1141	Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2877-2894.	0.8	22
1142	Treatment strategies in early-stage oropharyngeal squamous cell carcinoma: a French national survey. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2201-2207.	0.8	12

#	ARTICLE	IF	CITATIONS
1143	HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. <i>Annual Review of Medicine</i> , 2016, 67, 91-101.	5.0	97
1144	Radiotherapy-induced xerostomia, pre-clinical promise of LMS-611. <i>Supportive Care in Cancer</i> , 2016, 24, 629-636.	1.0	7
1145	Autofluorescence imaging in recurrent oral squamous cell carcinoma. <i>Oral and Maxillofacial Surgery</i> , 2016, 20, 27-33.	0.6	25
1146	Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2157-2169.	0.8	33
1147	No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 1841-1848.	0.8	5
1148	Ultrasonography-guided fine-needle aspiration with concurrent small core biopsy of neck masses and lymph nodes yields adequate material for HPV testing in head and neck squamous cell carcinomas. <i>Journal of the American Society of Cytopathology</i> , 2016, 5, 22-30.	0.2	31
1149	Prognostic value of posttreatment neutrophil-lymphocyte ratio in head and neck squamous cell carcinoma treated by chemoradiotherapy. <i>Auris Nasus Larynx</i> , 2017, 44, 199-204.	0.5	34
1150	Long-Term, Prospective Performance of the MDAnderson Dysphagia Inventory in Low-Intermediate Risk Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 700-708.	0.4	46
1151	pRb and CyclinD1 Complement p16 as Immunohistochemical Surrogate Markers of HPV Infection in Head and Neck Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 366-373.	0.6	14
1152	Outcomes of intensity-modulated radiotherapy as primary treatment for oropharyngeal squamous cell carcinoma a European single institution analysis. <i>Clinical Otolaryngology</i> , 2017, 42, 115-122.	0.6	28
1153	Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer. <i>International Journal of Cancer</i> , 2017, 140, 1968-1975.	2.3	104
1154	Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2017, 2, 10-18.	0.6	54
1155	Development of oncolytic virotherapy for the treatment of oral cancer At the waiting stage for clinical use. <i>Oral Science International</i> , 2017, 14, 1-12.	0.3	7
1156	Rapid development of HPV-mediated oropharyngeal squamous cell carcinoma in the setting of immune suppression following autologous stem cell transplantation for Hodgkin lymphoma. <i>Human Pathology: Case Reports</i> , 2017, 9, 43-45.	0.2	1
1157	The changing landscape of oropharyngeal cancer management. <i>Journal of Laryngology and Otology</i> , 2017, 131, 3-7.	0.4	15
1158	Human papillomavirus 16 as a risk factor for oral leukoplakia: A meta-analysis. <i>Meta Gene</i> , 2017, 12, 43-46.	0.3	3
1159	Fine-needle aspiration biopsy of HPV-related squamous cell carcinoma of the head and neck: Current ancillary testing methods for determining HPV status. <i>Diagnostic Cytopathology</i> , 2017, 45, 221-229.	0.5	20
1160	Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances <i>In Vitro</i> and <i>In Vivo</i> Cytotoxicity in Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 591-600.	1.9	52

#	ARTICLE	IF	CITATIONS
1161	Epithelial to mesenchymal transition and HPV infection in squamous cell oropharyngeal carcinomas: the papillophar study. <i>British Journal of Cancer</i> , 2017, 116, 362-369.	2.9	21
1162	HPV DNA in saliva from patients with SCC of the head and neck is specific for p16-positive oropharyngeal tumours. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2017, 46, 3.	0.9	24
1163	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017, 54, 43-57.	3.4	28
1164	Notch1 Overexpression Correlates to Improved Survival in Cancer of the Oropharynx. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 156, 652-659.	1.1	12
1165	The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings. <i>British Journal of Radiology</i> , 2017, 90, 20150404.	1.0	7
1166	Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: A retrospective multicentre study. <i>European Journal of Cancer</i> , 2017, 74, 73-81.	1.3	59
1167	Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. <i>Oral Oncology</i> , 2017, 67, 77-82.	0.8	28
1168	The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation. <i>Practical Radiation Oncology</i> , 2017, 7, e317-e321.	1.1	6
1169	E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynxâ€”ECOG-ACRIN Cancer Research Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 490-497.	0.8	359
1170	The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. <i>Cancer</i> , 2017, 123, 1566-1575.	2.0	187
1171	Integration of highâ€risk human papillomavirus into cellular cancerâ€related genes in head and neck cancer cell lines. <i>Head and Neck</i> , 2017, 39, 840-852.	0.9	34
1172	Characterization of key transcription factors as molecular signatures of <sc>HPV</sc>-positive and <sc>HPV</sc>-negative oral cancers. <i>Cancer Medicine</i> , 2017, 6, 591-604.	1.3	29
1173	Oropharyngeal cancer prognosis by tumour HPV status in France: The multicentric Papillophar study. <i>Oral Oncology</i> , 2017, 67, 29-36.	0.8	52
1174	Radiomics in Head and Neck Cancer: Extracting Valuable Information from Data beyond Recognition. <i>Orl</i> , 2017, 79, 65-71.	0.6	11
1175	AHNS series: Do you know your guidelines? Management of head and neck cancer in the era of human papillomavirus: Educating our patients on human papillomavirus. <i>Head and Neck</i> , 2017, 39, 833-839.	0.9	7
1176	Evolving disparities in the epidemiology of oral cavity and oropharyngeal cancers. <i>Cancer Causes and Control</i> , 2017, 28, 635-645.	0.8	20
1177	Pathologic Markers in Surgically Treated HPV-Associated Oropharyngeal Cancer: Retrospective Study, Systematic Review, and Meta-analysis. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2017, 126, 365-374.	0.6	18
1178	Management of Recurrent and Metastatic HPV-Positive Oropharyngeal Squamous Cell Carcinoma after Transoral Robotic Surgery. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 157, 69-76.	1.1	26



#	ARTICLE	IF	CITATIONS
1179	Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 157, 239-251.	1.1	16
1181	Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study. <i>Oral Oncology</i> , 2017, 69, 56-61.	0.8	24
1182	Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 803-811.	5.1	261
1183	Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients. <i>European Journal of Cancer</i> , 2017, 78, 91-102.	1.3	129
1184	Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2). <i>Oral Oncology</i> , 2017, 70, 65-72.	0.8	8
1185	Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes. <i>Pathology</i> , 2017, 49, 397-404.	0.3	43
1186	Primary, secondary and tertiary prevention of human papillomavirus-driven head and neck cancers. <i>European Journal of Cancer</i> , 2017, 78, 105-115.	1.3	14
1187	HPV16 DNA and integration in normal and malignant epithelium: implications for the etiology of laryngeal squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1105-1110.	0.6	24
1188	CXCR4: A New Player in an Old Scene?. <i>Orl</i> , 2017, 79, 34-42.	0.6	4
1190	Solid Lymph Nodes as an Imaging Biomarker for Risk Stratification in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. <i>American Journal of Neuroradiology</i> , 2017, 38, 1405-1410.	1.2	18
1191	Oncological outcome following de-intensification of treatment for stage I and II HPV negative oropharyngeal cancers with transoral robotic surgery (TORS): A prospective trial. <i>Oral Oncology</i> , 2017, 69, 80-83.	0.8	28
1192	A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN)†. <i>Oral Oncology</i> , 2017, 71, 1-10.	0.8	8
1193	Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer. <i>Microbes and Infection</i> , 2017, 19, 464-475.	1.0	49
1194	Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer. <i>Oral Oncology</i> , 2017, 70, 43-50.	0.8	28
1195	Asian and non-Asian disparities in outcomes of non-nasopharyngeal head and neck cancer. <i>Laryngoscope</i> , 2017, 127, 2528-2533.	1.1	4
1196	Barriers to generating PDX models of HPV-related head and neck cancer. <i>Laryngoscope</i> , 2017, 127, 2777-2783.	1.1	33
1197	Survival analysis of 287 oropharyngeal squamous cell carcinoma patients in a single institution: a retrospective comparison of two consecutive time intervals with surgical and conservative treatment approaches. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 3211-3219.	0.8	3
1198	Advances in Radiation Oncology. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 755-764.	0.5	7



#	ARTICLE	IF	CITATIONS
1199	The impact of developing a speech and swallow rehab program: Improving patient satisfaction and multidisciplinary care. <i>Laryngoscope</i> , 2017, 127, 2578-2581.	1.1	20
1200	<scp>HPV</scp>/E7 induces chemotherapyâ€mediated tumor suppression by ceramideâ€dependent mitophagy. <i>EMBO Molecular Medicine</i> , 2017, 9, 1030-1051.	3.3	44
1201	Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 13-18.	0.9	8
1202	Oropharyngeal squamous cell carcinoma and HPV. Systematic review on overall management. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2017, 118, 103-108.	0.5	8
1204	The use of rapid and cost-effective blood-based biomarkers in combination with tumour TNM stage for individual head and neck cancer patient treatment selection. <i>Medical Oncology</i> , 2017, 34, 63.	1.2	2
1205	Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3. <i>Clinical Cancer Research</i> , 2017, 23, 4501-4510.	3.2	45
1206	Measures of economic advantage associated with HPV-positive head and neck cancers among non-Hispanic black and white males identified through the National Cancer Database. <i>Cancer Epidemiology</i> , 2017, 48, 1-7.	0.8	16
1207	Treatment outcomes in veterans with HPV-positive head and neck cancer. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2017, 38, 188-192.	0.6	16
1208	Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. <i>Laryngoscope</i> , 2017, 127, 842-848.	1.1	37
1209	Influence of human papillomavirus on the clinical presentation of oropharyngeal carcinoma in the United States. <i>Laryngoscope</i> , 2017, 127, 2270-2278.	1.1	36
1210	The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 253.	1.2	26
1211	The Presence of HPV DNA in Neck Lymph Node Metastasis Correlates with Improved Overall Survival of Patients with Oropharyngeal Cancer Undergoing Surgical Treatment. <i>Oncology</i> , 2017, 92, 87-93.	0.9	5
1212	Incidence of contralateral-bilateral nodes in the human papillomavirus era. <i>Laryngoscope</i> , 2017, 127, 1328-1333.	1.1	15
1214	The <i>KRAS</i>-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer. <i>JAMA Oncology</i> , 2017, 3, 483.	3.4	51
1215	p16INK4 expression is of prognostic and predictive value in oropharyngeal cancers independent of human papillomavirus status: a Hungarian study. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1959-1965.	0.8	8
1216	Utility of the Roche Cobas 4800 for detection of high-risk human papillomavirus in formalin-fixed paraffin-embedded oropharyngeal squamous cell carcinoma. <i>Experimental and Molecular Pathology</i> , 2017, 102, 47-49.	0.9	8
1217	Prevalence of HPV infection in racialâ€ethnic subgroups of head and neck cancer patients. <i>Carcinogenesis</i> , 2017, 38, 218-229.	1.3	33
1218	Human papillomavirus status and the relative biological effectiveness of proton radiotherapy in head and neck cancer cells. <i>Head and Neck</i> , 2017, 39, 708-715.	0.9	24

#	ARTICLE	IF	CITATIONS
1219	Human papillomavirus (HPV) infection in a case-control study of oral squamous cell carcinoma and its increasing trend in northeastern Thailand. <i>Journal of Medical Virology</i> , 2017, 89, 1096-1101.	2.5	17
1220	Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. <i>Clinical Cancer Research</i> , 2017, 23, 3072-3083.	3.2	45
1221	DNA p16 <sup>INK4A</sup> expression in oropharyngeal squamous cell carcinoma: Correlations with human papillomavirus status and recurrence after transoral robotic surgery. <i>Head and Neck</i> , 2017, 39, 206-214.	0.9	3
1222	Long-term Functional and Quality-of-Life Outcomes After Transoral Robotic Surgery in Patients With Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 18-27.	1.2	34
1223	Spontaneous regression of laryngeal carcinoma in 10 year old boy: A case report and review of literature. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2017, 103, 10-13.	0.4	10
1224	Upregulation of pAKT(Ser473) expression in progression of HPV-positive oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 2397-2405.	0.9	14
1225	Prevalence of oral HPV infection among healthy individuals and head and neck cancer cases in the French West Indies. <i>Cancer Causes and Control</i> , 2017, 28, 1333-1340.	0.8	15
1226	The Role of Radiotherapy in the Definitive and Postoperative Treatment of Advanced Head and Neck Cancer. <i>Oncology Research and Treatment</i> , 2017, 40, 347-352.	0.8	25
1227	Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer. <i>Cancer</i> , 2017, 123, 4841-4850.	2.0	107
1228	Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma. <i>Acta Oncologica</i> , 2017, 56, 1562-1570.	0.8	9
1229	Did the addition of concurrent chemotherapy to conventional radiotherapy improve survival for patients with HPV+ve and HPV-ve Oropharynx cancer? A population-based study. <i>British Journal of Cancer</i> , 2017, 117, 1105-1112.	2.9	10
1230	Tumour-derived plasma cell-free DNA in patients with head and neck cancer: A short review. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2017, 21, 554-556.	0.6	3
1231	Significance of human papillomavirus positivity in sinonasal squamous cell carcinoma. <i>International Forum of Allergy and Rhinology</i> , 2017, 7, 980-989.	1.5	52
1232	Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7276-7287.	3.2	46
1233	Testing for high-risk HPV in cervical and tonsillar paraffin-embedded tissue using a cartridge-based assay. <i>Apmis</i> , 2017, 125, 910-915.	0.9	2
1234	Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance. <i>Clinical Cancer Research</i> , 2017, 23, 6781-6789.	3.2	110
1235	Quantitative Evaluation of Head and Neck Cancer Treatment-Related Dysphagia in the Development of a Personalized Treatment Deintensification Paradigm. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1271-1278.	0.4	13
1236	Human papillomavirus associated head and neck squamous cell carcinoma: Controversies and new concepts. <i>Journal of Oral Biology and Craniofacial Research</i> , 2017, 7, 198-205.	0.8	64

#	ARTICLE	IF	CITATIONS
1237	Human papillomavirus in oropharyngeal squamous cell carcinoma in South-Eastern Norway: prevalence, genotype, and survival. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 4003-4010.	0.8	25
1238	Nonuniform Distribution of High-risk Human Papillomavirus in Squamous Cell Carcinomas of the Oropharynx. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1722-1728.	2.1	46
1240	Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with primary surgery. <i>Head and Neck</i> , 2017, 39, 2004-2015.	0.9	14
1241	Interpretation of HPV DNA in situ hybridization in HPV-related head and neck squamous cell carcinoma: an achievable task in cell block and small biopsy material. <i>Journal of the American Society of Cytopathology</i> , 2017, 6, 89-95.	0.2	10
1242	Correlation between HPV status at T and N sites of oropharyngeal squamous cell carcinomas. <i>Acta Oto-Laryngologica</i> , 2017, 137, 1260-1264.	0.3	0
1243	The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2017, 2, 99-103.	0.6	14
1244	Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study. <i>Head and Neck</i> , 2017, 39, 2187-2199.	0.9	6
1245	The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 449-461.	2.7	37
1246	HPV-16 in a distinct subset of oral epithelial dysplasia. <i>Modern Pathology</i> , 2017, 30, 1646-1654.	2.9	45
1247	Tumor DNA: an emerging biomarker in head and neck cancer. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 515-523.	2.7	41
1248	Radiomic analysis in prediction of Human Papilloma Virus status. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 49-54.	0.9	49
1249	Current understanding of cancer stem cells: Review of their radiobiology and role in head and neck cancers. <i>Head and Neck</i> , 2017, 39, 1920-1932.	0.9	40
1250	Long-term toxicities in 10-year survivors of radiation treatment for head and neck cancer. <i>Oral Oncology</i> , 2017, 71, 122-128.	0.8	41
1251	Decision Making for Diagnosis and Management. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 783-792.	0.5	1
1252	Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: A systematic review. <i>European Journal of Cancer</i> , 2017, 82, 115-127.	1.3	192
1253	Dual role for p16 in the metastasis process of HPV positive head and neck cancers. <i>Molecular Cancer</i> , 2017, 16, 113.	7.9	18
1254	Independent prognostic role of human papillomavirus genotype in cervical cancer. <i>BMC Infectious Diseases</i> , 2017, 17, 391.	1.3	43
1255	Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18F-FDG-PET-CT and/or diffusion-weighted MRI. <i>BMC Cancer</i> , 2017, 17, 256.	1.1	9

#	ARTICLE	IF	CITATIONS
1256	Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site – current status and challenges. <i>Radiation Oncology</i> , 2017, 12, 82.	1.2	33
1257	Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study. <i>Radiation Oncology</i> , 2017, 12, 97.	1.2	18
1258	Role of transoral robotic surgery in current head&neck practice. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2017, 15, 147-154.	0.8	21
1259	Human polyomavirus and human papillomavirus prevalence and viral load in non-malignant tonsillar tissue and tonsillar carcinoma. <i>Medical Microbiology and Immunology</i> , 2017, 206, 93-103.	2.6	36
1260	Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. <i>Head and Neck</i> , 2017, 39, E34-E39.	0.9	12
1261	Diagnostic accuracy of p16 <sup>INK4a</sup> immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2017, 140, 1186-1198.	2.3	190
1262	Copy number gain of 11q13.3 genes associates with pathological stage in hypopharyngeal squamous cell carcinoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 185-198.	1.5	10
1263	The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 51-64.	157.7	516
1264	Nonkeratinizing Squamous Cell Carcinoma In Situ of the Upper Aerodigestive Tract: An HPV-Related Entity. <i>Head and Neck Pathology</i> , 2017, 11, 152-161.	1.3	7
1265	Clinical relevance and implications of HPV-induced neoplasia in different anatomical locations. <i>Mutation Research - Reviews in Mutation Research</i> , 2017, 772, 51-66.	2.4	40
1266	Relationship Between the Eating Assessment Tool-10 and Objective Clinical Ratings of Swallowing Function in Individuals with Head and Neck Cancer. <i>Dysphagia</i> , 2017, 32, 83-89.	1.0	61
1267	Oral health and human papillomavirus-associated head and neck squamous cell carcinoma. <i>Cancer</i> , 2017, 123, 71-80.	2.0	45
1268	Human papillomavirus as a favorable prognostic factor in a subset of head and neck squamous cell carcinomas: A meta-analysis. <i>Journal of Medical Virology</i> , 2017, 89, 710-725.	2.5	29
1269	Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 125.	3.4	2
1270	The national landscape of human papillomavirus-associated oropharynx squamous cell carcinoma. <i>International Journal of Cancer</i> , 2017, 140, 504-512.	2.3	46
1271	HPV Infection in Head and Neck Cancer. <i>Recent Results in Cancer Research</i> , 2017, , .	1.8	7
1272	Prognostic significance of p16 in squamous cell carcinoma of the larynx and hypopharynx. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2017, 38, 31-37.	0.6	30
1273	Human Papillomavirus (HPV): A Criterion for Therapeutic Decision in Squamous Cell Carcinoma of the Head and Neck?. <i>Recent Results in Cancer Research</i> , 2017, 206, 137-147.	1.8	7

#	ARTICLE	IF	CITATIONS
1274	The Role of Conventional Surgery in Oropharyngeal Cancer. <i>Recent Results in Cancer Research</i> , 2017, 206, 185-195.	1.8	1
1275	Risk Groups for Survival in HPV-Positive and HPV-Negative OPSCC. <i>Recent Results in Cancer Research</i> , 2017, 206, 221-231.	1.8	0
1276	Twenty-four signature genes predict the prognosis of oral squamous cell carcinoma with high accuracy and repeatability. <i>Molecular Medicine Reports</i> , 2018, 17, 2982-2990.	1.1	12
1277	Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. <i>Scientific Reports</i> , 2017, 7, 10117.	1.6	391
1278	Swallowing Exercises in Head and Neck Cancer. <i>Perspectives of the ASHA Special Interest Groups</i> , 2017, 2, 21-26.	0.4	1
1279	Human papillomavirus in head and neck cancer in India: Current status and consensus recommendations. <i>South Asian Journal of Cancer</i> , 2017, 06, 093-098.	0.2	33
1280	Integration of Human Papillomavirus Genomes in Head and Neck Cancer: Is It Time to Consider a Paradigm Shift?. <i>Viruses</i> , 2017, 9, 208.	1.5	46
1281	Coinfection with Epstein-Barr Virus (EBV), Human Papilloma Virus (HPV) and Polyoma BK Virus (BKPyV) in Laryngeal, Oropharyngeal and Oral Cavity Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2752.	1.8	51
1282	Prognostic Impact of AJCC/UICC 8th Edition New Staging Rules in Oropharyngeal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2017, 7, 129.	1.3	97
1283	Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. <i>JCI Insight</i> , 2017, 2, .	2.3	203
1284	In vitro investigation of head and neck cancer stem cell proportions and their changes following X-ray irradiation as a function of HPV status. <i>PLoS ONE</i> , 2017, 12, e0186186.	1.1	18
1285	A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. <i>BMC Medicine</i> , 2017, 15, 165.	2.3	56
1286	HPV infection and p53 and p16 expression in esophageal cancer: are they prognostic factors?. <i>Infectious Agents and Cancer</i> , 2017, 12, 54.	1.2	16
1287	Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas. <i>Clinical Epigenetics</i> , 2017, 9, 95.	1.8	17
1288	Biomarker driven treatment of head and neck squamous cell cancer. <i>Cancers of the Head &amp; Neck</i> , 2017, 2, 6.	6.2	19
1289	Overall Survival in Stage III and IV High-Risk Head and Neck Squamous Cell Carcinoma Patients who received Adjuvant Chemotherapy and Radiation without Cisplatin. <i>Cancer and Clinical Oncology</i> , 2017, 7, 1.	0.2	0
1290	Dental Epidemiology. , 2017, , 258-263.		1
1291	Loss of heterozygosity in FANCG, FANCF and BRIP1 from head and neck squamous cell carcinoma of the oral cavity. <i>International Journal of Oncology</i> , 2017, 50, 2207-2220.	1.4	10

#	ARTICLE	IF	CITATIONS
1292	Human Papillomavirus Subtype 16 and the Pathologic Characteristics of Laryngeal Cancer. <i>OTO Open</i> , 2017, 1, 2473974X1770792.	0.6	3
1293	HPV impacts survival of stage IVC non-oro-pharyngeal HNSCC cancer patients. <i>Otorhinolaryngology-head and Neck Surgery</i> , 2017, 2, .	0.1	8
1294	HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancer. <i>Oncotarget</i> , 2017, 8, 51530-51541.	0.8	40
1295	Misregulation of DNA damage repair pathways in HPV-positive head and neck squamous cell carcinoma contributes to cellular radiosensitivity. <i>Oncotarget</i> , 2017, 8, 29963-29975.	0.8	73
1296	ECOG-ACRIN 1308: Commentary on a Negative Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1969-1970.	0.8	3
1297	Reply to A. Garden et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1970-1971.	0.8	1
1298	Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 4057-4065.	0.8	124
1299	Molecular Biology of Human Papillomavirusâ€“Mediated Head and Neck Cancer. , 2017, , 275-284.		0
1300	Is Induction Chemotherapy Needed to Select Patients for Deintensified Treatment of Human Papillomavirus-Associated Oropharyngeal Cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, 479-481.	0.8	6
1301	Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer. <i>Future Oncology</i> , 2018, 14, 1547-1558.	1.1	4
1302	De-escalation treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma: an evidence-based review for the locally advanced disease. <i>Current Opinion in Oncology</i> , 2018, 30, 146-151.	1.1	14
1303	STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. <i>Oral Oncology</i> , 2018, 78, 186-193.	0.8	42
1304	Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1107-1116.	0.4	57
1305	Evaluating oropharyngeal carcinoma with transcervical ultrasound, CT, and MRI. <i>Oral Oncology</i> , 2018, 78, 177-185.	0.8	13
1306	Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease. <i>Oral Oncology</i> , 2018, 78, 151-155.	0.8	16
1307	Is Human Papilloma Virus Associated with Breast Cancer? A Review of the Molecular Evidence. <i>Acta Cytologica</i> , 2018, 62, 166-177.	0.7	13
1308	Cell-Free Plasma DNA for Disease Stratification and Prognosis in Head and Neck Cancer. <i>Clinical Chemistry</i> , 2018, 64, 959-970.	1.5	27
1309	Radiomics: Big Data statt Biopsie in der Zukunft?. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, S114-S141.	0.2	9



#	ARTICLE	IF	CITATIONS
1310	Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. <i>Annals of Oncology</i> , 2018, 29, 1130-1140.	0.6	94
1312	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. <i>Seminars in Cancer Biology</i> , 2018, 52, 228-240.	4.3	314
1313	Clinicopathologic Characteristics and Survival Outcomes in Floor of Mouth Squamous Cell Carcinoma: A Population-Based Study. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 159, 51-58.	1.1	19
1314	Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. <i>Cancer Research</i> , 2018, 78, 2383-2395.	0.4	31
1315	Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 295-304.	1.6	93
1316	Leveraging Genomics for Head and Neck Cancer Treatment. <i>Journal of Dental Research</i> , 2018, 97, 603-613.	2.5	8
1317	Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?. <i>Anti-Cancer Drugs</i> , 2018, 29, 287-294.	0.7	3
1318	Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing. <i>Annals of Oncology</i> , 2018, 29, 1273-1279.	0.6	122
1319	Trends in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma Incidence, Vermont 1999-2013. <i>Journal of Community Health</i> , 2018, 43, 731-737.	1.9	12
1320	Prognostic significance of HPV status in the re-irradiation of recurrent and second primary cancers of the head and neck. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2018, 39, 257-260.	0.6	8
1321	Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharyngeal, and Hypopharyngeal Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, e79-e85.	0.6	32
1322	Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1210-1216.	0.4	26
1323	Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 32-37.	4.5	16
1324	Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2018, 52, 125-134.	4.3	51
1325	Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 559-597.	1.2	393
1326	Human papillomavirus and nasopharyngeal cancer. <i>Head and Neck</i> , 2018, 40, 696-706.	0.9	31
1327	Unknown primary squamous cell carcinoma of the head and neck: retrospective analysis of 80 cases. <i>Acta Oto-Laryngologica</i> , 2018, 138, 590-596.	0.3	13
1328	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.3	17



#	ARTICLE	IF	CITATIONS
1329	Assessing the performance of a Loop Mediated Isothermal Amplification (LAMP) assay for the detection and subtyping of high-risk suotypes of Human Papilloma Virus (HPV) for Oropharyngeal Squamous Cell Carcinoma (OPSCC) without DNA purification. <i>BMC Cancer</i> , 2018, 18, 166.	1.1	23
1331	Increasing prevalence of human papillomavirusâ€“positive oropharyngeal cancers among older adults. <i>Cancer</i> , 2018, 124, 2993-2999.	2.0	111
1332	Human papillomavirus prevalence in a Midâ€“European oral squamous cell cancer population: A cohort study. <i>Oral Diseases</i> , 2018, 24, 948-956.	1.5	13
1333	Patients with integrated HPV16 in head and neck cancer show poor survival. <i>Oral Oncology</i> , 2018, 80, 52-55.	0.8	42
1334	The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer. <i>World Journal of Urology</i> , 2018, 36, 1431-1440.	1.2	31
1335	Experiences of Head and Neck Cancer Patients in Middle Adulthood: Consequences and Coping. <i>Global Qualitative Nursing Research</i> , 2018, 5, 233339361876033.	0.7	15
1336	Combinational chromosomal aneuploidies and HPV status for prediction of head and neck squamous cell carcinoma prognosis in biopsies and cytological preparations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1129-1141.	1.2	3
1337	Does smoking alter the mutation profile of human papillomavirusâ€“driven head and neck cancers?. <i>European Journal of Cancer</i> , 2018, 94, 61-69.	1.3	29
1338	Prognostic factors for human papillomavirusâ€“positive and negative oropharyngeal carcinomas. <i>Laryngoscope</i> , 2018, 128, E288-E296.	1.1	20
1339	Vulvar cancer: Two pathways with different localization and prognosis. <i>Gynecologic Oncology</i> , 2018, 149, 310-317.	0.6	60
1341	Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer. <i>Oral Oncology</i> , 2018, 79, 64-70.	0.8	42
1342	Biological predictors of radiosensitivity in head and neck squamous cell carcinoma. <i>Clinical Oral Investigations</i> , 2018, 22, 189-200.	1.4	29
1343	Human Papillomavirus in Head and Neck Squamous Cell Carcinoma. <i>Indian Journal of Surgery</i> , 2018, 80, 322-326.	0.2	0
1344	Predictors of Clinicopathologic Stage Discrepancy in Oropharyngeal Squamous Cell Carcinoma: A National Cancer Database Study. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 158, 309-318.	1.1	7
1345	A matched comparison of human papillomavirusâ€“induced squamous cancer of unknown primary with early oropharynx cancer. <i>Laryngoscope</i> , 2018, 128, 1379-1385.	1.1	13
1346	Does HPV status influence survival after vulvar cancer?. <i>International Journal of Cancer</i> , 2018, 142, 1158-1165.	2.3	47
1347	Patientâ€“reported qualityâ€“ofâ€“life outcomes after deâ€“escalated chemoradiation for human papillomavirusâ€“positive oropharyngeal carcinoma: Findings from a phase 2 trial. <i>Cancer</i> , 2018, 124, 521-529.	2.0	21
1348	Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 53-61.	1.2	11

#	ARTICLE	IF	CITATIONS
1349	Urban and rural differences in outcomes of head and neck cancer. <i>Laryngoscope</i> , 2018, 128, 852-858.	1.1	17
1350	Antibodies against human papillomaviruses as diagnostic and prognostic biomarker in patients with neck squamous cell carcinoma from unknown primary tumor. <i>International Journal of Cancer</i> , 2018, 142, 1361-1368.	2.3	25
1351	Cause-specific mortality in HPV+ and HPV+ oropharyngeal cancer patients: insights from a population-based cohort. <i>Cancer Medicine</i> , 2018, 7, 87-94.	1.3	13
1352	Current Status and Future Directions of Treatment Deintensification in Human Papilloma Virus-associated Oropharyngeal Squamous Cell Carcinoma. <i>Seminars in Radiation Oncology</i> , 2018, 28, 27-34.	1.0	29
1353	Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2018, 28, 2-11.	1.0	23
1354	Presenting symptoms and clinical findings in HPV-positive and HPV-negative oropharyngeal cancer patients. <i>Acta Oto-Laryngologica</i> , 2018, 138, 513-518.	0.3	41
1355	Detection of clinically occult primary tumours in patients with cervical metastases of unknown primary tumours: comparison of three-dimensional THRIVE MRI, two-dimensional spin-echo MRI, and contrast-enhanced CT. <i>Clinical Radiology</i> , 2018, 73, 410.e9-410.e15.	0.5	10
1356	P16 positivity and regression grade predict survival after neoadjuvant radiotherapy of OSCC. <i>Oral Diseases</i> , 2018, 24, 544-551.	1.5	3
1357	Human Papillomavirus Genome Integration and Head and Neck Cancer. <i>Journal of Dental Research</i> , 2018, 97, 691-700.	2.5	41
1358	Expression and Significance of Cytokeratin 7, a Squamocolumnar Junction Marker, in Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2018, 12, 448-454.	1.3	6
1359	Treatment deintensification in human papillomavirus-positive oropharynx cancer: Outcomes from the National Cancer Data Base. <i>Cancer</i> , 2018, 124, 717-726.	2.0	41
1360	Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site. <i>Oral Oncology</i> , 2018, 76, 8-15.	0.8	29
1361	Five-year relative survival for human papillomavirus-associated cancer sites. <i>Cancer</i> , 2018, 124, 203-211.	2.0	45
1362	Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?. <i>Clinical and Translational Radiation Oncology</i> , 2018, 8, 4-11.	0.9	141
1363	Modulators of Redox Metabolism in Head and Neck Cancer. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 1660-1690.	2.5	14
1364	Epidemiological and treatment-related factors contribute to improved outcome of oropharyngeal squamous cell carcinoma in Finland. <i>Acta Oncologica</i> , 2018, 57, 541-551.	0.8	15
1365	The NOTCH4-HEY1 Pathway Induces Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 619-633.	3.2	63
1366	Imbalance Between Clinical and Pathologic Staging in the Updated American Joint Commission on Cancer Staging System for Human Papillomavirus-Positive Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 217-219.	0.8	25

#	ARTICLE	IF	CITATIONS
1367	Detection of High-Risk Human Papillomavirus in Oral Cavity Squamous Cell Carcinoma Using Multiple Analytes and Their Role in Patient Survival. <i>Journal of Global Oncology</i> , 2018, 4, 1-33.	0.5	17
1368	HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis. <i>Cancers of the Head &amp; Neck</i> , 2018, 3, 12.	6.2	83
1370	Personalizing Postoperative Treatment of Head and Neck Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 515-522.	1.8	22
1371	Detection of HPV infection in head and neck cancers: Promise and pitfalls in the last ten years: A meta-analysis. <i>Molecular and Clinical Oncology</i> , 2019, 10, 17-28.	0.4	14
1372	De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma. <i>The Cochrane Library</i> , 2018, 12, CD012939.	1.5	24
1373	The pathology of oral cancer. <i>British Dental Journal</i> , 2018, 225, 841-847.	0.3	45
1374	HPV Assessment in Oropharynx Cancer: What is the Gold Standard?. , 2018, , 119-147.		1
1375	Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration. <i>IScience</i> , 2018, 9, 451-460.	1.9	69
1376	Can We Expect Less Toxicities with Newer Forms of Radiotherapy?. , 2018, , 181-212.		0
1377	Cortactin expression: Association with disease progression and survival in oral squamous cell carcinoma. <i>Head and Neck</i> , 2018, 40, 2685-2694.	0.9	6
1378	Development of Care Pathways to Standardize and Optimally Integrate Multidisciplinary Care for Head and Neck Cancer. <i>Oncology Issues</i> , 2018, 33, 28-44.	0.0	6
1379	Dose-Modifying Factor of Radiation Therapy with Concurrent Cisplatin Treatment in HPV-Positive Squamous Cell Carcinoma: A Preclinical Study. <i>Radiation Research</i> , 2018, 189, 644.	0.7	11
1381	Is HPV-Associated Oropharyngeal Cancer Becoming More Common in Older Patients?. <i>Laryngoscope Investigative Otolaryngology</i> , 2018, 3, 446-449.	0.6	3
1382	Treatment Outcomes in HPV-Negative Oropharyngeal Cancer: Surgery plus Radiotherapy Vs. Definitive Chemoradiotherapy. <i>Ear, Nose and Throat Journal</i> , 2018, 97, E1-E7.	0.4	10
1383	Survival and associated factors among patients with oral squamous cell carcinoma (OSCC) in Mulago hospital, Kampala, Uganda. <i>Cancers of the Head &amp; Neck</i> , 2018, 3, 9.	6.2	16
1384	Sensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human Papillomavirus. <i>PLoS ONE</i> , 2018, 13, e0207934.	1.1	12
1385	Prognostic value of textural indices extracted from pretherapeutic <sup>18</sup> F FDG-PET/CT in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 495-502.	0.9	36
1386	Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. <i>The Cochrane Library</i> , 2018, 12, CD006205.	1.5	22

#	ARTICLE	IF	CITATIONS
1387	Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC. <i>Cancers</i> , 2018, 10, 476.	1.7	21
1388	Prognostic role of HPV infection in esophageal squamous cell carcinoma. <i>Infectious Agents and Cancer</i> , 2018, 13, 38.	1.2	14
1389	Smoking-induced control of miR-133a-3p alters the expression of EGFR and HuR in HPV-infected oropharyngeal cancer. <i>PLoS ONE</i> , 2018, 13, e0205077.	1.1	22
1390	Salivary metabolite profiling distinguishes patients with oral cavity squamous cell carcinoma from normal controls. <i>PLoS ONE</i> , 2018, 13, e0204249.	1.1	62
1391	Transoral Robotic Surgery. , 2018, , 445-452.		0
1392	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1029-1035.	0.4	18
1393	Head and Neck Masses. <i>Medical Clinics of North America</i> , 2018, 102, 1013-1025.	1.1	19
1394	Treatment preferences in human papillomavirus-associated oropharyngeal cancer. <i>Future Oncology</i> , 2018, 14, 2521-2530.	1.1	20
1395	Identifying Risk Factors for Morbidity and Mortality in Patients with Primary Head and Neck Cancers in a Nigerian Population. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491878398.	0.6	1
1396	Head and Neck Cancer Research and Support Foundations. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2018, 30, 459-469.	0.4	12
1397	Framework for Speech and Language Pathology Services in Patients with Oral Cavity and Oropharyngeal Cancers. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2018, 30, 397-410.	0.4	6
1398	Outcome of salvage procedures for recurrent oral and oropharyngeal cancer. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2018, 56, 847-853.	0.4	13
1399	Radiomic Profiling of Head and Neck Cancer: <sup>18</sup> F-FDG PET Texture Analysis as Predictor of Patient Survival. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-8.	0.4	36
1400	Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma. <i>Cell Reports</i> , 2018, 25, 1318-1331.e4.	2.9	56
1401	Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. <i>Annals of Oncology</i> , 2018, 29, 2313-2327.	0.6	47
1402	The role of NF- $\kappa$ B and miRNA in oral cancer and cancer stem cells with or without HPV16 infection. <i>PLoS ONE</i> , 2018, 13, e0205518.	1.1	26
1403	Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. <i>Annals of Oncology</i> , 2018, 29, 2247-2253.	0.6	101
1404	Distinct co-expression networks using multi-omic data reveal novel interventional targets in HPV-positive and negative head-and-neck squamous cell cancer. <i>Scientific Reports</i> , 2018, 8, 15254.	1.6	28

#	ARTICLE	IF	CITATIONS
1405	HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. <i>Oral Oncology</i> , 2018, 86, 69-74.	0.8	4
1406	Head and Neck Cytopathology. <i>Surgical Pathology Clinics</i> , 2018, 11, 501-514.	0.7	10
1407	Prognostic significance of cell cycle-associated proteins p16, pRB, cyclin D1 and p53 in resected oropharyngeal carcinoma. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2018, 47, 53.	0.9	22
1408	Matrix metalloproteinase (MMP) and immunosuppressive biomarker profiles of seven head and neck squamous cell carcinoma (HNSCC) cell lines. <i>Translational Cancer Research</i> , 2018, 7, 533-542.	0.4	25
1409	Non-smoking, non-drinking elderly females, a 5-year follow-up of a clinically distinct cohort of oral squamous cell carcinoma patients. <i>Oral Oncology</i> , 2018, 86, 113-120.	0.8	31
1410	Comparison of PI3K Pathway in HPV-Associated Oropharyngeal Cancer With and Without Tobacco Exposure. <i>Laryngoscope Investigative Otolaryngology</i> , 2018, 3, 283-289.	0.6	7
1412	Potential clinical implications of HPV status and expressions of p53 and cyclin D1 among oropharyngeal cancer patients. <i>Journal of Oral Pathology and Medicine</i> , 2018, 47, 945-953.	1.4	9
1413	Effectiveness Outcomes in Patients With Recurrent or Refractory Head and Neck Cancers: Retrospective Analysis of Data From a Community Oncology Database. <i>Clinical Therapeutics</i> , 2018, 40, 1522-1537.	1.1	5
1414	A Review of HPV-Related Head and Neck Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 241.	1.0	208
1415	The role of regulatory T cells in pathogenesis and therapy of human papillomavirus-related diseases, especially in cancer. <i>Infection, Genetics and Evolution</i> , 2018, 65, 406-413.	1.0	13
1416	Sex differences in patients with high risk HPV-associated and HPV negative oropharyngeal and oral cavity squamous cell carcinomas. <i>Cancers of the Head &amp; Neck</i> , 2018, 3, 4.	6.2	19
1417	A cross-sectional survey of awareness of human papillomavirus-associated oropharyngeal cancers among general practitioners in the UK. <i>BMJ Open</i> , 2018, 8, e023339.	0.8	20
1418	Head and Neck Tumors. , 2018, , 1-136.		1
1419	Oligometastatic status as predictor of survival in metastatic human papillomavirus-positive oropharyngeal carcinoma. <i>Head and Neck</i> , 2018, 40, 1685-1690.	0.9	25
1420	Circulating human papillomavirus DNA as a surveillance tool in head and neck squamous cell carcinoma: A systematic review and meta-analysis. <i>Clinical Otolaryngology</i> , 2018, 43, 1242-1249.	0.6	33
1421	Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA combined with cisplatin inhibits cellular growth and induces apoptosis in HPV-positive head and neck cancer cells. <i>Cancer Gene Therapy</i> , 2018, 25, 274-283.	2.2	11
1422	HPV status, like politics, is local—evaluating p16 staining and a new staging system in a Dutch cohort of oropharynx cancer. <i>Annals of Oncology</i> , 2018, 29, 1089-1090.	0.6	7
1423	Experimental investigation of radiobiology in head and neck cancer cell lines as a function of HPV status, by MTT assay. <i>Scientific Reports</i> , 2018, 8, 7744.	1.6	6

#	ARTICLE	IF	CITATIONS
1424	Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 759-770.	1.0	23
1425	HPV – Das andere Kopf-Hals-Karzinom. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, S48-S113.	0.2	35
1426	Cystic masses of the lateral neck – Proposition of an algorithm for increased treatment efficiency. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2018, 46, 1664-1668.	0.7	16
1427	Vanderbilt head and neck symptom survey, version 2.0: Clinical and research utility for identification of symptom clusters and changes in symptoms over time. <i>Oral Oncology</i> , 2018, 83, 25-31.	0.8	7
1428	Oropharyngeal cancer is no longer a disease of younger patients and the prognostic advantage of Human Papillomavirus is attenuated among older patients: Analysis of the National Cancer Database. <i>Oral Oncology</i> , 2018, 83, 147-153.	0.8	65
1429	Radiotherapy dose–volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. <i>Radiotherapy and Oncology</i> , 2018, 128, 442-451.	0.3	28
1430	Human papillomavirus prevalence and clinicopathological associations in oropharyngeal squamous cell carcinoma in the Lebanese population. <i>Journal of Laryngology and Otology</i> , 2018, 132, 636-641.	0.4	6
1431	Checkpoint Inhibitors in Head and Neck Cancer: Current Knowledge and Perspectives. <i>Journal of Investigative Medicine</i> , 2018, 66, 1023-1030.	0.7	26
1432	Metastatic squamous cell carcinoma of known and unknown primary origin treated with axillary or inguinal lymphadenectomy. <i>American Journal of Surgery</i> , 2018, 216, 963-968.	0.9	4
1433	Racial and Ethnic Disparities in Travel for Head and Neck Cancer Treatment and the Impact of Travel Distance on Survival. <i>Cancer</i> , 2018, 124, 3181-3191.	2.0	47
1434	Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck – clinical results from the cohort of the clinical cooperation group – Personalized Radiotherapy in Head and Neck Cancer – Radiation Oncology, 2018, 13, 123.	1.2	24
1435	Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy. <i>Oncolmmunology</i> , 2018, 7, e1498439.	2.1	124
1436	Photoacoustic Imaging as an Early Biomarker of Radio Therapeutic Efficacy in Head and Neck Cancer. <i>Theranostics</i> , 2018, 8, 2064-2078.	4.6	39
1437	Survival Rates for Patients With Barrett High-grade Dysplasia and Esophageal Adenocarcinoma With or Without Human Papillomavirus Infection. <i>JAMA Network Open</i> , 2018, 1, e181054.	2.8	20
1438	Emerging and re-emerging infectious disease in otorhinolaryngology. <i>Acta Otorhinolaryngologica Italica</i> , 2018, 38, S1-S106.	0.7	6
1439	High NOTCH1 mRNA Expression Is Associated with Better Survival in HNSCC. <i>International Journal of Molecular Sciences</i> , 2018, 19, 830.	1.8	11
1440	De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma. <i>The Cochrane Library</i> , 2018, , .	1.5	2
1441	Prognostic Significance of HPV and p16 Status in Men Diagnosed with Penile Cancer: A Systematic Review and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1123-1132.	1.1	64



#	ARTICLE	IF	CITATIONS
1442	Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer. <i>PLoS ONE</i> , 2018, 13, e0200509.	1.1	6
1443	Effect of neoadjuvant chemotherapy and its correlation with HPV status, EGFR, Her-2-neu, and GADD45 expression in oral squamous cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2018, 16, 20.	0.8	14
1444	Association of Human Papillomavirus Status at Head and Neck Carcinoma Subsites With Overall Survival. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 519.	1.2	106
1445	Expressional analysis of disease-relevant signalling-pathways in primary tumours and metastasis of head and neck cancers. <i>Scientific Reports</i> , 2018, 8, 7326.	1.6	16
1446	Cancer stage and pack-years, but not p16 or HPV, are relevant for survival in hypopharyngeal and laryngeal squamous cell carcinomas. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 1837-1843.	0.8	22
1447	Retrospective study of survival in human papillomavirus-negative oropharyngeal squamous cell carcinoma treated with primary surgery and associated prognostic factors. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2355-2362.	1.0	2
1448	Loss of Function of Canonical Notch Signaling Drives Head and Neck Carcinogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 6308-6318.	3.2	43
1449	MAGE-A9 in head and neck cancer: Prognostic value and preclinical findings in the context of irradiation. <i>Molecular and Clinical Oncology</i> , 2018, 8, 513-519.	0.4	3
1451	Evaluation and validation of HPV real-time PCR assay for the detection of HPV DNA in oral cytobrush and FFPE samples. <i>Scientific Reports</i> , 2018, 8, 11313.	1.6	16
1452	Biology and Epidemiology of Human Papillomavirus-Related Head and Neck Cancer. <i>Current Cancer Research</i> , 2018, , 545-583.	0.2	0
1453	Biomarkers for early identification of recurrences in HPV-driven oropharyngeal cancer. <i>Oral Oncology</i> , 2018, 82, 108-114.	0.8	26
1457	Early HPV-Related Tonsil Cancer. , 2018, , 628-648.		0
1458	Early HPV-Related Base of Tongue Cancer. , 2018, , 649-676.		0
1459	Advanced HPV-Related Oropharynx Cancer. , 2018, , 677-699.		0
1460	Advanced HPV-Unrelated Pharynx Cancer. , 2018, , 700-760.		0
1461	Impact of HPV-associated p16-expression and other clinical factors on therapeutic decision-making in patients with oropharyngeal cancer: A GETTEC multicentric study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1908-1913.	0.5	14
1462	Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1393-1399.	3.0	43
1463	Smoking impact on HPV driven head and neck cancer's oncological outcomes?. <i>Oral Oncology</i> , 2018, 82, 131-137.	0.8	44

#	ARTICLE	IF	CITATIONS
1464	Correlation of human papillomavirus infection and clinical parameters with five-year survival in oral squamous cell carcinoma. <i>Journal of Laryngology and Otology</i> , 2018, 132, 628-635.	0.4	8
1465	International Endocervical Adenocarcinoma Criteria and Classification. <i>American Journal of Surgical Pathology</i> , 2019, 43, 75-83.	2.1	66
1466	The role of tumor DNA as a diagnostic tool for head and neck squamous cell carcinoma. <i>Seminars in Cancer Biology</i> , 2019, 55, 1-7.	4.3	43
1467	Retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia and cetuximab for carcinoma of the buccal mucosa with N3 lymph node metastasis: a case report. <i>Oral Radiology</i> , 2019, 35, 77-83.	0.9	3
1468	Predicting cancer outcome: Artificial intelligence vs. pathologists. <i>Oral Diseases</i> , 2019, 25, 643-645.	1.5	8
1469	High Level Expression of MHC-II in HPV+ Head and Neck Cancers Suggests that Tumor Epithelial Cells Serve an Important Role as Accessory Antigen Presenting Cells. <i>Cancers</i> , 2019, 11, 1129.	1.7	20
1470	Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients. <i>Oral Science International</i> , 2019, 16, 49-68.	0.3	2
1471	The changing landscape of head and neck cancer radiotherapy patients: is high-risk, prolonged feeding tube use indicative of on-treatment weight loss?. <i>Journal of Medical Radiation Sciences</i> , 2019, 66, 250-258.	0.8	8
1472	Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 548-558.	0.4	37
1473	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
1474	NSD1 mutations by HPV status in head and neck cancer: differences in survival and response to DNA-damaging agents. <i>Cancers of the Head &amp; Neck</i> , 2019, 4, 3.	6.2	21
1475	Antitumour effects of metformin and curcumin in human papillomavirus positive and negative head and neck cancer cells. <i>Molecular Carcinogenesis</i> , 2019, 58, 1946-1959.	1.3	17
1476	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2019, 11, 1057.	1.7	25
1477	Outcomes in surgically resectable oropharynx cancer treated with transoral robotic surgery versus definitive chemoradiation. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2019, 40, 673-677.	0.6	27
1478	Development and validation of radiomic signatures of head and neck squamous cell carcinoma molecular features and subtypes. <i>EBioMedicine</i> , 2019, 45, 70-80.	2.7	74
1479	Isoform-Specific Role of Akt in Oral Squamous Cell Carcinoma. <i>Biomolecules</i> , 2019, 9, 253.	1.8	38
1480	ATR inhibition sensitizes HPV <sup>-</sup> and HPV+ head and neck squamous cell carcinoma to cisplatin. <i>Oral Oncology</i> , 2019, 95, 35-42.	0.8	34
1481	p16 immunocytochemistry on aspirate smears of neck masses: Another option for determining the HPV status in metastatic head and neck squamous cell carcinoma. <i>Cancer Cytopathology</i> , 2019, 127, 423-425.	1.4	0

#	ARTICLE	IF	CITATIONS
1482	Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells. , 2019, 7, 261.		82
1483	Immune gene expression in head and neck squamous cell carcinoma patients. <i>European Journal of Cancer</i> , 2019, 121, 210-223.	1.3	45
1484	Multi-institutional analysis of outcomes following transoral surgery for HPV-positive oropharyngeal squamous cell carcinoma in elderly patients. <i>Head and Neck</i> , 2019, 41, 3933-3939.	0.9	8
1485	The role of the innate and adaptive immune response in HPV-associated oropharyngeal squamous cell carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 508-512.	0.6	10
1486	Selections from the current literature. <i>Journal of the American Dental Association</i> , 2019, 150, 979-981.	0.7	0
1487	The evolving landscape of HPV-related neoplasia in the head and neck. <i>Human Pathology</i> , 2019, 94, 29-39.	1.1	15
1488	Low prevalence of p16-positive HPV-related head-neck cancers in Thailand: tertiary referral center experience. <i>BMC Cancer</i> , 2019, 19, 1050.	1.1	25
1489	Radiotherapy-induced xerostomia: a randomised, double-blind, controlled trial of Visco-ease, a oral spray compared with placebo in patients with cancer of the head and neck. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2019, 57, 1119-1125.	0.4	8
1490	The 100 most cited manuscripts in head and neck cancer: a bibliometric analysis. <i>Journal of Laryngology and Otology</i> , 2019, 133, 936-942.	0.4	9
1491	Deintensification of Adjuvant Treatment After Transoral Surgery in Patients With Human Papillomavirus-Positive Oropharyngeal Cancer: The Conception of the PATHOS Study and Its Development. <i>Frontiers in Oncology</i> , 2019, 9, 936.	1.3	43
1492	Serotipos de alto riesgo del virus de papiloma humano (VPH) en pacientes con lesiones exofíticas en la cavidad oral. <i>Salud Uninorte</i> , 2019, 34, 420-429.	0.0	0
1493	MRI for Radiation Therapy Planning in Human Papillomavirus-associated Gynecologic Cancers. <i>Radiographics</i> , 2019, 39, 1476-1500.	1.4	4
1494	Treatment trends in oropharyngeal carcinoma: Surgical technology meets the epidemic. <i>Oral Oncology</i> , 2019, 97, 62-68.	0.8	16
1495	Human papillomavirus-associated squamous cell carcinoma of the larynx or hypopharynx: Clinical outcomes and implications for laryngeal preservation. <i>Oral Oncology</i> , 2019, 98, 20-27.	0.8	24
1496	Burden of treatment: Reported outcomes in a head and neck cancer survivorship clinic. <i>Laryngoscope</i> , 2019, 129, E437-E444.	1.1	36
1497	Head and Neck Tumors. , 2019, , 627-762.		0
1498	Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 640-648.	1.0	8
1499	Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2019, 15, 909-923.	1.1	10

#	ARTICLE	IF	CITATIONS
1500	Histoeypigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments. <i>Oncogene</i> , 2019, 38, 3551-3568.	2.6	20
1501	Treatment trends in head and neck cancer: Surveillance, Epidemiology, and End Results (SEER) Patterns of Care analysis. <i>Cancer Causes and Control</i> , 2019, 30, 721-732.	0.8	25
1502	In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer. <i>Human Pathology</i> , 2019, 90, 97-105.	1.1	39
1503	Projected oropharyngeal carcinoma incidence among middle-aged US men. <i>Head and Neck</i> , 2019, 41, 3226-3234.	0.9	33
1504	Paediatric virology and human papillomaviruses: An update. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 4337-4343.	0.8	20
1505	Expression of estrogen receptor alpha is associated with pathogenesis and prognosis of human papillomavirus-positive oropharyngeal cancer. <i>International Journal of Cancer</i> , 2019, 145, 1547-1557.	2.3	25
1506	Human papillomavirus and lung cancer: an overview and a meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1919-1937.	1.2	17
1507	Biomarkers in Head and Neck Cancer an Update. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2019, 71, 1002-1011.	0.3	17
1508	Oncological outcome following initiation of treatment for stage III and IV HPV negative oropharyngeal cancers with transoral robotic surgery (TORS). <i>European Journal of Surgical Oncology</i> , 2019, 45, 2137-2142.	0.5	16
1509	High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the serum are associated with poor prognosis in HPV-negative squamous cell oropharyngeal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1263-1272.	2.0	12
1510	Priorities of human papillomavirus-associated oropharyngeal cancer patients at diagnosis and after treatment. <i>Oral Oncology</i> , 2019, 95, 11-15.	0.8	19
1511	Dental intervention against osteoradionecrosis of the jaws in irradiated patients with head and neck malignancy: a single-arm prospective study. <i>Oral and Maxillofacial Surgery</i> , 2019, 23, 297-305.	0.6	17
1512	The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status. <i>Radiotherapy and Oncology</i> , 2019, 140, 54-61.	0.3	23
1513	HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8+ T-cell Tumor Infiltration in OPSCC. <i>Cancer Immunology Research</i> , 2019, 7, 1202-1213.	1.6	24
1514	Immune checkpoint inhibitors in the treatment of virus-associated cancers. <i>Journal of Hematology and Oncology</i> , 2019, 12, 58.	6.9	43
1515	Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1909-1918.	0.8	150
1516	A histopathological evaluation and potential prognostic implications of oral squamous cell carcinoma with adverse features. <i>Oral Oncology</i> , 2019, 95, 65-73.	0.8	32
1517	Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 364-372.	1.8	26

#	ARTICLE	IF	CITATIONS
1518	Prognostic value of pre-treatment CT texture analysis in combination with change in size of the primary tumor in response to induction chemotherapy for HPV-positive oropharyngeal squamous cell carcinoma. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 399-408.	1.1	13
1519	Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx. <i>International Journal of Cancer</i> , 2019, 145, 3152-3162.	2.3	48
1520	Survival outcomes by high-risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: A propensity-scored analysis of the National Cancer Data Base. <i>Cancer</i> , 2019, 125, 2782-2793.	2.0	40
1521	Unlocking the Potential of Saliva-Based Test to Detect HPV-16-Driven Oropharyngeal Cancer. <i>Cancers</i> , 2019, 11, 473.	1.7	32
1522	Proteomes of exosomes from HPV(+) or HPV(-) head and neck cancer cells: differential enrichment in immunoregulatory proteins. <i>Oncolmmunology</i> , 2019, 8, e1593808.	2.1	30
1523	Development and Assessment of a Novel Composite Pathologic Risk Stratification for Surgically Resected Human Papillomavirus-Associated Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 1105.	1.2	5
1524	HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1920-1928.	1.4	72
1525	Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 985.	3.4	71
1526	Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma. <i>Cancers</i> , 2019, 11, 584.	1.7	12
1527	Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals. <i>Journal of Clinical Oncology</i> , 2019, 37, 1538-1546.	0.8	127
1528	Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 52.	1.8	222
1529	HPV in Head and Neck Carcinomas: Different HPV Profiles in Oropharyngeal Carcinomas – Why?. <i>Acta Cytologica</i> , 2019, 63, 124-142.	0.7	24
1530	Dynamic host immune response in virus-associated cancers. <i>Communications Biology</i> , 2019, 2, 109.	2.0	34
1531	Role of Infectious Agents on Development of Esophageal Carcinomas. <i>Current Cancer Research</i> , 2019, , 39-65.	0.2	0
1532	Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG1016 and De-ESCALaTE. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 1275-1281.	0.8	13
1533	Molecular Diagnostics in Head and Neck Squamous Cell Carcinoma. , 2019, , 165-185.		3
1534	Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden. <i>Annals of Oncology</i> , 2019, 30, 744-756.	0.6	134
1535	Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in cancer stem cell heterogeneity, plasticity and treatment response. <i>Radiotherapy and Oncology</i> , 2019, 135, 1-12.	0.3	24

#	ARTICLE	IF	CITATIONS
1536	Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment. <i>Cancer Research</i> , 2019, 79, 2054-2064.	0.4	53
1537	Validation of NRG oncology/RTOGâ€œ129 risk groups for HPVâ€œpositive and HPVâ€œnegative oropharyngeal squamous cell cancer: Implications for riskâ€œbased therapeutic intensity trials. <i>Cancer</i> , 2019, 125, 2027-2038.	2.0	58
1538	Human Papillomavirus Genotype Detection in Oral Gargle Samples Among Men With Newly Diagnosed Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 460.	1.2	12
1539	Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer. <i>Molecular Medicine Reports</i> , 2019, 19, 2781-2791.	1.1	3
1540	Patients' preferences concerning followâ€œup after curative head and neck cancer treatment: A crossâ€œsectional pilot study. <i>Head and Neck</i> , 2019, 41, 2174-2181.	0.9	13
1542	Inter-observer and segmentation method variability of textural analysis in pre-therapeutic FDG PET/CT in head and neck cancer. <i>PLoS ONE</i> , 2019, 14, e0214299.	1.1	23
1543	Human papillomavirus DNA detection, p16INK4a, and oral cavity cancer in a U.S. population. <i>Oral Oncology</i> , 2019, 91, 92-96.	0.8	15
1544	Detection of Solid Tumor Molecular Residual Diseaseâ€œ(MRD) Using Circulating Tumor DNA (ctDNA). <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 311-331.	1.6	123
1545	Infections Related to Development of Head and Neck Cancers. <i>Current Cancer Research</i> , 2019, , 185-203.	0.2	0
1546	Impact of Smoking on Outcomes of HPV-related Oropharyngeal Cancer Treated with Primary Radiation or Surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1125-1131.	0.4	46
1547	Lymphocyte telomere length predicts clinical outcomes of HPV-positive oropharyngeal cancer patients after definitive radiotherapy. <i>Carcinogenesis</i> , 2019, 40, 735-741.	1.3	5
1548	Real-time PCR HPV genotyping in fine needle aspirations of metastatic head and neck squamous cell carcinoma: Exposing the limitations of conventional p16 immunostaining. <i>Oral Oncology</i> , 2019, 90, 74-79.	0.8	16
1549	Examining adjuvant radiation dose in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 2133-2142.	0.9	5
1550	Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for P <sup>32</sup> Np63I <sub>±</sub> . <i>British Journal of Cancer</i> , 2019, 120, 658-667.	2.9	37
1551	Postoperative Treatment of Oropharyngeal Cancer in the Era of Human Papillomavirus. <i>Current Treatment Options in Oncology</i> , 2019, 20, 20.	1.3	11
1552	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2019, 29, 111-125.	1.0	4
1553	Infiltration of FoxP3+ Regulatory T Cells is a Strong and Independent Prognostic Factor in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2019, 11, 227.	1.7	64
1554	Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirusâ€œassociated oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 857-864.	0.9	28



#	ARTICLE	IF	CITATIONS
1555	<i>JAK3</i> Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients. <i>Cancer Prevention Research</i> , 2019, 12, 255-270.	0.7	19
1556	Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 1221-1229.	0.8	5
1557	Enhanced Radiation Sensitivity of Human Papillomavirus-Driven Head and Neck Cancer: Focus on Immunological Aspects. <i>Frontiers in Immunology</i> , 2019, 10, 2831.	2.2	19
1558	Current Standards for Organ Preservation in Locoregionally Advanced Non-nasopharyngeal Head and Neck Cancer and Evolving Strategies for Favorable-Risk and Platinum-Ineligible Populations. <i>Current Treatment Options in Oncology</i> , 2019, 20, 89.	1.3	4
1559	Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 588-596.	0.9	5
1560	Human Papillomavirus-Associated Oropharyngeal High-Grade Neuroendocrine Carcinoma in an Adolescent: Case Report and Review of Literature. <i>Clinical Medicine Insights Pediatrics</i> , 2019, 13, 117955651987052.	0.7	5
1561	Susceptibility of Multiple Primary Cancers in Patients With Head and Neck Cancer: Nature or Nurture?. <i>Frontiers in Oncology</i> , 2019, 9, 1275.	1.3	10
1562	ACLY (ATP Citrate Lyase) Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas and is a Novel Predictive Radiotherapy Biomarker. <i>Cancers</i> , 2019, 11, 1971.	1.7	21
1563	HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes. <i>Laryngoscope</i> , 2019, 129, 684-691.	1.1	34
1564	Racial disparities in tumor features and outcomes of patients with squamous cell carcinoma of the tonsil. <i>Laryngoscope</i> , 2019, 129, 643-654.	1.1	15
1565	The IL-1/IL-1R axis induces greater fibroblast-derived chemokine release in human papillomavirus-negative compared to positive oropharyngeal cancer. <i>International Journal of Cancer</i> , 2019, 144, 334-344.	2.3	14
1566	Survival analysis of head and neck cancer: Results from a hospital based cancer registry in southern Karnataka. <i>Clinical Epidemiology and Global Health</i> , 2019, 7, 346-350.	0.9	5
1567	Initial presentation of human papillomavirus-related head and neck cancer: A retrospective review. <i>Laryngoscope</i> , 2019, 129, 877-882.	1.1	19
1568	Outcomes of relapsed human papillomavirus-related oropharyngeal squamous cell carcinoma treated with curative intent. <i>Head and Neck</i> , 2019, 41, 1312-1319.	0.9	10
1569	High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: Systematic review and meta-analysis. <i>Head and Neck</i> , 2019, 41, 1525-1535.	0.9	61
1570	Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 126-137.	3.3	12
1571	The Impact of a Stepwise Approach to Primary Tumor Detection in Squamous Cell Carcinoma of the Neck With Unknown Primary. <i>Laryngoscope</i> , 2019, 129, 1610-1616.	1.1	30
1572	Smoking and papillomavirus DNA in patients with p16-positive N3 oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 1039-1045.	0.9	3

#	ARTICLE	IF	CITATIONS
1573	Human Papillomavirus (HPV) Testing of Head and Neck Cancers. , 2019, , 181-197.		3
1574	Virus-associated carcinomas of the head & neck: Update from the 2017 WHO classification. Annals of Diagnostic Pathology, 2019, 38, 29-42.	0.6	8
1575	Prevalence of comorbidities and effect on survival in survivors of human papillomavirus-related and human papillomavirus-unrelated head and neck cancer in the United States. Cancer, 2019, 125, 249-260.	2.0	32
1576	Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms. Head and Neck Pathology, 2019, 13, 397-414.	1.3	5
1577	Cytopathologic characteristics of HPV-related small cell carcinoma of the oropharynx. Cancer Cytopathology, 2019, 127, 35-43.	1.4	5
1578	Risk stratification models in human papillomavirus-associated oropharyngeal squamous cell carcinoma: The Nova Scotia distribution. Journal of Otolaryngology - Head and Neck Surgery, 2019, 48, 3.	0.9	3
1579	APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene, 2019, 38, 3475-3487.	2.6	81
1580	Systematic review on location and timing of distant progression in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas. Head and Neck, 2019, 41, 793-798.	0.9	15
1581	Evolving role of human papillomavirus as a clinically significant biomarker in head and neck squamous cell carcinoma. Expert Review of Molecular Diagnostics, 2019, 19, 63-70.	1.5	12
1582	Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. Oral Oncology, 2019, 89, 72-78.	0.8	28
1583	Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity. Journal of the National Cancer Institute, 2019, 111, 233-244.	3.0	21
1584	The Human Papillomavirus as a Common Pathogen in Oropharyngeal, Anal and Cervical Cancers. Clinical Oncology, 2019, 31, 81-90.	0.6	30
1585	Radiographic muscle invasion not a recurrence predictor in HPV-associated oropharyngeal squamous cell carcinoma. Laryngoscope, 2019, 129, 871-876.	1.1	0
1586	Genomic Applications in Head and Neck Cancers. , 2019, , 309-324.		0
1587	HIV/AIDS-Associated Viral Oncogenesis. Cancer Treatment and Research, 2019, , .	0.2	0
1588	Molecular Diagnostics in Cytopathology. , 2019, , .		0
1589	The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status. Cancer, 2019, 125, 761-769.	2.0	69
1590	ERCC1, XPF and XPA-related locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma. Clinical Oral Investigations, 2019, 23, 3319-3329.	1.4	17

#	ARTICLE	IF	CITATIONS
1591	Short half-life of HPV16 E6 and E7 mRNAs sensitizes HPV16-positive tonsillar cancer cell line HN26 to DNA-damaging drugs. <i>International Journal of Cancer</i> , 2019, 144, 297-310.	2.3	9
1592	Human papillomavirus and oral and oropharyngeal carcinoma: the essentials. <i>Australian Dental Journal</i> , 2019, 64, 11-18.	0.6	25
1593	Individualized survival prediction for patients with oropharyngeal cancer in the human papillomavirus era. <i>Cancer</i> , 2019, 125, 68-78.	2.0	16
1594	Time series analysis of TP53 gene mutations in recurrent HPV-negative vulvar squamous cell carcinoma. <i>Modern Pathology</i> , 2019, 32, 415-422.	2.9	12
1595	Automated RNA In Situ Hybridization for 18 High Risk Human Papilloma Viruses in Squamous Cell Carcinoma of the Head and Neck: Comparison With p16 Immunohistochemistry. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 160-164.	0.6	8
1596	Serum Adenosine Deaminase Levels and Human Papillomavirus as Prognostic and Predictive Factors for Laryngeal and Pharyngeal Carcinomas. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2019, 71, 522-527.	0.3	2
1597	Tumor-infiltrating lymphocyte quantification stratifies early-stage human papillomavirus oropharynx cancer prognosis. <i>Laryngoscope</i> , 2020, 130, 930-938.	1.1	24
1598	From presumed benign neck masses to delayed recognition of human papillomavirus-positive oropharyngeal cancer. <i>Laryngoscope</i> , 2020, 130, 392-397.	1.1	6
1599	Tumour Cell Anaplasia and Multinucleation as Prognosticators in Oropharyngeal Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2020, 14, 606-615.	1.3	6
1600	Radiation-Induced Hypothyroidism After Radical Intensity Modulated Radiation Therapy for Oropharyngeal Carcinoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 111-119.	0.6	14
1601	Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?. <i>Cancer</i> , 2020, 126, 58-66.	2.0	10
1602	Effects of HPV Status on Responsiveness to Ionizing Radiation vs Photodynamic Therapy in Head and Neck Cancer Cell lines. <i>Photochemistry and Photobiology</i> , 2020, 96, 652-657.	1.3	19
1603	Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable. <i>International Journal of Cancer</i> , 2020, 146, 2166-2174.	2.3	8
1604	Comparative Performance of High-Risk Human Papillomavirus RNA and DNA In Situ Hybridization on College of American Pathologists Proficiency Tests. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 344-349.	1.2	22
1606	Prognostic significance of MTOR expression in HPV positive and negative head and neck cancers treated by chemoradiation. <i>Head and Neck</i> , 2020, 42, 153-162.	0.9	4
1607	Conjunctival mucoepidermoid carcinoma™ revisited: a revision of terminology, based on morphologic, immunohistochemical and molecular findings of 14 cases, and the 2018 WHO Classification of Tumours of the Eye. <i>Modern Pathology</i> , 2020, 33, 1242-1255.	2.9	6
1608	The role of multidisciplinary decision making in oropharyngeal cancer: do we follow guidelines and are treatment decisions being implemented?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 947-952.	0.8	1
1609	Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age. <i>Oral Oncology</i> , 2020, 101, 104522.	0.8	19

#	ARTICLE	IF	CITATIONS
1610	Human papilloma virus related squamous cell carcinomas of the head and neck: diagnosis, clinical implications and detection of HPV. <i>Pathology</i> , 2020, 52, 179-191.	0.3	60
1611	Oropharyngeal Squamous Cell Carcinoma in 390 Patients: Analysis of Clinical and Histological Criteria Which Significantly Impact Outcome. <i>Head and Neck Pathology</i> , 2020, 14, 666-688.	1.3	22
1612	A global epidemic increase of an HPV-induced tonsil and tongue base cancer – potential benefit from a pan-gender use of HPV vaccine. <i>Journal of Internal Medicine</i> , 2020, 287, 134-152.	2.7	71
1613	Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma. <i>Cancer</i> , 2020, 126, 1413-1423.	2.0	41
1614	Oropharyngeal Human Papillomavirus and Head and Neck Cancer. , 2020, , 205-217.		0
1615	The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis. <i>Pathology Research and Practice</i> , 2020, 216, 152768.	1.0	20
1616	Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples. <i>Oral Oncology</i> , 2020, 100, 104487.	0.8	4
1617	HPV33+HNSCC is associated with poor prognosis and has unique genomic and immunologic landscapes. <i>Oral Oncology</i> , 2020, 100, 104488.	0.8	33
1618	An Analysis and Comparison of Survival and Functional Outcomes in Oropharyngeal Squamous Cell Carcinoma Patients Treated with Concurrent Chemoradiation Therapy within City of Hope Cancer Center Sites. <i>Journal of Clinical Medicine</i> , 2020, 9, 3083.	1.0	1
1619	Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging. <i>Oral Oncology</i> , 2020, 111, 105030.	0.8	7
1620	Prognostic nomograms based on immune scores for head-neck squamous cell carcinoma patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 278, 2493-2500.	0.8	6
1622	Open Versus Robotic Surgery for Oropharyngeal Cancer. <i>Otolaryngologic Clinics of North America</i> , 2020, 53, 995-1003.	0.5	6
1623	CTEN Induces Tumour Cell Invasion and Survival and Is Prognostic in Radiotherapy-Treated Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 2963.	1.7	5
1624	Current Indications for Transoral Robotic Surgery in Oropharyngeal Cancer. <i>Otolaryngologic Clinics of North America</i> , 2020, 53, 949-964.	0.5	9
1625	Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7621.	1.8	12
1626	Functional and survival outcomes in elderly patients undergoing transoral robotic surgery. <i>Oral Oncology</i> , 2020, 111, 104954.	0.8	3
1627	Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7032.	1.8	20
1628	Prediction of survival outcome based on clinical features and pretreatment 18FDG-PET/CT for HNSCC patients. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 195, 105669.	2.6	11

#	ARTICLE	IF	CITATIONS
1629	Cross validated serum small extracellular vesicle microRNAs for the detection of oropharyngeal squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 280.	1.8	11
1630	A multi-objective radiomics model for the prediction of locoregional recurrence in head and neck squamous cell cancer. <i>Medical Physics</i> , 2020, 47, 5392-5400.	1.6	20
1631	Head and neck squamous cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2020, 6, 92.	18.1	1,649
1632	Characterization of human papillomavirus (HPV) 16 E6 seropositive individuals without HPV-associated malignancies after 10 years of follow-up in the UK Biobank. <i>EBioMedicine</i> , 2020, 62, 103123.	2.7	21
1633	Bilateral inguinal HPV-related squamous cell carcinomas with warty-basaloid features: An unusual presentation in a non-penile location. <i>Current Problems in Cancer Case Reports</i> , 2020, 2, 100036.	0.1	0
1634	Human Papillomavirus Infection in Head and Neck Squamous Cell Carcinomas: Transcriptional Triggers and Changed Disease Patterns. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 537650.	1.8	22
1635	Role of Human Papillomavirus Infection in Head and Neck Cancer in Italy: The HPV-AHEAD Study. <i>Cancers</i> , 2020, 12, 3567.	1.7	23
1636	Human papillomavirus infection predicts better survival rate in patients with an oropharyngeal cancer. <i>Archives of Medical Science</i> , 2021, 17, 1308-1316.	0.4	6
1637	HPV sensitizes OPSCC cells to cisplatin-induced apoptosis by inhibiting autophagy through E7-mediated degradation of AMBRA1. <i>Autophagy</i> , 2021, 17, 2842-2855.	4.3	25
1638	Long-term outcomes in patients with recurrent human papillomavirus-positive oropharyngeal cancer after upfront transoral robotic surgery. <i>Head and Neck</i> , 2020, 42, 3490-3496.	0.9	6
1639	Clinico-pathological peculiarities of human papilloma virus driven head and neck squamous cell carcinoma: A comprehensive update. <i>Life Sciences</i> , 2020, 245, 117383.	2.0	21
1640	Tumor infiltrating lymphocytes after neoadjuvant IRIX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. <i>Oral Oncology</i> , 2020, 111, 104928.	0.8	9
1641	HIV Vpr Modulates the Host DNA Damage Response at Two Independent Steps to Damage DNA and Repress Double-Strand DNA Break Repair. <i>MBio</i> , 2020, 11, .	1.8	11
1642	Comprehensive analysis of significant genes and immune cell infiltration in HPV-related head and neck squamous cell carcinoma. <i>International Immunopharmacology</i> , 2020, 87, 106844.	1.7	6
1643	Differential Change in Size of Human Papillomavirus-Positive Cystic Versus Solid Squamous Cell Carcinoma Lymph Node Metastases in Response to Induction Chemotherapy. <i>Journal of Computer Assisted Tomography</i> , 2020, 44, 389-392.	0.5	1
1644	Applying nomograms based on the surveillance, epidemiology and end results database to predict long-term overall survival and cancer-specific survival in patients with oropharyngeal squamous cell carcinomas. <i>Medicine (United States)</i> , 2020, 99, e20703.	0.4	3
1645	Oropharyngeal carcinoma: A single institution study of 338 primaries with special reference to high-risk human papillomavirus-mediated carcinoma with aggressive behavior. <i>Pathology Research and Practice</i> , 2020, 216, 153243.	1.0	5
1646	Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2020, 40, 3847-3855.	0.5	1

#	ARTICLE	IF	CITATIONS
1647	Identification of Clinical and Socioeconomic Predictors of Adjuvant Therapy after Trans-Oral Robotic Surgery in Patients with Oropharyngeal Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2474.	1.7	5
1648	Immunological Network in Head and Neck Squamous Cell Carcinoma—A Prognostic Tool Beyond HPV Status. <i>Frontiers in Oncology</i> , 2020, 10, 1701.	1.3	18
1649	Combination of ACY-241 and JQ1 Synergistically Suppresses Metastasis of HNSCC via Regulation of MMP-2 and MMP-9. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6873.	1.8	15
1650	Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. <i>BMC Cancer</i> , 2020, 20, 912.	1.1	31
1651	HPV infection related immune infiltration gene associated therapeutic strategy and clinical outcome in HNSCC. <i>BMC Cancer</i> , 2020, 20, 796.	1.1	8
1652	Influences of Semaphorin 3A Expression on Clinicopathological Features, Human Papillomavirus Status, and Prognosis in Oropharyngeal Carcinoma. <i>Microorganisms</i> , 2020, 8, 1286.	1.6	2
1653	Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01). <i>BMC Cancer</i> , 2020, 20, 813.	1.1	39
1654	Disparities in Head and Neck Cancer: A Case for Chemoprevention with Vitamin D. <i>Nutrients</i> , 2020, 12, 2638.	1.7	6
1655	Epigenetic stratification of head and neck cancer survivors reveals differences in lycopene levels, alcohol consumption, and methylation of immune regulatory genes. <i>Clinical Epigenetics</i> , 2020, 12, 138.	1.8	10
1658	Radiomic features based on Hessian index for prediction of prognosis in head-and-neck cancer patients. <i>Scientific Reports</i> , 2020, 10, 21301.	1.6	9
1659	Apoptosis-related Proteins Are Altered by Selective Tyrosine Kinase Inhibitors and Everolimus in HPV-dependent SCC. <i>Anticancer Research</i> , 2020, 40, 6195-6203.	0.5	2
1660	Phase I trial of dose-escalated stereotactic radiosurgery (SRS) boost for unfavorable locally advanced oropharyngeal cancer. <i>Radiation Oncology</i> , 2020, 15, 278.	1.2	5
1661	Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 3743.	1.7	19
1662	The role of vitamin D in head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 1079-1088.	0.6	3
1663	A systematic review of different treatment strategies for the squamous cell carcinoma of the posterior pharyngeal wall. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 2663-2672.	0.8	2
1664	HPV-positive Squamous Cell Carcinoma of the Larynx, Oral Cavity, and Hypopharynx. <i>American Journal of Surgical Pathology</i> , 2020, 44, 691-702.	2.1	19
1665	[18F]-HX4 PET/CT hypoxia in patients with squamous cell carcinoma of the head and neck treated with chemoradiotherapy: Prognostic results from two prospective trials. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 9-15.	0.9	12
1666	Active HPV infection and its influence on survival in head and neck squamous-cell cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1677-1692.	1.2	22



#	ARTICLE	IF	CITATIONS
1667	Association of Salivary Human Papillomavirus Infection and Oral and Oropharyngeal Cancer: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1305.	1.0	12
1668	Evaluation of pathologic staging using number of nodes in p16-negative head and neck cancer. <i>Oral Oncology</i> , 2020, 108, 104800.	0.8	1
1669	Barriers and facilitators to discussing HPV with head and neck cancer patients: A qualitative study using the theoretical domains framework. <i>Patient Education and Counseling</i> , 2020, 103, 2451-2459.	1.0	0
1670	Rate of locoregional recurrence among patients with oropharyngeal squamous cell carcinoma with known HPV status: a systematic review. <i>Acta Oncologica</i> , 2020, 59, 1131-1136.	0.8	22
1671	Prevalence and Prognostic Value of HPV among Tunisian Patients with Laryngeal Cancer and Relationship between DNA HPV and p16, IGF-1R, Survivin, p53 Expressions. <i>Annals of Otolaryngology and Rhinology</i> , 2020, 129, 863-871.	0.6	2
1672	Identifying patterns of failure and secondary primary malignancies in HPV-related oropharyngeal squamous cell carcinomas. <i>Future Oncology</i> , 2020, 16, 199-207.	1.1	3
1674	HPV-related squamous cell carcinoma of oropharynx: a review. <i>Journal of Clinical Pathology</i> , 2020, 73, 624-629.	1.0	30
1675	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , 2020, 108, 104736.	0.8	40
1676	The Evolution of Care of Cancers of the Head and Neck Region: State of the Science in 2020. <i>Cancers</i> , 2020, 12, 1543.	1.7	18
1677	Radiotherapy dose and survival outcomes in human papillomavirus positive oropharyngeal cancer. <i>Journal of Laryngology and Otolaryngology</i> , 2020, 134, 533-540.	0.4	2
1678	Estrogen receptor $\beta$ as a predictive biomarker for survival in human papillomavirus-positive oropharyngeal squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 240.	1.8	12
1679	Sociodemographic correlates of head and neck cancer survival among patients with metastatic disease. <i>Head and Neck</i> , 2020, 42, 2505-2515.	0.9	7
1680	Targeting DNA Double-Strand Break Repair Enhances Radiosensitivity of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma to Photons and Protons. <i>Cancers</i> , 2020, 12, 1490.	1.7	34
1681	The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2020, 49, 886-896.	1.4	12
1682	The Emerging Role of Exosomes in Diagnosis, Prognosis, and Therapy in Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4072.	1.8	48
1683	Rethinking the 10-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis. <i>Cancer</i> , 2020, 126, 2784-2790.	2.0	9
1684	Longitudinal effects of a novel advanced pneumatic compression device on patient-reported outcomes in the management of cancer-related head and neck lymphedema: A preliminary report. <i>Head and Neck</i> , 2020, 42, 1791-1799.	0.9	14
1685	Predictors of survival in patients undergoing oropharyngeal surgery for cancer recurrence after radiation therapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 2085-2093.	0.8	3

#	ARTICLE	IF	CITATIONS
1686	Molecular mechanisms underlying increased radiosensitivity in human papillomavirus-associated oropharyngeal squamous cell carcinoma. <i>International Journal of Biological Sciences</i> , 2020, 16, 1035-1043.	2.6	9
1687	ViroPanel. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 476-487.	1.2	6
1688	Factors associated with HPV testing in oropharyngeal cancer in the National Cancer Data Base from 2013 to 2015. <i>Oral Oncology</i> , 2020, 104, 104609.	0.8	9
1689	Post-treatment FDG PET-CT in head and neck carcinoma: comparative analysis of 4 qualitative interpretative criteria in a large patient cohort. <i>Scientific Reports</i> , 2020, 10, 4086.	1.6	37
1690	B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 3345-3359.	3.2	117
1691	Novel Strategies to Effectively De-escalate Curative-Intent Therapy for Patients With HPV-Associated Oropharyngeal Cancer: Current and Future Directions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 257-269.	1.8	18
1692	Effect of HPV Status on Survival of Oropharynx Cancer with Distant Metastasis. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 372-374.	1.1	6
1693	Sphingolipids and Mitochondrial Dynamic. <i>Cells</i> , 2020, 9, 581.	1.8	46
1695	Most Cited Articles in Head and Neck Oncology. <i>Ear, Nose and Throat Journal</i> , 2020, 100, 014556132093492.	0.4	2
1696	Identifying epigenetic biomarkers of established prognostic factors and survival in a clinical cohort of individuals with oropharyngeal cancer. <i>Clinical Epigenetics</i> , 2020, 12, 95.	1.8	6
1697	Potential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 1778.	1.7	36
1699	Risk factors for human papillomavirus-positive nonoropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 1954-1962.	0.9	6
1700	An update on systemic therapy for penile cancer. <i>Current Opinion in Urology</i> , 2020, 30, 229-233.	0.9	9
1701	The role of Glial cell derived neurotrophic factor in head and neck cancer. <i>PLoS ONE</i> , 2020, 15, e0229311.	1.1	0
1702	Synergistic effect of cisplatin chemotherapy combined with fractionated radiotherapy regimen in HPV-positive and HPV-negative experimental pharyngeal squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 1563.	1.6	13
1703	Assessing patient-reported symptom burden of long-term head and neck cancer survivors at annual surveillance in survivorship clinic. <i>Head and Neck</i> , 2020, 42, 1919-1927.	0.9	15
1704	Essential characterisation of human papillomavirus positive head and neck cancer cell lines. <i>Oral Oncology</i> , 2020, 103, 104613.	0.8	7
1705	Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 1522.	1.3	17

#	ARTICLE	IF	CITATIONS
1706	Association of Biomarkers for Human Papillomavirus With Survival Among Adults With Barrett High-grade Dysplasia and Esophageal Adenocarcinoma. <i>JAMA Network Open</i> , 2020, 3, e1921189.	2.8	8
1707	Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 100-106.	1.2	29
1708	Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study. <i>Clinical and Translational Oncology</i> , 2020, 22, 1645-1650.	1.2	8
1709	Burden of comorbidities is higher among elderly survivors of oropharyngeal cancer compared with controls. <i>Cancer</i> , 2020, 126, 1793-1803.	2.0	14
1710	Survival-Associated Metabolic Genes in Human Papillomavirus-Positive Head and Neck Cancers. <i>Cancers</i> , 2020, 12, 253.	1.7	40
1711	Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. <i>Head and Neck</i> , 2020, 42, 1728-1737.	0.9	6
1712	Trends in Head and Neck Cancer. , 2020, , 1-19.		1
1713	Intraoperative Primary Tumor Identification and Margin Assessment in Head and Neck Unknown Primary Tumors. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 162, 313-318.	1.1	11
1715	Stratification of HPV-associated and HPV-negative oropharyngeal squamous cell carcinomas based on DNA methylation epigenotypes. <i>International Journal of Cancer</i> , 2020, 146, 2460-2474.	2.3	16
1716	Retropharyngeal Lymph Node Involvement in Oropharyngeal Carcinoma: Impact upon Risk of Distant Metastases and Survival Outcomes. <i>Cancers</i> , 2020, 12, 83.	1.7	8
1717	NRF2, p53, and p16: Predictive biomarkers to stratify human papillomavirus associated head and neck cancer patients for de-escalation of cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102885.	2.0	23
1718	HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2020, 12, 1060.	1.7	40
1719	Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions. <i>Oral Oncology</i> , 2020, 105, 104652.	0.8	60
1720	Management of HPV-Related Squamous Cell Carcinoma of the Head and Neck: Pitfalls and Caveat. <i>Cancers</i> , 2020, 12, 975.	1.7	30
1721	Epithelial stem cell marker LGR6 expression identifies a low-risk subgroup in human papillomavirus positive oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 105, 104657.	0.8	4
1722	Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status. <i>Diagnostic Pathology</i> , 2020, 15, 30.	0.9	10
1723	The role of tumour morphology in assigning HPV status in oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 105, 104670.	0.8	7
1724	Prognostic Significance of Smoking in Human Papillomavirus-Positive Oropharyngeal Cancer Under American Joint Committee on Cancer Eighth Edition Stage. <i>Laryngoscope</i> , 2020, 130, 1961-1966.	1.1	7

#	ARTICLE	IF	CITATIONS
1725	Epstein-Barr virus (EBV) and polyomaviruses are detectable in oropharyngeal cancer and EBV may have prognostic impact. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1615-1626.	2.0	18
1726	Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 167.	1.8	45
1727	Epidemiological Correlations Between Head and Neck Cancer and Hepatitis B Core Antibody Positivity. <i>Anticancer Research</i> , 2020, 40, 2393-2403.	0.5	8
1728	The impact of skeletal muscle depletion on older adult patients with head and neck cancer undergoing primary surgery. <i>Journal of Geriatric Oncology</i> , 2021, 12, 128-133.	0.5	13
1729	Survival outcomes following modern multidisciplinary management of oral squamous cell carcinoma in Australia. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 131, 92-98.	0.2	8
1730	Socioeconomic Status Drives Racial Disparities in HPV-negative Head and Neck Cancer Outcomes. <i>Laryngoscope</i> , 2021, 131, 1301-1309.	1.1	15
1731	Transoral robotic surgery and intensity-modulated radiotherapy in the treatment of the oropharyngeal carcinoma: a systematic review and meta-analysis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 1321-1335.	0.8	35
1732	Association of human papillomavirus integration with better patient outcomes in oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 544-557.	0.9	14
1733	Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives. <i>Oncologist</i> , 2021, 26, 40-48.	1.9	57
1734	Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 1240-1248.	1.1	5
1735	Revisiting the Recommendation for Contralateral Tonsillectomy in HPV-Associated Tonsillar Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 1222-1229.	1.1	5
1736	In situ hybridization for high risk HPV E6/E7 mRNA in oropharyngeal squamous cell carcinoma. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, 42, 102782.	0.6	8
1737	AKR1C3 is a biomarker and druggable target for oropharyngeal tumors. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 357-372.	2.1	7
1738	Human papillomavirus genotype distribution in head and neck cancer: Informing developing strategies for cancer prevention, diagnosis, treatment and surveillance. <i>Oral Oncology</i> , 2021, 113, 105109.	0.8	16
1739	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. <i>Cancer</i> , 2021, 127, 1228-1237.	2.0	2
1740	Influence of p16 status on indication and outcome of salvage neck dissection in oropharyngeal cancer. <i>Acta Oto-Laryngologica</i> , 2021, 141, 187-192.	0.3	2
1741	National trends in oropharyngeal cancer incidence and survival within the Veterans Affairs Health Care System. <i>Head and Neck</i> , 2021, 43, 108-115.	0.9	12
1742	Oropharyngeal cancer: First relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric study. <i>European Journal of Cancer</i> , 2021, 143, 168-177.	1.3	13

#	ARTICLE	IF	CITATIONS
1743	Identification and Complete Validation of Prognostic Gene Signatures for Human Papillomavirus-Associated Cancers: Integrated Approach Covering Different Anatomical Locations. <i>Journal of Virology</i> , 2021, 95, .	1.5	4
1744	Staging and treatment outcomes in oropharyngeal squamous cell carcinoma: a single-centre UK cohort. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2021, 59, 28-34.	0.4	1
1745	The utility of high-risk human papillomavirus E6/E7 mRNA in situ hybridization in assessing HPV status on cell block. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 225-230.	0.2	3
1746	HPV+ve/âve oral-tongue cancer stem cells: A potential target for relapse-free therapy. <i>Translational Oncology</i> , 2021, 14, 100919.	1.7	10
1747	Utility of p16 and HPV testing in oropharyngeal squamous cell carcinoma: An institutional review. <i>Diagnostic Cytopathology</i> , 2021, 49, 54-59.	0.5	5
1748	Insurance Status as a Predictor of Treatment in Human Papillomavirus Positive Oropharyngeal Cancer. <i>Laryngoscope</i> , 2021, 131, 776-781.	1.1	8
1749	Liquid phase human papillomavirus genotype analysis of aspirated metastatic head and neck squamous cell carcinoma: Fine needle aspiration supernatant is a rich source of tumor <scp>DNA</scp> that can increase the diagnostic yield. <i>Diagnostic Cytopathology</i> , 2021, 49, 25-30.	0.5	5
1750	Aspirin use predicts prolonged survival in patients with oropharyngeal cancer: Nationwide Veterans Affairs database study. <i>Head and Neck</i> , 2021, 43, 247-254.	0.9	1
1751	Combined chemo-photothermal treatment of three-dimensional head and neck squamous cell carcinomas by gold nano-architectures. <i>Journal of Colloid and Interface Science</i> , 2021, 582, 1003-1011.	5.0	34
1752	Decline in circulating viral and human tumor markers after resection of head and neck carcinoma. <i>Head and Neck</i> , 2021, 43, 27-34.	0.9	10
1753	Prognostic value of lymph node ratio versus American Joint Committee on Cancer N classification for surgically resected human papillomavirusâ€associated oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 1476-1486.	0.9	0
1754	Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC. <i>Frontiers in Oncology</i> , 2020, 10, 591063.	1.3	3
1755	Identification of Three Autophagy-Related Long Non-Coding RNAs as a Novel Head and Neck Squamous Cell Carcinoma Prognostic Signature. <i>Frontiers in Oncology</i> , 2020, 10, 603864.	1.3	11
1756	The effect of psychological and medical conditions on sexuality. , 2021, , 195-234.		0
1757	[18F]PARPi Imaging Is Not Affected by HPV Status In Vitro. <i>Molecular Imaging</i> , 2021, 2021, 1-10.	0.7	2
1759	Pathogenic TP53 mutations influence chemotherapy response and survival rate of HPV-negative oral carcinomas. <i>Vojnosanitetski Pregled</i> , 2022, 79, 1063-1072.	0.1	0
1760	Altered presentation of oropharyngeal cancer, a 6â€year review. <i>ANZ Journal of Surgery</i> , 2021, 91, 1240-1245.	0.3	3
1761	Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). <i>JCO Precision Oncology</i> , 2021, 5, 215-226.	1.5	22

#	ARTICLE	IF	CITATIONS
1762	Prevalence of Human Papillomavirus (HPV) 16 and 18 in oral malignant and potentially malignant disorders: A polymerase chain reaction analysis – A comparative study. <i>Annals of Maxillofacial Surgery</i> , 2021, 11, 6.	0.2	7
1763	Green Salad Intake Is Associated with Improved Oral Cancer Survival and Lower Soluble CD44 Levels. <i>Nutrients</i> , 2021, 13, 372.	1.7	5
1764	Social Disparities in Survival from Head and Neck Cancers in Europe. , 2021, , 141-158.		1
1765	The prevalence and clinicopathological correlation of human papillomavirus in head and neck squamous cell carcinoma in India: A systematic review article. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100301.	0.7	16
1766	The course of health-related quality of life from diagnosis to two years follow-up in patients with oropharyngeal cancer: does HPV status matter?. <i>Supportive Care in Cancer</i> , 2021, 29, 4473-4483.	1.0	14
1767	Mutation patterns in recurrent and/or metastatic oropharyngeal squamous cell carcinomas in relation to human papillomavirus status. <i>Cancer Medicine</i> , 2021, 10, 1347-1356.	1.3	9
1768	The Prognostic Value and Mechanisms of TMEM16A in Human Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 542156.	1.6	6
1770	Molecular detection of human papillomavirus-16 among Sudanese patients diagnosed with squamous cell carcinoma and salivary gland carcinoma. <i>BMC Research Notes</i> , 2021, 14, 56.	0.6	7
1771	Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome. <i>Scientific Reports</i> , 2021, 11, 4578.	1.6	17
1772	Distinguishable Prognostic miRNA Signatures of Head and Neck Squamous Cell Cancer With or Without HPV Infection. <i>Frontiers in Oncology</i> , 2020, 10, 614487.	1.3	10
1773	Characteristics of an Impaired PDT Response. <i>Photochemistry and Photobiology</i> , 2021, 97, 837-840.	1.3	3
1774	Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA. <i>Current Treatment Options in Oncology</i> , 2021, 22, 21.	1.3	6
1775	Low-risk human papilloma virus positive oropharyngeal cancer with one positive lymph node: Equivalent outcomes in patients treated with surgery and radiation therapy versus surgery alone. <i>Head and Neck</i> , 2021, 43, 1759-1768.	0.9	1
1776	Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis. <i>Infectious Agents and Cancer</i> , 2021, 16, 13.	1.2	10
1777	Increased Abundance of Tumour-Associated Neutrophils in HPV-Negative Compared to HPV-Positive Oropharyngeal Squamous Cell Carcinoma Is Mediated by IL-1R Signalling. <i>Frontiers in Oral Health</i> , 2021, 2, 604565.	1.2	9
1778	HPV DNA/RNA detection in various oral and oropharyngeal biomaterials identifies active HPV infections also in non-neoplastic tonsils. <i>Translational Oncology</i> , 2021, 14, 101002.	1.7	6
1779	Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma. <i>Cell Reports</i> , 2021, 34, 108769.	2.9	42
1780	The cytokine milieu compromises functional capacity of tumor-infiltrating plasmacytoid dendritic cells in HPV-negative but not in HPV-positive HNSCC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2545-2557.	2.0	9



#	ARTICLE	IF	CITATIONS
1781	Does HPV Subtype Predict Outcomes in Head and Neck Cancers?. International Journal of Otolaryngology, 2021, 2021, 1-11.	1.0	7
1782	Differences in clinical and imaging characteristics between p16-positive non-smokers and p16-positive smokers or p16-negative patients in oropharyngeal carcinoma. Scientific Reports, 2021, 11, 3314.	1.6	5
1783	Prognostic Value of HPV Infection Assessed by p16 Immunohistochemistry and the Influence of Tobacco Usage in Oropharyngeal Cancers: Real World Scenario. Indian Journal of Otolaryngology and Head and Neck Surgery, 2022, 74, 5823-5831.	0.3	1
1785	Radiation Dose De-Escalation in HPV-Positive Oropharynx Cancer: When Will It Be an Acceptable Standard of Care?. Journal of Clinical Oncology, 2021, 39, 947-949.	0.8	9
1787	Disease Profile and Oncologic Outcomes After Delayed Diagnosis of Human Papillomavirus-Associated Oropharyngeal Cancer. Otolaryngology - Head and Neck Surgery, 2021, 165, 830-837.	1.1	4
1789	Risk Factors for the Development of Malignant Tumors of the Head and Neck. Epidemiologiya I Vaktsinoprofilaktika, 2021, 20, 92-99.	0.2	1
1790	The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-effects model analysis of a prospective observational cohort registry. Cancer, 2021, 127, 2453-2464.	2.0	7
1791	Survival advantage in patients with human papillomavirus-driven oropharyngeal cancer and variation by demographic characteristics and serologic response: Findings from Head and Neck 5000. Cancer, 2021, 127, 2442-2452.	2.0	8
1792	Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). Journal of Clinical Oncology, 2021, 39, 956-965.	0.8	195
1793	Photodynamic Therapy as a Potent Radiosensitizer in Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 1193.	1.7	11
1794	Triplet induction chemotherapy followed by less invasive surgery without reconstruction for human papillomavirus-associated oropharyngeal cancers: Why is it successful or unsuccessful?. International Journal of Clinical Oncology, 2021, 26, 1039-1048.	1.0	3
1795	Benefit of postoperative radiotherapy in patients with oropharyngeal squamous cell carcinoma in human papillomavirus (HPV) era: A Surveillance, Epidemiology, and End Results (SEER) database analysis. Surgery, 2021, 170, 541-549.	1.0	1
1796	Correlation of transcriptionally active human papillomavirus status with the clinical and molecular profiles of head and neck squamous cell carcinomas. Head and Neck, 2021, 43, 2032-2044.	0.9	1
1797	Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. Cancers, 2021, 13, 1413.	1.7	13
1798	Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC. , 2021, 9, e001259.		9
1799	Radioterapia dei cancri oto-rino-laringoiatrici. EMC - Otorinolaringoiatria, 2021, 20, 1-10.	0.0	0
1800	<sc>High-risk</sc> human papillomavirus and <sc>ZEB1</sc> in ocular adnexal sebaceous carcinoma. Journal of Cutaneous Pathology, 2021, 48, 1027-1033.	0.7	5
1801	Frequency and Localization of Second Primary Tumors in Patients with Oropharyngeal Carcinoma- The Influence of the Human Papilloma Virus. Cancers, 2021, 13, 1755.	1.7	8

#	ARTICLE	IF	CITATIONS
1802	Oropharyngeal Squamous Cell Carcinoma Morphology and Subtypes by Human Papillomavirus Type and by 16 Lineages and Sublineages. <i>Head and Neck Pathology</i> , 2021, 15, 1089-1098.	1.3	12
1803	MRI Dynamic Contrast Imaging of Oral Cavity and Oropharyngeal Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2021, 30, 97-104.	0.7	1
1804	Understanding the impact of high-risk human papillomavirus on oropharyngeal squamous cell carcinomas in Taiwan: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0250530.	1.1	9
1805	Tonsillar Carcinoma Spreading Metastases to Central Nervous System: Case Report and Literature Review. <i>Journal of Neurological Surgery Reports</i> , 2021, 82, e11-e16.	0.3	1
1806	ROC analysis of p16 expression in cell blocks of metastatic head and neck squamous cell carcinoma. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 423-428.	0.2	6
1807	RB1, p16, and Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2021, 15, 1109-1118.	1.3	8
1808	DNA Methylation and HPV-Associated Head and Neck Cancer. <i>Microorganisms</i> , 2021, 9, 801.	1.6	17
1809	Pre-treatment absolute lymphocyte count predicts for improved survival in human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2021, 116, 105245.	0.8	8
1810	Oncologic outcomes of human papillomavirus-associated oropharynx carcinoma treated with surgery alone: A 12-institution study of 344 patients. <i>Cancer</i> , 2021, 127, 3092-3106.	2.0	13
1811	Prediction of Human Papillomavirus (HPV) Association of Oropharyngeal Cancer (OPC) Using Radiomics: The Impact of the Variation of CT Scanner. <i>Cancers</i> , 2021, 13, 2269.	1.7	10
1812	MICA A5.1 homozygous genotype is associated with a risk for early-onset oral cancer. <i>Oral Oncology</i> , 2021, 116, 105256.	0.8	3
1813	Human papillomavirus 16 infection and p16 expression in oral squamous cell carcinoma. <i>Oncology Letters</i> , 2021, 22, 528.	0.8	15
1814	Histopathological image and gene expression pattern analysis for predicting molecular features and prognosis of head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 4615-4628.	1.3	11
1815	Molecular Tumor Subtypes of HPV-Positive Head and Neck Cancers: Biological Characteristics and Implications for Clinical Outcomes. <i>Cancers</i> , 2021, 13, 2721.	1.7	10
1816	20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, 42, 102915.	0.6	15
1817	Oropharyngeal squamous cell carcinoma: p16/p53 immunohistochemistry as a strong predictor of HPV tumour status. <i>Histopathology</i> , 2021, 79, 381-390.	1.6	16
1818	IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK. <i>Scientific Reports</i> , 2021, 11, 10826.	1.6	9
1819	Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status. <i>Cancers</i> , 2021, 13, 2553.	1.7	18

#	ARTICLE	IF	CITATIONS
1821	Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS. Laryngoscope, 2021, 131, E2865-E2873.	1.1	13
1823	Comparison of Selected Immune and Hematological Parameters and Their Impact on Survival in Patients with HPV-Related and HPV-Unrelated Oropharyngeal Cancer. Cancers, 2021, 13, 3256.	1.7	11
1824	The microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis. Oral Oncology, 2021, 117, 105305.	0.8	14
1825	B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nature Communications, 2021, 12, 3349.	5.8	142
1826	Oncologic outcomes of transoral robotic surgery for HPV-negative oropharyngeal carcinomas. Head and Neck, 2021, 43, 2923-2934.	0.9	5
1827	Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the Oropharynx. International Journal of Radiation Oncology Biology Physics, 2021, 110, 396-402.	0.4	0
1828	Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status. Cancers, 2021, 13, 2811.	1.7	5
1829	Long Intergenic Non-Coding RNAs in HNSCC: From "Junk DNA" to Important Prognostic Factor. Cancers, 2021, 13, 2949.	1.7	17
1830	RTOG-129 risk groups are reproducible in a prospective multicenter heterogeneously treated cohort. Cancer, 2021, 127, 3523-3530.	2.0	1
1831	Gastrostomy tube dependence and patient-reported quality of life outcomes based on type of treatment for human papillomavirus-associated oropharyngeal cancer: Systematic review and meta-analysis. Head and Neck, 2021, 43, 3681-3696.	0.9	5
1832	Prevalence of oral human papillomavirus infection among Indian HIV-positive men who have sex with men: a cross-sectional study. BMC Infectious Diseases, 2021, 21, 675.	1.3	6
1833	Lower disease control rates and survival outcomes among Blacks with pharyngeal squamous cell carcinomas compared with Whites: a retrospective analysis at the University of Florida. Cancer Causes and Control, 2021, 32, 1269-1278.	0.8	2
1834	Epidemiologic distinctions between base of tongue and tonsil oropharyngeal carcinomas. Head and Neck, 2021, 43, 3076-3085.	0.9	4
1835	Ninety-day mortality after radiotherapy for head and neck cancer: Population-based comparison between rural and urban patients. Head and Neck, 2021, 43, 3306-3313.	0.9	2
1836	Current salivary biomarkers for detection of human papilloma virus-induced oropharyngeal squamous cell carcinoma. Head and Neck, 2021, 43, 3618-3630.	0.9	6
1837	Phytochemicals as Potential Chemopreventive and Chemotherapeutic Agents for Emerging Human Papillomavirus-Driven Head and Neck Cancer: Current Evidence and Future Prospects. Frontiers in Pharmacology, 2021, 12, 699044.	1.6	6
1838	Costs Associated With Imaging Surveillance After Treatment for Head and Neck Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 632.	1.2	17
1839	The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer. Frontiers in Oncology, 2021, 11, 649963.	1.3	4

#	ARTICLE	IF	CITATIONS
1840	Manual Therapy for Fibrosis-Related Late Effect Dysphagia in head and neck cancer survivors: the pilot MANTLE trial. <i>BMJ Open</i> , 2021, 11, e047830.	0.8	6
1841	Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103424.	2.0	19
1842	Systematic Review and Meta-Analysis of Post-Treatment PET/CT in HPV-Associated Oropharyngeal Cancer. <i>Annals of Otology, Rhinology and Laryngology</i> , 2021, , 000348942110368.	0.6	1
1843	A proposal for risk-based and strategy-adapted de-escalation in human papillomavirus-positive oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2021, 127, 4330-4338.	2.0	5
1844	Progressive Increase Trend in HPV-Related Oropharyngeal Squamous Cell Carcinoma in Brazil. <i>International Archives of Otorhinolaryngology</i> , 2022, 26, e132-e136.	0.3	2
1845	Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 16134.	1.6	31
1846	Combined loss of expression of involucrin and cytokeratin 13 is associated with poor prognosis in squamous cell carcinoma of mobile tongue. <i>Head and Neck</i> , 2021, 43, 3374-3385.	0.9	8
1847	Personalised Precision Medicine- a Novel Approach for Oral Cancer Management. , 0, , .		2
1848	Detection of Human Papillomavirus Integration in Brain Metastases from Oropharyngeal Tumors by Targeted Sequencing. <i>Viruses</i> , 2021, 13, 1536.	1.5	5
1849	Development and Assessment of a Model for Predicting Individualized Outcomes in Patients With Oropharyngeal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2120055.	2.8	6
1850	Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma. <i>International Immunopharmacology</i> , 2021, 97, 107817.	1.7	10
1851	Feasibility of DW-MRI analysis of salivary glands during head and neck radiotherapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2021, 19, 46-51.	0.6	3
1852	Human Papillomavirus Associated Oropharyngeal Carcinoma-Diagnosis and Management. , 0, , .		0
1853	Prognostic Significance of a Scoring System Combining p16, Smoking, and Drinking Status in a Series of 131 Patients with Oropharyngeal Cancers. <i>International Journal of Otolaryngology</i> , 2021, 2021, 1-6.	1.0	9
1854	Human Papillomavirus-Negative Oropharyngeal Cancer Survival Outcomes Based on Primary Treatment: National Cancer Database Analysis. <i>Otolaryngology - Head and Neck Surgery</i> , 2022, 167, 100-108.	1.1	1
1855	Survey of radiation field and dose in human papillomavirus-positive oropharyngeal cancer: is de-escalation actually applied in clinical practice?. <i>Radiation Oncology Journal</i> , 2021, 39, 174-183.	0.7	4
1857	Quality of life after radiation and transoral robotic surgery in advanced oropharyngeal cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2021, 6, 983-990.	0.6	3
1858	A combination of intra-tumor genetic heterogeneity, estrogen receptor alpha and human papillomavirus status predicts outcomes in head and neck squamous cell carcinoma following chemoradiotherapy. <i>Oral Oncology</i> , 2021, 120, 105421.	0.8	5

#	ARTICLE	IF	CITATIONS
1859	HPV Status as Prognostic Biomarker in Head and Neck Cancer—Which Method Fits the Best for Outcome Prediction?. <i>Cancers</i> , 2021, 13, 4730.	1.7	13
1860	Dynamic stochastic deep learning approaches for predicting geometric changes in head and neck cancer. <i>Physics in Medicine and Biology</i> , 2021, 66, 225006.	1.6	3
1861	Radiomic Features Associated With HPV Status on Pretreatment Computed Tomography in Oropharyngeal Squamous Cell Carcinoma Inform Clinical Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 744250.	1.3	16
1862	HPV Positive Status Is a Favorable Prognostic Factor in Non-Nasopharyngeal Head and Neck Squamous Cell Carcinoma Patients: A Retrospective Study From the Surveillance, Epidemiology, and End Results Database. <i>Frontiers in Oncology</i> , 2021, 11, 688615.	1.3	13
1863	Cancer of the Oropharynx and the Association with Human Papillomavirus. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 913-931.	0.9	3
1864	Integrin alpha 6 as a stemness driver is a novel promising target for HPV (+) head and neck squamous cell carcinoma. <i>Experimental Cell Research</i> , 2021, 407, 112815.	1.2	6
1865	Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients. <i>European Journal of Cancer</i> , 2021, 156, 109-118.	1.3	2
1866	Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 309-323.	1.0	0
1867	The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis. <i>Oral Oncology</i> , 2021, 121, 105454.	0.8	4
1868	Multicentre Investigation of Prognostic Factors Incorporating p16 and Tumour Infiltrating Lymphocytes for Anal Cancer After Chemoradiotherapy. <i>Clinical Oncology</i> , 2021, 33, 638-649.	0.6	8
1869	Biologic and behavioral associations of estrogen receptor alpha positivity in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2021, 121, 105461.	0.8	2
1870	Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 100, 108128.	1.7	13
1871	Putative precancerous lesions of vulvar squamous cell carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 27-36.	1.0	7
1872	The importance of smoking status at diagnosis in human papillomavirus-associated oropharyngeal cancer. <i>Head and Neck</i> , 2021, 43, 1440-1450.	0.9	3
1873	Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance. <i>Frontiers in Oral Health</i> , 2020, 1, 603160.	1.2	32
1874	Human papillomavirus oropharynx carcinoma: Aggressive de-escalation of adjuvant therapy. <i>Head and Neck</i> , 2021, 43, 229-237.	0.9	19
1875	Classification, Clinical Features, and Molecular Genetic Models. , 2010, , 1-21.		1
1876	Human Papillomavirus and Head and Neck Cancer. , 2010, , 87-116.		8

#	ARTICLE	IF	CITATIONS
1877	HPV and EBV in Head and Neck Cancer. , 2011, , 121-134.		2
1878	DNA Damage Proteins and Response to Therapy in Head and Neck Cancer. , 2014, , 259-282.		1
1879	Molecular Features and Treatment Modalities of "Classic" Versus Human Papilloma Virus-Associated Head and Neck Cancer. , 2014, , 7-21.		2
1880	Epidemiology of HPV in Head and Neck Cancer: Variant Strains, Discrete Protein Function. , 2014, , 23-53.		1
1881	Human Papillomavirus Testing in Head and Neck Squamous Cell Carcinoma: Best Practice for Diagnosis. <i>Methods in Molecular Biology</i> , 2014, 1180, 237-255.	0.4	14
1882	Human Papilloma Virus (HPV) Modulation of the HNSCC Epigenome. <i>Methods in Molecular Biology</i> , 2015, 1238, 369-379.	0.4	5
1883	HPV-Associated Oropharyngeal Cancer in the HIV/AIDS Patient. <i>Cancer Treatment and Research</i> , 2019, 177, 131-181.	0.2	6
1884	Treatment Strategies in Head and Neck Cancers. , 2020, , 273-294.		1
1885	Detection Methods for Human Papillomavirus (HPV) in Head and Neck Cancers. <i>Textbooks in Contemporary Dentistry</i> , 2020, , 119-125.	0.2	1
1886	Biomarkers for Individualized Oral Cancer Therapy. , 2015, , 43-60.		1
1887	HPV and EBV in Head and Neck Cancer. , 2016, , 163-179.		4
1888	Other Carcinomas. <i>Pediatric Oncology</i> , 2017, , 477-507.	0.5	1
1889	The Genome-Wide Molecular Landscape of HPV-Driven and HPV-Negative Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Research</i> , 2018, , 293-325.	0.2	4
1890	Epidemiology of Oral HPV Infection and HPV-Associated Head and Neck Cancer. <i>Head and Neck Cancer Clinics</i> , 2015, , 13-39.	0.0	3
1891	The Molecular Biology of HPV-Related Head and Neck Cancer. <i>Head and Neck Cancer Clinics</i> , 2015, , 51-63.	0.0	1
1892	Prognostic value of the lymph node ratio in oropharyngeal carcinoma stratified for HPV-status. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 515-524.	0.8	18
1893	The Genomics, Epigenomics, and Transcriptomics of HPV-Associated Oropharyngeal Cancer "Understanding the Basis of a Rapidly Evolving Disease. <i>Advances in Genetics</i> , 2016, 93, 1-56.	0.8	27
1894	Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1333-1343.	1.2	28



#	ARTICLE	IF	CITATIONS
1895	Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. <i>Oral Oncology</i> , 2020, 107, 104754.	0.8	7
1896	Evaluation of HPV16 E7 expression in head and neck carcinoma cell lines and clinical specimens. <i>Scientific Reports</i> , 2020, 10, 22138.	1.6	7
1899	Impact of HPV infection on gene expression and methylation in oral cancer patients. <i>Journal of Medical Microbiology</i> , 2019, 68, 440-445.	0.7	9
1903	Oropharyngeal carcinoma related to human papillomavirus. <i>BMJ: British Medical Journal</i> , 2010, 340, c1439-c1439.	2.4	93
1904	Landscape of natural killer cell activity in head and neck squamous cell carcinoma. , 2020, 8, e001523.		36
1905	Epidemiology and Molecular Biology of Head and Neck Cancer. <i>Oncology Research and Treatment</i> , 2017, 40, 328-332.	0.8	112
1906	Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	44
1907	HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. <i>Journal of Clinical Investigation</i> , 2013, 123, 2488-2501.	3.9	109
1908	Is head and neck cancer infectious? Human papilloma virus in oral and pharyngeal cancer. <i>Faculty Dental Journal</i> , 2010, 1, 108-113.	0.0	3
1909	DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. <i>PLoS ONE</i> , 2014, 9, e102112.	1.1	14
1910	Human Papillomavirus Infection in 674 Chinese Patients with Laryngeal Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e115914.	1.1	32
1911	Human Papillomavirus Prevalence in Invasive Laryngeal Cancer in the United States. <i>PLoS ONE</i> , 2014, 9, e115931.	1.1	41
1912	Association between P16INK4a Promoter Methylation and HNSCC: A Meta-Analysis of 21 Published Studies. <i>PLoS ONE</i> , 2015, 10, e0122302.	1.1	20
1913	Prognostic Value of Overexpressed p16INK4a in Vulvar Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0152459.	1.1	19
1914	Impact of Sonic Hedgehog Pathway Expression on Outcome in HPV Negative Head and Neck Carcinoma Patients after Surgery and Adjuvant Radiotherapy. <i>PLoS ONE</i> , 2016, 11, e0167665.	1.1	12
1915	The prognostic impact of human papillomavirus status following treatment failure in oropharyngeal cancer. <i>PLoS ONE</i> , 2017, 12, e0181108.	1.1	10
1916	Association of an intact E2 gene with higher HPV viral load, higher viral oncogene expression, and improved clinical outcome in HPV16 positive head and neck squamous cell carcinoma. <i>PLoS ONE</i> , 2018, 13, e0191581.	1.1	29
1917	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy. <i>PLoS ONE</i> , 2020, 15, e0232639.	1.1	35

#	ARTICLE	IF	CITATIONS
1918	Bone Marrow Failure in HPV-Associated Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Otolaryngology-ENT Research</i> , 2018, 10, .	0.1	2
1919	Education, tobacco smoking, alcohol consumption, and IL-2 and IL-6 gene polymorphisms in the survival of head and neck cancer. <i>Brazilian Journal of Medical and Biological Research</i> , 2011, 44, 1006-1012.	0.7	24
1920	p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy. <i>Critical Reviews in Oncogenesis</i> , 2018, 23, 173-187.	0.2	10
1921	Evaluation of the Prevalence Rate and the Prognostic Effect of Human Papilloma Virus Infection in a Group of Patients With Oral Cavity Squamous Cell Carcinoma. <i>Iranian Journal of Cancer Prevention</i> , 2016, In Press, e3998.	0.7	9
1922	Chronic Inflammation and Carcinogenesis â€œ Emerging Role of Chronic Inflammatory Periodontal Disease. <i>Cancer Research Frontiers</i> , 2016, 2, 200-225.	0.2	10
1923	Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog. <i>Genes and Cancer</i> , 2015, 6, 169-181.	0.6	45
1924	TriCurin, a novel formulation of curcumin, epicatechin gallate, and resveratrol, inhibits the tumorigenicity of human papillomavirus-positive head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 60025-60035.	0.8	22
1925	ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines. <i>Oncotarget</i> , 2016, 7, 79388-79400.	0.8	25
1926	Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status. <i>Oncotarget</i> , 2017, 8, 14847-14859.	0.8	24
1927	LncRNAs as an intermediate in HPV16 promoting myeloid-derived suppressor cell recruitment of head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 42061-42075.	0.8	40
1928	DEK associates with tumor stage and outcome in HPV16 positive oropharyngeal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 23414-23426.	0.8	9
1929	Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer. <i>Oncotarget</i> , 2017, 8, 71512-71519.	0.8	29
1930	High infiltration of CD68+ macrophages is associated with poor prognoses of head and neck squamous cell carcinoma patients and is influenced by human papillomavirus. <i>Oncotarget</i> , 2018, 9, 11046-11059.	0.8	53
1931	High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines. <i>Oncotarget</i> , 2018, 9, 26064-26071.	0.8	13
1932	Viral DNA integration and methylation of human papillomavirus type 16 in high-grade oral epithelial dysplasia and head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 30419-30433.	0.8	12
1933	The virome of HPV-positive tonsil squamous cell carcinoma and neck metastasis. <i>Oncotarget</i> , 2020, 11, 282-293.	0.8	6
1934	Differentially expressed full-length, fusion and novel isoforms transcripts-based signature of well-differentiated keratinized oral squamous cell carcinoma. <i>Oncotarget</i> , 2020, 11, 3227-3243.	0.8	9
1935	Potential impact of human papilloma virus on survival of basaloid squamous carcinoma of the head and neck. <i>Oncotarget</i> , 2015, 6, 3462-3470.	0.8	18

#	ARTICLE	IF	CITATIONS
1936	A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. <i>Oncotarget</i> , 2012, 3, 31-43.	0.8	60
1937	DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 26995-27007.	0.8	75
1938	High expression of myoferlin is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with HPV-status. <i>Oncotarget</i> , 2016, 7, 18665-18677.	0.8	27
1939	Selective antitumor activity of roscovitine in head and neck cancer. <i>Oncotarget</i> , 2016, 7, 38598-38611.	0.8	16
1940	De-intensification strategies in HPV-related oropharyngeal squamous cell carcinoma—a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1601-1601.	0.7	25
1941	HPV in non-oropharyngeal head and neck cancer: does it matter?. <i>Annals of Translational Medicine</i> , 2020, 8, 1120-1120.	0.7	6
1942	Molecular characterization of head and neck cancer: how close to personalized targeted therapy?. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 209-22.	1.6	14
1943	Spheroid-based 3D Cell Cultures Enable Personalized Therapy Testing and Drug Discovery in Head and Neck Cancer. <i>Anticancer Research</i> , 2017, 37, 2201-2210.	0.5	79
1944	Surveillance Imaging in HPV-related Oropharyngeal Cancer. <i>Anticancer Research</i> , 2018, 38, 1525-1529.	0.5	9
1945	Numerical Imbalances of Chromosome 7 in Oral Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 2339-2342.	0.5	2
1946	Developments in therapeutic human papillomavirus vaccination. <i>Acta Chirurgica Iugoslavica</i> , 2009, 56, 29-37.	0.0	2
1947	Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2016, 13, 87-100.	1.4	21
1948	Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. <i>GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery</i> , 2012, 11, Doc09.	0.8	54
1949	Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis. <i>Cellular Oncology</i> , 2009, 31, 291-300.	1.9	42
1950	Identifying the Causes of Cancer Health Disparities. <i>Californian Journal of Health Promotion</i> , 2010, 8, 101-111.	0.3	2
1951	Primary Treatment and Survival Outcomes in Oropharyngeal Cancer. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , 2019, 62, 49-56.	0.0	1
1952	Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review. <i>Cancers</i> , 2015, 7, 1716-1742.	1.7	11
1953	Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring. <i>Cells</i> , 2021, 10, 48.	1.8	16

#	ARTICLE	IF	CITATIONS
1954	PRINS lncRNA Is a New Biomarker Candidate for HPV Infection and Prognosis of Head and Neck Squamous Cell Carcinomas. <i>Diagnostics</i> , 2020, 10, 762.	1.3	20
1955	Prognosis of HPV-positive head and neck cancers: implication of smoking and immunosuppression. <i>Advances in Cellular and Molecular Otolaryngology</i> , 2014, 2, 25717.	0.4	5
1956	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8389.	1.4	22
1957	Importance of investigating high-risk human papillomavirus in lymph node metastasis of esophageal adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 2729-2739.	1.4	2
1958	Human papillomavirus tumor infection in esophageal squamous cell carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 287-95.	0.6	56
1959	The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy. <i>Annals of Translational Medicine</i> , 2015, 3, S14.	0.7	8
1960	Human papillomavirus 16 and 18 in squamous cell carcinoma of oral cavity and sexual practices: A pilot study at a Tertiary Care Hospital of North India. <i>National Journal of Maxillofacial Surgery</i> , 2015, 6, 185.	0.1	8
1961	Evaluation of human papillomavirus (HPV) prediction using the International Endocervical Adenocarcinoma Criteria and Classification system, compared to p16 immunohistochemistry and HPV RNA in-situ hybridization. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 480-488.	0.4	11
1962	Timing of Restaging PET/CT and Neck Dissection after Chemoradiation for Advanced Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology (Sunnyvale, Calif)</i> , 2013, 03, .	0.0	1
1963	Multimodality functional imaging using DW-MRI and <sup>18</sup> F-FDG-PET/CT during radiation therapy for human papillomavirus negative head and neck squamous cell carcinoma: Meixoeiro Hospital of Vigo Experience. <i>World Journal of Radiology</i> , 2017, 9, 17.	0.5	11
1964	The current role of imaging in head and neck cancer: a clinician's perspective. <i>Swiss Medical Weekly</i> , 2014, 144, w14015.	0.8	10
1965	Infecção por Papilomavírus Humano e Câncer Oral: Revisão da literatura atual. <i>Cadernos UniFOA</i> , 2017, 6, 103.	0.0	1
1966	Cancer Virus: The Story of Human Papillomavirus. <i>World Journal of Dentistry</i> , 2017, 8, 71-72.	0.1	1
1967	A comparison of three methods to detect human papilloma virus in oropharyngeal carcinoma: PCR-invader, Hybrid Capture and p16 immunohistochemistry staining. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2013, 23, 163-168.	0.0	3
1968	Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches. <i>World Journal of Clinical Oncology</i> , 2016, 7, 15.	0.9	14
1969	HUMAN PAPILLOMAVIRUS IN THE ETIOLOGY OF HEAD AND NECK CARCINOMAS. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2010, 154, 9-12.	0.2	13
1970	HPV, protein p16 and squamous cell carcinoma of the oral cavity. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2020, 164, 292-299.	0.2	9
1971	Has the time come for de-escalation in the management of oropharyngeal carcinoma?. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2019, 163, 293-301.	0.2	3

#	ARTICLE	IF	CITATIONS
1972	Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit. Chinese Journal of Cancer, 2012, 31, 319-326.	4.9	14
1973	An Update on Molecular Diagnostics of Squamous and Salivary Gland Tumors of the Head and Neck. Archives of Pathology and Laboratory Medicine, 2011, 135, 602-609.	1.2	26
1974	P53 and PCNA is Positively Correlated with HPV Infection in Laryngeal Epitheliopapillomatous Lesions in Patiets with Different Ethnic Backgrounds in Xinjiang. Asian Pacific Journal of Cancer Prevention, 2012, 13, 5439-5444.	0.5	5
1975	Human Papilloma Virus Attributable Head and Neck Cancer in the Sudan Assessed by p16<sup>INK4A</sup>Immunostaining. Asian Pacific Journal of Cancer Prevention, 2012, 13, 6083-6086.	0.5	14
1976	Human Papillomavirus Infection and Prognostic Predictors in Patients with Oropharyngeal Squamous Cell Carcinoma. Asian Pacific Journal of Cancer Prevention, 2012, 13, 891-896.	0.5	29
1977	Expression of EGFR and p53 in Head and Neck Tumors among Sudanese Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6415-6418.	0.5	17
1978	Lack of Association between High-risk Human Papillomaviruses and Oral Squamous Cell Carcinoma in Young Japanese Patients. Asian Pacific Journal of Cancer Prevention, 2014, 15, 4135-4141.	0.5	18
1979	Prevalence of Human Papillomavirus Infection in Oral Squamous Cell Carcinoma: a Case-control Study in Wuhan, China. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5861-5865.	0.5	34
1980	Risk Stratification of Early Stage Oral Tongue Cancers Based on HPV Status and p16 Immunoexpression. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8351-8359.	0.5	45
1981	HPV-Associated p16INK4A Expression and Response to Therapy and Survival in Selected Head and Neck Cancers. Asian Pacific Journal of Cancer Prevention, 2015, 16, 253-258.	0.5	8
1982	Human Papilloma Virus (HPV) Induced Head & Neck Squamous Cell Carcinoma: A Comprehensive Retrospect. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, ZE01-4.	0.8	4
1983	Radioresistance and genomic alterations in head and neck squamous cell cancer: Subâ€analysis of the <sc>ProfilER</sc> protocol. Head and Neck, 2021, 43, 3899-3910.	0.9	2
1984	p62/SQSTM1-induced caspase-8 aggresomes are essential for ionizing radiation-mediated apoptosis. Cell Death and Disease, 2021, 12, 997.	2.7	14
1985	The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications. Cancers, 2021, 13, 5206.	1.7	30
1986	Genomic Signatures in HPV-Associated Tumors. Viruses, 2021, 13, 1998.	1.5	9
1987	The tumor immune microenvironments of <sc>HPV</sc><sup>+</sup> and <sc>HPV</sc><sup>âˆ’</sup> head and neck cancers. WIREs Mechanisms of Disease, 2022, 14, e1539.	1.5	13
1988	Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). Journal of Clinical Oncology, 2022, 40, 138-149.	0.8	162
1989	Staging of human papilloma virus related cancers of the oropharynx. Journal of Surgical Oncology, 2021, 124, 931-934.	0.8	1

#	ARTICLE	IF	CITATIONS
1990	Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. Nature Communications, 2021, 12, 5945.	5.8	10
1991	Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncology, 2021, 122, 105566.	0.8	10
1992	A sexually transmitted disease?. BMJ: British Medical Journal, 2008, 337, a2077-a2077.	2.4	0
1993	Oropharynx: Epidemiology and Treatment Outcome. Medical Radiology, 2009, , 15-29.	0.0	1
1994	Association of Cystic Neck Metastases and Human Papillomavirusâ€œPositive Oropharyngeal Squamous Cell Carcinoma. Archives of Pathology and Laboratory Medicine, 2009, 133, 1798-1803.	1.2	13
1995	Cancer of the Oropharynx. , 2010, , 546-587.		0
1996	Clinical Significance of FDG-PET in Evaluating of Head and Neck Cancer. Practica Otologica, 2010, 103, 595-604.	0.0	0
1997	Oropharyngeal Cancer. , 2010, , 117-129.		0
1998	Cancer of the Head and Neck region. , 2010, , 60-97.		0
1999	Targeting EGFR in HPV-Associated Cancer. , 2010, , 211-234.		0
2000	Prevalence and prognosis of human papillomavirus in oropharyngeal cancer. Japanese Journal of Head and Neck Cancer, 2010, 36, 498-501.	0.0	1
2001	Cancer of the Hypopharynx. , 2010, , 613-641.		0
2002	Recent advances in managing human papillomavirus-positive oropharyngeal tumors. F1000 Medicine Reports, 2010, 2, .	2.9	0
2003	Use of a Linear Array for the Detection of Human Papillomavirus Genotypes in Head and Neck Cancer. Archives of Pathology and Laboratory Medicine, 2010, 134, 1813-1817.	1.2	17
2004	Lower Recurrence in HPV-Positive Head and Neck Squamous Cell Carcinoma Mediated by Down-Regulation of Sphingosine Kinase 1. Otolaryngology (Sunnyvale, Calif ), 2011, 01, .	0.0	0
2005	Head and Neck Cancer Prevention. , 2011, , 41-55.		1
2007	Translational Research in Head and Neck Oncology. , 2011, , 179-189.		0
2008	Strategy for personalized treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma. Japanese Journal of Head and Neck Cancer, 2011, 37, 394-397.	0.0	0



#	ARTICLE	IF	CITATIONS
2009	Multidisciplinary Management of Oropharynx Carcinomas. , 2011, , 401-430.		0
2010	Biomarkers in Head and Neck Cancer. , 2011, , 157-167.		0
2011	Cetuximab in the Treatment of Locally Advanced Head and Neck Cancer. European Oncology and Haematology, 2011, 07, 16.	0.0	0
2013	Human papillomavirus in oropharyngeal squamous cell carcinoma-A multicenter prospective study in Japan-. Japanese Journal of Head and Neck Cancer, 2011, 37, 398-404.	0.0	3
2015	Human Papillomavirus and Oropharyngeal Squamous Cell Carcinoma: Clinical Considerations. , 2012, , 183-192.		0
2016	Methods for Detection of Human Papillomavirus in Head and Neck Cancer. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2012, 55, 8.	0.0	0
2017	The Role of Human Papillomavirus in Head and Neck Cancers. , 0, , .		0
2018	Oropharyngeal Cancer. , 2012, , 585-617.		0
2019	Current status of human papilloma virus infection in oropharynx cancer. Japanese Journal of Head and Neck Cancer, 2012, 38, 390-393.	0.0	0
2020	Human Papilloma Virus Positive Oropharyngeal Cancer. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2012, 55, 71.	0.0	1
2021	Retrospective study of patients with squamous cell carcinoma of lateral wall oropharyngeal carcinoma. Japanese Journal of Head and Neck Cancer, 2012, 38, 415-419.	0.0	0
2022	Head and Neck Tumours. , 2012, , 19-59.		0
2023	Human Papilloma Virus-Induced Head and Neck Cancer. Otolaryngology (Sunnyvale, Calif ), 2012, s2, .	0.0	0
2024	Implications of Human Papillomavirus Infections in the Biology of Head and Neck Cancers. , 0, , .		0
2025	Ulcerative Conditions. , 2012, , 22-78.		0
2027	HPV in Head and Neck Cancer: Treatment. Journal of Clinical Otolaryngology, 2012, 23, 27-31.	0.1	0
2028	HPV in Head and Neck Cancer: Diagnosis. Journal of Clinical Otolaryngology, 2012, 23, 17-26.	0.1	0
2029	Anal Carcinoma Surveillance Counterpoint: USA. , 2013, , 207-213.		0

#	ARTICLE	IF	CITATIONS
2030	Capturing and Deciphering the Molecular Signatures of Head and Neck Cancer. , 2013, , 97-130.		0
2031	Human papillomavirus association in epithelial cancers: a systematic review of the literature. Oncology Discovery, 2013, 1, 5.	0.5	0
2032	Combined analysis of HPV status and p16 expression in patients with oropharyngeal squamous cell carcinoma. Japanese Journal of Head and Neck Cancer, 2013, 39, 334-338.	0.0	4
2033	Does Surgery Have a Relevant Role in the Primary Treatment of Locoregionally Advanced Oropharyngeal Carcinomas?. International Journal of Otolaryngology and Head & Neck Surgery, 2013, 02, 263-270.	0.1	0
2034	Role of Surgery in Treatment of Head and Neck Cancer. , 2013, , 509-562.		1
2035	Challenges in Community-Based Head and Neck Cancer Prevention Programs. , 2013, , 73-86.		0
2036	Viruses and Head and Neck Cancer. , 2013, , 377-400.		0
2038	The current status of treatment for oropharyngeal cancer in Japan. Japanese Journal of Head and Neck Cancer, 2013, 39, 449-455.	0.0	1
2039	Treatment outcomes for oropharyngeal squamous cell carcinoma and the influence of p16INK4a. Journal of Japan Society for Head and Neck Surgery, 2013, 23, 199-204.	0.0	0
2040	Casualties of Intimacy. ASHA Leader, 2013, 18, 38-43.	0.2	0
2042	Current Treatment of Oropharyngeal Cancer. Journal of Clinical Otolaryngology, 2013, 24, 150-155.	0.1	0
2043	Human Papillomavirus in Head and Neck Cancer: Several Questions. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2014, 57, 143.	0.0	1
2044	Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and New Approaches. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 205-231.	0.1	0
2045	A Review of Literature Pertaining to Head and Neck Squamous Cell Carcinoma with Emphasis on the Role of the Human Papilloma Virus. International Journal of Otolaryngology and Head & Neck Surgery, 2014, 03, 279-292.	0.1	0
2046	Role of HPV in Head and Neck Cancer. Advances in Tumor Virology, 0, 4, 1-6.	0.0	0
2047	Hypoxia and Radioresistance in Head and Neck Cancer. , 2014, , 283-302.		0
2048	HUMAN PAPILLOMAVIRUS INFECTION AND HEAD AND NECK CANCER PROGRESSION. Russian Journal of Infection and Immunity, 2014, 4, 162.	0.2	1
2049	Frequency of Human Papillomavirus in Larynx Squamous Cell Carcinoma and Clinicopathological Correlation of P53 and Ki-67 Expression. Adnan Menderes Üniversitesi Tıp Fakültesi/Journal of Adnan Menderes University Medical Faculty, 2014, 15, 55-61.	0.0	0

#	ARTICLE	IF	CITATIONS
2050	Clinical Management of HPV-Related Oropharyngeal Cancer. <i>Head and Neck Cancer Clinics</i> , 2015, , 87-97.	0.0	0
2051	Premalignant Lesions. , 2015, , 273-292.		0
2052	Statistical evaluation of oropharyngeal squamous cell carcinoma and p16 immunostaining. <i>Japanese Journal of Head and Neck Cancer</i> , 2015, 41, 57-62.	0.0	1
2053	Human Papillomavirus-Related Cancers. , 2015, , 243-291.		0
2054	Targeting the PI3K-mTOR Signaling Circuitry in HPV-Associated Oral Malignancies: Novel Precision Molecular Therapies. , 2015, , 153-169.		0
2055	Head and Neck Tumors: Viewpointâ€”Fractionated Radiation Therapy and Chemotherapy. , 2015, , 549-562.		0
2056	Differences and Similarities Between HPV-Associated OPSCC and Cervical Cancer. , 2015, , 213-229.		0
2057	Current and future roles of chemoradiation for oropharyngeal cancer based on HPV status. <i>Japanese Journal of Head and Neck Cancer</i> , 2015, 41, 325-329.	0.0	3
2058	HPV and oral lesions: preventive possibilities, vaccines and early diagnosis of malignant lesions. <i>ORAL and Implantology</i> , 2015, 8, 45-51.	0.3	4
2059	Clinical Presentation of HPV-Driven Oropharyngeal Carcinoma. , 2015, , 195-212.		0
2060	Significance of Human Papillomavirus in Head and Neck Cancers. <i>Journal of the Advanced Practitioner in Oncology</i> , 2015, 6, 256-62.	0.2	2
2061	Re-emergence of Surgery in the Management of Head & Neck Cancer. <i>Perspectives on Swallowing and Swallowing Disorders (Dysphagia)</i> , 2015, 24, 79-88.	0.2	0
2062	Patterns of Relapse in Squamous Cell Carcinoma of the Tonsil - Unilateral vs. Bilateral Radiation in the HPV-Era. <i>Cureus</i> , 2015, 7, e322.	0.2	8
2065	Oropharyngeal Carcinoma. , 2016, , 426-429.		0
2066	Diagnostic Applications of Nuclear Medicine: Head and Neck Cancer. , 2016, , 1-37.		0
2067	The clinical aspects of HPV-positive cancer of the oral cavity and oropharynx. <i>Vestnik Otorinolaringologii</i> , 2016, 81, 72.	0.0	5
2068	Cervical Lymph Node Metastases of Squamous Cell Carcinoma from an Unknown Primary Site. , 2016, , 665-672.		0
2069	Assessing the Changing Oral and Pharyngeal Cancer Demographic in the United States. , 2016, , 3-19.		0

#	ARTICLE	IF	CITATIONS
2070	Biomarkers in Head and Neck Cancer. , 2016, , 149-162.		0
2071	Translational Research in Head and Neck Oncology. , 2016, , 215-227.		0
2072	Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer. , 2016, , 337-348.		0
2073	Multidisciplinary Management of Oropharynx Carcinomas. , 2016, , 475-510.		0
2074	Head and Neck Brachytherapy: A Description of Methods and a Summary of Results. Medical Radiology, 2016, , 71-143.	0.0	1
2076	Head and Neck Brachytherapy. , 2017, , 219-272.		0
2077	To review the role and issue of pharmacotherapy for head and neck cancer clarified from previous clinical trials. Japanese Journal of Head and Neck Cancer, 2017, 43, 425-429.	0.0	0
2078	Diagnostic Applications of Nuclear Medicine: Head and Neck Cancer. , 2017, , 507-543.		0
2080	Association of uncommon sexual practices with Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma. Journal of Medical Science and Clinical Research, 2017, 5, .	0.0	0
2081	Communicate or Die â€“ A Model for HPV+ and HPVâ€“ CSCs and Their Interactions with SDF-1 $\beta$ . Anticancer Research, 2017, 37, 4827-4836.	0.5	4
2083	Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program. Journal of Japanese Society of Oral Oncology, 2018, 30, 144-150.	0.0	0
2084	Effect of multimodal-treatment for oropharyngeal squamous cell carcinoma with or without human papilloma virus infection. Japanese Journal of Head and Neck Cancer, 2018, 44, 18-22.	0.0	0
2085	Detection of human papilloma virus-E6/E7 proteins of high-risk human papilloma virus in saliva and lesional tissue of oral squamous cell carcinoma patients using nested multiplex polymerase chain reaction: A comparative study. Journal of Oral and Maxillofacial Pathology, 2018, 22, 318.	0.3	6
2086	Immune check point inhibitors for head and neck cancer. Japanese Journal of Head and Neck Cancer, 2018, 44, 336-341.	0.0	0
2087	The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma. Current Cancer Research, 2018, , 397-438.	0.2	0
2088	Human Papillomavirus and Head and Neck Cancer. , 2018, , 349-364.		0
2089	Treatment Paradigms in HPV-Associated SCCHN. Current Cancer Research, 2018, , 585-615.	0.2	0
2090	Nonâ€“HPV-Associated Oropharyngeal Cancer. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
2091	Significado pronóstico de la proteína p16 en el cáncer laríngeo. Acta De Otorrinolaringología & Cirugía De Cabeza Y Cuello, 2018, 41, 186-191.	0.0	0
2092	Strategies For a New Generation of Oral Cancer Patients. ASHA Leader, 2018, 23, 42-44.	0.2	0
2093	No operation of oropharyngeal cancer in head and neck. Japanese Journal of Head and Neck Cancer, 2019, 45, 280-285.	0.0	0
2094	Oropharynx, Nasopharynx, and Waldeyer Ring. , 2019, , 39-58.		0
2095	Squamous Cell Carcinoma of the Head and Neck. , 2019, , 697-720.		1
2096	Human Papillomavirus-Related Head and Neck Cancer. , 2019, , 45-68.		0
2097	EPIDEMIOLOGY ASPECTS OF HUMAN PAPILLOMAVIRUS INFECTION OF LUNG CANCER: A REVIEW. Epidemiology and Infectious Diseases (Russian Journal), 2019, 24, 32-42.	0.1	0
2098	Situation of Human Papilloma Virus: Generalities and current treatments. Revista Bionatura, 2019, 02, .	0.1	1
2099	Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma. Annals of Translational Medicine, 2019, 7, S22-S22.	0.7	2
2101	HPV infections in head and neck cancers (HNSCC) – clinical course and efficiency of therapy. Pomeranian Journal of Life Sciences, 2019, 65, 36-40.	0.1	0
2102	Immunotherapy in Oral Cancer: A Fourth Dimension of Cancer Treatment. , 2020, , 129-154.		1
2103	Assessing survival rate of HPV-positive and HPV-negative cervical cancer patients. Russian Journal of Infection and Immunity, 2019, 9, 595-599.	0.2	0
2104	THE ASSOCIATION BETWEEN HUMAN PAPILLOMA VIRUS AND LARYNGEAL MASSES. Basrah Journal of Surgery, 2019, 25, 39-46.	0.0	0
2105	PET in the Diagnosis of Head and Neck Cancer. , 2020, , 187-221.		0
2106	Head and neck cancer in Styria. Wiener Klinische Wochenschrift, 2020, 132, 444-451.	1.0	1
2109	Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma. Oral Oncology, 2021, 123, 105570.	0.8	2
2110	Inclusion of an E7 DNA Amplification Test Improves the Robustness of Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma Diagnosis. World Journal of Oncology, 2020, 11, 1-8.	0.6	1
2112	DNA methylation biomarkers in peripheral blood of patients with head and neck squamous cell carcinomas. A systematic review. PLoS ONE, 2020, 15, e0244101.	1.1	8

#	ARTICLE	IF	CITATIONS
2113	Neoplasms of the Oral Cavity and Oropharynx. , 2021, , 427-447.		0
2114	Human Papillomavirus Testing in Head and Neck Squamous Cell Carcinoma: Impact of the 2018 College of American Pathologists Guideline Among Referral Cases at a Large Academic Institution. Archives of Pathology and Laboratory Medicine, 2021, 145, 1123-1131.	1.2	3
2115	ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer. Cancers of the Head & Neck, 2020, 5, 12.	6.2	5
2116	Ultrasound diagnosis of oropharyngeal squamous cell carcinoma and ultrasound evaluation of treatment efficacy (changes in tumor volume). Opuholi Golovy I Sei, 2019, 9, 12-23.	0.1	1
2117	Deintensification of Treatment for HPV-Associated Cancers of the Oropharynx. Textbooks in Contemporary Dentistry, 2020, , 303-309.	0.2	0
2118	Human Papillomavirus-related Sinonasal Carcinoma: Report of Two Cases. Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology), 2020, 59, 363-369.	0.0	1
2119	Therapeutic Outcomes of HPV Positive and HPV Negative Oropharyngeal Squamous Cell Carcinomas. Journal of Cancer Therapy, 2020, 11, 507-518.	0.1	0
2120	Treatment-Related Patient Outcomes for Head and Neck Cancer. , 2020, , 21-38.		1
2123	Viral Modulation of the DNA Damage Response and Innate Immunity: Two Sides of the Same Coin. Journal of Molecular Biology, 2022, 434, 167327.	2.0	5
2124	Tumor Glucose Metabolism and Its Heterogeneity on F-18 FDG PET/CT Provide Better Prognostication in Nonmetastatic Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. Cancers, 2021, 13, 5538.	1.7	5
2127	CD8 + T Cell Infiltration Predicts Chemoradiosensitivity in Nasopharyngeal or Oropharyngeal Cancer. Laryngoscope, 2021, 131, E1179-E1189.	1.1	9
2128	Human Papilloma Virus (HPV) in head and neck region: review of literature. Acta Otorhinolaryngologica Italica, 2009, 29, 119-26.	0.7	48
2129	New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngologica Italica, 2013, 33, 77-87.	0.7	74
2131	Prognostic significance of high-risk human papillomavirus and p16(INK4A) in patients with esophageal squamous cell carcinoma. International Journal of Clinical and Experimental Medicine, 2014, 7, 3430-8.	1.3	13
2132	HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngologica Italica, 2014, 34, 299-309.	0.7	105
2133	Biomarkers of head and neck cancer, tools or a gordian knot?. International Journal of Clinical and Experimental Medicine, 2015, 8, 10340-57.	1.3	27
2135	Pathway Analysis using Gene-expression Profiles of HPV-positive and HPV-negative Oropharyngeal Cancer Patients in a Hispanic Population: Methodological Procedures. Puerto Rico Health Sciences Journal, 2016, 35, 3-8.	0.2	11
2136	Identifying the Causes of Cancer Health Disparities: Biologic and Non Biologic Determinants. Californian Journal of Health Promotion, 2010, 8, 101-111.	0.3	1



#	ARTICLE	IF	CITATIONS
2137	The potential for liquid biopsies in head and neck cancer. <i>Discovery Medicine</i> , 2018, 25, 251-257.	0.5	19
2138	MiR-31 is a potential biomarker for diagnosis of head and neck squamous cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 4339-4345.	0.5	8
2139	Heterogeneous nuclear ribonucleoprotein K is overexpressed and contributes to radioresistance irrespective of HPV status in head and neck squamous cell carcinoma. <i>International Journal of Molecular Medicine</i> , 2020, 46, 1733-1742.	1.8	0
2140	Tumoren im Kopf-Hals-Bereich. , 2022, , 230-241.		0
2141	Defining <sc>high-risk</sc> elective contralateral neck radiation volumes for oropharynx cancer. <i>Head and Neck</i> , 2022, 44, 317-324.	0.9	1
2142	The Prevalence of High- and Low-Risk Types of HPV in Patients with Squamous Cell Carcinoma of the Head and Neck, Patients with Chronic Tonsillitis, and Healthy Individuals Living in Poland. <i>Diagnostics</i> , 2021, 11, 2180.	1.3	4
2143	Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists. <i>Cancers</i> , 2021, 13, 5716.	1.7	13
2144	Swallowing After Primary TORS and Unilateral or Bilateral Radiation for Low-to Intermediate-Risk Tonsil Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2022, 167, 484-493.	1.1	2
2145	Radioimmunotherapy and Targeted Radiotherapy of Squamous Cell Carcinoma of the Head and Neck. , 2022, , 457-469.		0
2146	Immune Landscape and Role of Immunotherapy in Treatment of HPV-Associated Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Otorhinolaryngology Reports</i> , 2022, 10, 96-107.	0.2	0
2147	Biomarker-Based Evaluation of Treatment Response and Surveillance of HPV-Associated Squamous Cell Carcinoma. <i>Current Otorhinolaryngology Reports</i> , 0, , 1.	0.2	1
2148	[18F]Fluoro-DCP, a first generation PET radiotracer for monitoring protein sulfenylation in vivo. <i>Redox Biology</i> , 2022, 49, 102218.	3.9	2
2149	Heterogeneous nuclear ribonucleoprotein K is overexpressed and contributes to radioresistance irrespective of HPV status in head and neck squamous cell carcinoma. <i>International Journal of Molecular Medicine</i> , 2020, 46, 1733-1742.	1.8	3
2150	Significance of P16INK4A Expression and PTEN Loss of Heterozygosity in Human Papilloma Virus-related Oral Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2020, 40, 6355-6366.	0.5	3
2151	Dietary Carotenoids in Head and Neck Cancer—Molecular and Clinical Implications. <i>Nutrients</i> , 2022, 14, 531.	1.7	6
2152	Prevalence of HPV Infection and p16INK4a Overexpression in Surgically Treated Laryngeal Squamous Cell Carcinoma. <i>Vaccines</i> , 2022, 10, 204.	2.1	7
2153	Evolution of a Paradigm Switch in Diagnosis and Treatment of HPV-Driven Head and Neck Cancer—Striking the Balance Between Toxicity and Cure. <i>Frontiers in Pharmacology</i> , 2021, 12, 753387.	1.6	10
2154	Repositioning Fenofibrate to Reactivate p53 and Reprogram the Tumor-Immune Microenvironment in HPV+ Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 282.	1.7	6

#	ARTICLE	IF	CITATIONS
2155	Interpreting ORATOR: Lessons Learned From a Randomized Comparison of Primary Surgical and Radiation Approaches for Early-Stage Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 814-817.	0.8	3
2156	Trends in the incidence of head and neck cancer by subsite between 1993 and 2015 in Japan. <i>Cancer Medicine</i> , 2022, 11, 1553-1560.	1.3	29
2157	Epigenetic biomarkers of ageing are predictive of mortality risk in a longitudinal clinical cohort of individuals diagnosed with oropharyngeal cancer. <i>Clinical Epigenetics</i> , 2022, 14, 1.	1.8	17
2158	Patterns of disease events and causes of death in patients with HPV-positive versus HPV-negative oropharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2022, 168, 40-45.	0.3	10
2159	Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2022, 128, 2193-2204.	2.0	35
2160	Oropharyngeal Cancer Incidence and Mortality Trends in All 50 States in the US, 2001-2017. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 155.	1.2	48
2161	Importance of immune cell infiltration in tumor microenvironment of head and neck cancer. <i>Onkologie (Czech Republic)</i> , 2021, 15, 67-72.	0.0	0
2162	Induction Chemotherapy in Low-Risk HPV+ Oropharyngeal Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 54-67.	1.3	1
2163	Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma. <i>Npj Precision Oncology</i> , 2022, 6, 10.	2.3	23
2164	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
2165	Decoding the influence of the immune system and immunotherapy targets on carcinomas: A hidden prism in oral cancer therapy. <i>Disease-a-Month</i> , 2023, 69, 101353.	0.4	4
2166	NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 224-234.	2.3	169
2167	Context-dependent activation of p53 target genes and induction of apoptosis by actinomycin D in aerodigestive tract cancers. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2022, 27, 342-353.	2.2	3
2168	The World of Oral Cancer and Its Risk Factors Viewed from the Aspect of MicroRNA Expression Patterns. <i>Genes</i> , 2022, 13, 594.	1.0	11
2169	Head and neck cancer organoids as a promising tool for personalized cancer therapy: A literature review. <i>Health Science Reports</i> , 2022, 5, e580.	0.6	2
2170	Prophylactic contralateral neck dissection has no advantage in patients with early stage HPV-positive tonsil cancer. <i>Acta Oto-Laryngologica</i> , 2022, , 1-5.	0.3	0
2171	Anaplasia and multinucleation in metastases of oropharyngeal squamous cell carcinoma is associated with poorer outcomes. <i>Journal of the American Society of Cytopathology</i> , 2022, 11, 201-209.	0.2	1
2172	Expression of DNA-damage response and repair genes after exposure to DNA-damaging agents in isogenic head and neck cells with altered radiosensitivity. <i>Radiology and Oncology</i> , 2022, 56, 173-184.	0.6	4

#	ARTICLE	IF	CITATIONS
2173	PET/Computed Tomography. PET Clinics, 2022, 17, 319-326.	1.5	6
2174	Young non-smokers with oral cancer: What are we missing and why?. Oral Oncology, 2022, 127, 105803.	0.8	9
2175	Concurrent Cetuximab-based bioradiotherapy versus Cisplatin-based Chemoradiotherapy in the Definitive Management of Favourable Biology Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma: Systematic Review and Meta-analysis. Clinical Oncology, 2022, , .	0.6	1
2176	Quality of Life Analysis of HPV-Positive Oropharyngeal Cancer Patients in a Randomized Trial of Reduced-Dose Versus Standard Chemoradiotherapy: 5-Year Follow-Up. Frontiers in Oncology, 2022, 12, 859992.	1.3	2
2177	Prognostic Analysis of HPV Status in Sinonasal Squamous Cell Carcinoma. Cancers, 2022, 14, 1874.	1.7	8
2178	Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer. Oral Oncology, 2022, 128, 105805.	0.8	16
2179	Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. The Cochrane Library, 2021, 2021, CD006386.	1.5	11
2180	Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clinical Cancer Research, 2022, 28, 903-914.	3.2	14
2181	Comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma patients with extranodal extension or positive margins. Head and Neck, 2022, 44, 606-614.	0.9	1
2182	The Prevalence of Human Papillomavirusâ€“Positive Oropharyngeal Squamous Cell Carcinoma at One of the Largest Tertiary Care Centers in Sub-Saharan Africa. Archives of Pathology and Laboratory Medicine, 2022, 146, 1018-1023.	1.2	3
2183	Decision Support for Oropharyngeal Cancer Patients Based on Data-Driven Similarity Metrics for Medical Case Comparison. Diagnostics, 2022, 12, 999.	1.3	2
2184	Impact of AJCC 8th edition staging system and definitive treatment choice on the prognosis of complete responders with p16+ and p16â€” oropharyngeal squamous cell carcinomas. Oral Oncology, 2022, 128, 105861.	0.8	3
2185	Unraveling diverse roles of noncoding RNAs in various human papillomavirus negative cancers. , 2022, 238, 108188.		15
2186	Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients With Low-risk and Intermediate-risk p16-positive Oropharynx Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 202-207.	0.6	4
2187	An update on the pathobiological relevance of nuclear receptors for cancers of the head and neck. Histology and Histopathology, 2010, 25, 1093-104.	0.5	7
2189	Prevalence of Transcriptionally Active HPV Infection in Tumor-Free Oropharyngeal Tissue of OPSCC-Patients. Frontiers in Oncology, 2022, 12, 835814.	1.3	2
2190	The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review. Supportive Care in Cancer, 2022, 30, 7191-7204.	1.0	2
2191	Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 527-540.	1.8	9

#	ARTICLE	IF	CITATIONS
2192	Analysis of Selected Nutritional Parameters in Patients with HPV-Related and Non-HPV-Related Oropharyngeal Cancer before and after Radiotherapy Alone or Combined with Chemotherapy. <i>Cancers</i> , 2022, 14, 2335.	1.7	0
2193	Human Papillomavirus-Related Carcinomas of the Sinonasal Tract. <i>Current Otorhinolaryngology Reports</i> , 2022, 10, 291-302.	0.2	3
2194	Association of HPV status with survival after surgical salvage of oropharyngeal cancers. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2022, 43, 103491.	0.6	3
2195	Decreased CD1a + and CD83 + cells in tonsillar squamous cell carcinoma regardless of HPV status. <i>Journal of Applied Oral Science</i> , 2022, 30, e20210702.	0.7	1
2196	Does Tumor Volume Have a Prognostic Role in Oropharyngeal Squamous Cell Carcinoma? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 2465.	1.7	5
2197	Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4292-4301.	3.2	45
2198	Cecal mass: An unusual site of metastasis from HPV-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2022, 130, 105928.	0.8	0
2199	To study HPV and EBV in squamous cell carcinoma of upper aerodigestive tract by immunohistochemistry markers. <i>Indian Journal of Pathology and Oncology</i> , 2022, 9, 145-152.	0.1	0
2200	Treatment De-Intensification for Patients With HPV-Positive Head and Neck Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 596-599.	2.3	0
2201	De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma—Where Are We Now?. <i>Current Oncology</i> , 2022, 29, 3668-3697.	0.9	8
2202	A Lack of Effectiveness in the ATM-Orchestrated DNA Damage Response Contributes to the DNA Repair Defect of HPV-Positive Head and Neck Cancer Cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2203	Clinical decision support models for oropharyngeal cancer treatment: design and evaluation of a multi-stage knowledge abstraction and formalization process. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2022, 17, 1643-1650.	1.7	1
2206	Imaging of human papilloma virus associated oropharyngeal squamous cell carcinoma and its impact on diagnosis, prognostication, and response assessment. <i>British Journal of Radiology</i> , 2022, 95, .	1.0	3
2207	The discordant biomarker dilemma: What are the diagnostic implications of oropharyngeal squamous cell carcinomas with discrepant p16 and <sc>HPV</sc> results?. <i>Cancer Cytopathology</i> , 0, , .	1.4	0
2208	Role of Epstein-Barr Virus and Human Papilloma Virus in the Development of Oropharyngeal Cancer: A Literature Review. <i>International Journal of Dentistry</i> , 2022, 2022, 1-9.	0.5	5
2209	High-risk human papillomavirus testing in cytology aspiration samples from the head and neck part 2: a survey of the American Society of Cytopathology community. <i>Journal of the American Society of Cytopathology</i> , 2022, 11, 306-312.	0.2	1
2210	Usability of deep learning and H&E images predict disease outcome-emerging tool to optimize clinical trials. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	14
2211	Lifestyle choices following head and neck cancer treatment: A qualitative study. <i>Nutrition and Health</i> , 0, , 026010602211066.	0.6	1

#	ARTICLE	IF	CITATIONS
2212	Clinical impact of p16 positivity in nasopharyngeal carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2022, 7, 994-1001.	0.6	5
2213	Association Between Up-front Surgery and Risk of Stroke in US Veterans With Oropharyngeal Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 740.	1.2	9
2214	The effect of HPV DNA and p16 status on the prognosis of patients with hypopharyngeal carcinoma: a meta-analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
2215	Events prediction after treatment in HPV-driven oropharyngeal carcinoma using machine learning. <i>European Journal of Cancer</i> , 2022, 171, 106-113.	1.3	3
2216	Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
2217	A Novel Signature of Necroptosis-Associated Genes as a Potential Prognostic Tool for Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
2218	A Novel Necroptosis-Associated lncRNAs Signature for Prognosis of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
2219	Clinical Study of Prognostic Factors in Patients with P16-positive Oropharyngeal Cancer in Whom Surgery Was Selected as The Initial Treatment. <i>Nihon Jibi InkoKa Tokeibu GeKa Gakkai Kaiho</i> , 2022, 125, 986-992.	0.0	0
2220	Human Papillomavirus-Associated Oral Cavity Squamous Cell Carcinoma: An Entity with Distinct Morphologic and Clinical Features. <i>Head and Neck Pathology</i> , 2022, 16, 1073-1081.	1.3	7
2221	Diagnostic Delay in Human Papillomavirus Negative Oropharyngeal Squamous Cell Carcinoma. <i>Laryngoscope</i> , 0, , .	1.1	0
2222	Proteome and phosphoproteome signatures of recurrence for HPV+ head and neck squamous cell carcinoma. <i>Communications Medicine</i> , 2022, 2, .	1.9	2
2223	Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer. <i>Cancer Research Communications</i> , 2022, 2, 987-1004.	0.7	1
2224	Prediction of survival in oropharyngeal squamous cell carcinoma using machine learning algorithms: A study based on the surveillance, epidemiology, and end results database. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
2225	Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	7
2226	Current perspectives on recurrent HPV-mediated oropharyngeal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
2227	Advances in Surgical Therapy for HPV-Associated Squamous Cell Carcinoma. <i>Current Otorhinolaryngology Reports</i> , 0, , .	0.2	0
2228	Oncogenic viruses as etiological risk factors for head and neck cancers: An overview on prevalence, mechanism of infection and clinical relevance. <i>Archives of Oral Biology</i> , 2022, 143, 105526.	0.8	2
2229	Effectiveness of PARP inhibition in enhancing the radiosensitivity of 3D spheroids of head and neck squamous cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
2230	Radioimmunotherapy in HPV-Associated Head and Neck Squamous Cell Carcinoma. <i>Biomedicines</i> , 2022, 10, 1990.	1.4	2
2231	The HPV Induced Cancer Resource (THInCR): a Suite of Tools for Investigating HPV-Dependent Human Carcinogenesis. <i>MSphere</i> , 2022, 7, .	1.3	5
2232	Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 918.	1.2	4
2233	Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Clinical Trial Demographics. <i>Cancers</i> , 2022, 14, 4061.	1.7	4
2234	Prognostic factors in oropharyngeal squamous cell carcinoma in the state of São Paulo, Brazil: 10-year follow-up. <i>Brazilian Journal of Otorhinolaryngology</i> , 2022, .	0.4	0
2235	Current Evidence of a Deintensification Strategy for Patients with HPV-Related Oropharyngeal Cancer. <i>Cancers</i> , 2022, 14, 3969.	1.7	4
2236	HPV and head and neck cancers: Towards early diagnosis and prevention. <i>Tumour Virus Research</i> , 2022, 14, 200245.	1.5	15
2237	Adjuvant Radiotherapy in Surgically Treated HPV-Positive Oropharyngeal Carcinoma with Adverse Pathological Features. <i>Cancers</i> , 2022, 14, 4515.	1.7	2
2238	Pro-apoptotic and size-reducing effects of protein corona-modulating nano-architectures enclosing platinum prodrug in <i>in vivo</i> oral carcinoma. <i>Biomaterials Science</i> , 2022, 10, 6135-6145.	2.6	10
2239	Diagnostic Applications of Nuclear Medicine: Head and Neck Cancer. , 2022, , 607-641.		0
2240	Advances in Surgery and Reconstruction: TORS, TLM. , 2022, , 25-43.		0
2241	Epidemiology and Genomics of Head and Neck Squamous Cell Carcinoma. , 2022, , 115-128.		0
2242	De-intensification Strategies for Head and Neck Cancer. , 2022, , 1-12.		0
2243	Biomarkers in Head and Neck Cancer. , 2022, , 129-151.		0
2244	Margin Sampling and Survival Outcomes in Oral Cavity and p16-Positive Oropharyngeal Squamous Cell Carcinoma. <i>OTO Open</i> , 2022, 6, .	0.6	2
2245	CLINICOPATHOLOGICAL STUDY OF ORAL SQUAMOUS CELL CARCINOMAS WITH SPECIAL EMPHASIS ON E6, E7 ONCOPROTEIN EXPRESSION AND KI67 LABELLING INDEX. , 2022, , 27-29.		0
2246	Effect of p16 Status on Survival Outcomes in Sinonasal Squamous Cell Carcinoma. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 0, , 000348942211214.	0.6	0
2247	Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer: Results from the PREDICT-HN Study. <i>Current Oncology</i> , 2022, 29, 6303-6313.	0.9	6



#	ARTICLE	IF	CITATIONS
2248	Influence of sex on survival rates of HPV-positive oropharyngeal cancers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
2250	The Role of HPV in Determining Treatment, Survival, and Prognosis of Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4321.	1.7	9
2251	Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
2252	Gene polymorphisms and post-treatment toxicity and treatment response in head and neck squamous cell carcinoma: A scoping review. <i>Oral Science International</i> , 2023, 20, 151-164.	0.3	0
2253	Impact of HPV status in T1-2 oropharyngeal squamous cell carcinoma with bulky N3 nodes: a multicenter GETTEC study. <i>European Archives of Oto-Rhino-Laryngology</i> , 0, , .	0.8	0
2254	Predicting local persistence/recurrence after radiation therapy for head and neck cancer from PET/CT using a multi-objective, multi-classifier radiomics model. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2255	The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	24
2256	The Therapeutic Potential of Imidazole or Quinone-Based Compounds as Radiosensitisers in Combination with Radiotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4694.	1.7	5
2257	Image analysis reveals differences in tumor multinucleations in Black and White patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2022, 128, 3831-3842.	2.0	9
2258	One hundred most-cited articles in head and neck surgery and analysis of female authorship. <i>Head and Neck</i> , 0, , .	0.9	0
2259	A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. <i>Clinical Cancer Research</i> , 2022, 28, 5040-5048.	3.2	5
2260	Can Persistent Homology Features Capture More Intrinsic Information about Tumors from 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Images of Head and Neck Cancer Patients?. <i>Metabolites</i> , 2022, 12, 972.	1.3	3
2261	Nectin-4 is widely expressed in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2022, 13, 1166-1173.	0.8	6
2262	HPV infection and 5mC/5hmC epigenetic markers in penile squamous cell carcinoma: new insights into prognostics. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	2
2263	A Prospective Study of Mucosal Sparing Radiation Therapy in Resected Oropharyngeal Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	3
2264	EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188827.	3.3	7
2266	FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma. <i>Biomolecules</i> , 2022, 12, 1458.	1.8	4
2267	Impact of Alcohol and Smoking on Outcomes of HPV-Related Oropharyngeal Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 6510.	1.0	6

#	ARTICLE	IF	CITATIONS
2268	Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives. <i>Cancers</i> , 2022, 14, 5385.	1.7	2
2269	Mechanistic Contributions of lncRNAs to Cellular Signaling Pathways Crucial to the Lifecycle of Human Papillomaviruses. <i>Viruses</i> , 2022, 14, 2439.	1.5	2
2270	Image Guidance Volume-Modulated Arc Radiation Therapy Concurrently With Nab-Paclitaxel Plus Cisplatin for Patients With Locally Advanced Cervical Cancer: A Single-Arm Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 1197-1204.	0.4	2
2271	Squamousâ€“columnar junction of Von Ebnerâ€™s glands may be a significant origin of squamous cell carcinomas in the base of the tongue. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2272	Lacrimal sac ciliated HPV16 positive, adenosquamous carcinoma-A case report of a unique histological variant at this site and a review of the literature. <i>Orbit</i> , 0, , 1-6.	0.5	0
2273	Individualization of treatment policy for patients with regional metastatic oropharyngeal carcinoma associated with human papillomavirus. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2022, 11, 65.	0.0	0
2274	Clinical Utility of Human Papillomavirus Circulating Tumour DNA in Human Papillomavirus-positive Head and Neck Squamous Cell Carcinomas. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2022, 18, 125.	0.1	0
2276	Epidemiological Study of p16 Incidence in Head and Neck Squamous Cell Carcinoma 2005â€“2015 in a Representative Northern European Population. <i>Cancers</i> , 2022, 14, 5717.	1.7	3
2277	Treatment advances in the management of oropharyngeal carcinoma: from minimally invasive surgery to target radiotherapy. <i>Otorhinolaryngology(Italy)</i> , 2022, 72, .	0.1	0
2278	Fiveâ€“year survival outcomes in oropharyngeal squamous cell carcinoma following transoral laser microsurgery. <i>Laryngoscope Investigative Otolaryngology</i> , 0, , .	0.6	1
2279	Beta spectrin staining is associated with higher risk of recurrent disease in oral tongue squamous cell carcinoma (OTSCC). , 2022, , 100008.		0
2280	Survey of experiences and barriers to dental care postâ€“head and neck cancer in OraRad study participants. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2023, 135, 501-509.	0.2	1
2281	Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
2283	Squamous Cell Carcinoma of Head and Neck. , 0, , .		0
2284	Ex Vivo Functional Assay for Evaluating Treatment Response in Tumor Tissue of Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2023, 15, 478.	1.7	2
2285	Magnetic resonance imaging based radiomics prediction of Human Papillomavirus infection status and overall survival in oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2023, 137, 106307.	0.8	9
2287	Personalized precision radiotherapy and its evolving role for human papillomavirus-positive oropharyngeal cancer. <i>Journal of the National Cancer Center</i> , 2022, , .	3.0	0
2288	HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer. <i>Cancer Gene Therapy</i> , 0, , .	2.2	0

#	ARTICLE	IF	CITATIONS
2289	Top advances of the year: Head and neck cancer. <i>Cancer</i> , 0, , .	2.0	0
2290	Do We Have Enough Evidence to Specifically Recommend Transoral Robotic Surgery in HPV-Driven Oropharyngeal Cancer? A Systematic Review. <i>Pathogens</i> , 2023, 12, 160.	1.2	2
2291	Oropharyngeal Carcinoma with a Special Focus on HPV-Related Squamous Cell Carcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2023, 18, 515-535.	9.6	12
2292	Prognosis of HPV-Positive Oral Squamous Carcinoma: A Cohort Study from Japan. <i>Journal of Hard Tissue Biology</i> , 2023, 32, 77-82.	0.2	1
2293	Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2294	Diagnostic performance of computed tomography features in detecting oropharyngeal squamous cell carcinoma extranodal extension. <i>European Radiology</i> , 2023, 33, 3693-3703.	2.3	4
2295	Response to induction chemotherapy predicts survival outcomes in oropharyngeal cancer. <i>Cancer Medicine</i> , 2023, 12, 9175-9185.	1.3	3
2296	CD8+ T Cells and PD-L1 Expression as Prognostic Indicators in a Low Prevalence of HPV-Associated Oropharyngeal Squamous Cell Carcinoma. <i>Current Oncology</i> , 2023, 30, 1450-1460.	0.9	3
2297	Causal Link of Human Papillomavirus in Barrett Esophagus and Adenocarcinoma: Are We There Yet?. <i>Cancers</i> , 2023, 15, 873.	1.7	0
2298	Practical Application of Circulating Tumor-Related DNA of Human Papillomavirus in Liquid Biopsy to Evaluate the Molecular Response in Patients with Oropharyngeal Cancer. <i>Cancers</i> , 2023, 15, 1047.	1.7	2
2299	Targeting Cancer Stem Cells in Oral Cancer. <i>Journal of the California Dental Association</i> , 2016, 44, 112-120.	0.0	0
2300	Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study. <i>Cancer</i> , 2023, 129, 2373-2384.	2.0	2
2301	Induction chemotherapy in locally advanced head and neck cancers, is there a best choice?. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 186, 103986.	2.0	2
2302	Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. <i>Oral Oncology</i> , 2023, 138, 106311.	0.8	1
2303	Low p16 Cytoplasmic Staining Predicts Poor Treatment Outcome in Patients with p16-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving TPF Induction Chemotherapy. <i>Biomedicines</i> , 2023, 11, 339.	1.4	1
2304	Everolimus downregulates STAT3/HIF-1 $\alpha$ /VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC). <i>Oncotarget</i> , 2023, 14, 85-95.	0.8	6
2305	Positive Linear Relationship between Nucleophosmin Protein Expression and the Viral Load in HPV-Associated Oropharyngeal Squamous Cell Carcinoma: A Possible Tool for Stratification of Patients. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3482.	1.8	1
2306	Transcriptional analysis links B cells and TERT expression to favorable prognosis in head and neck cancer. , 2023, 2, .		2

#	ARTICLE	IF	CITATIONS
2307	Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers. <i>Diagnostics</i> , 2023, 13, 725.	1.3	9
2308	In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinoma. <i>Investigational New Drugs</i> , 2023, 41, 193-201.	1.2	2
2309	Management of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma: a Contemporary Review. <i>Current Oncology Reports</i> , 2023, 25, 501-510.	1.8	1
2310	Patient-Reported Outcome Measures of Psychosocial Quality of Life in Oropharyngeal Cancer Patients: A Scoping Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 2122.	1.0	1
2312	HPV16 E6 induces chromosomal instability due to polar chromosomes caused by E6AP-dependent degradation of the mitotic kinesin CENP-E. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	4
2313	IL17RB and IL17REL Expression Are Associated with Improved Prognosis in HPV-Infected Head and Neck Squamous Cell Carcinomas. <i>Pathogens</i> , 2023, 12, 572.	1.2	0
2314	Personalizing Surveillance in Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2023, , .	1.8	6
2324	Solid Swellings of the Anterior Triangle: Cervical Lymphadenopathy. , 2023, , 59-163.		0
2349	Clinical, morphologic and molecular heterogeneity of HPV-associated oropharyngeal cancer. <i>Oncogene</i> , 2023, 42, 2939-2955.	2.6	1
2357	Neoplasms of the Pharynx. , 2023, , 532-641.e9.		0
2367	What Special Considerations Are Needed in Patients With Head and Neck Cancer?. , 2023, , 425-432.		0
2377	Mucosal Malignancy: Cancers of the Oropharynx. , 2023, , 189-197.		0
2380	Deep learning for medical image segmentation. , 2024, , 107-135.		0